

ISHLT 37TH ANNUAL MEETING AND SCIENTIFIC SESSIONS

RECORDED SESSIONS TABLE OF CONTENTS

Click on the **Header Date** or a **Session Title** to view details.

WEDNESDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 05, 2017

SYMPOSIUM 01: Joint ISHLT/ICCAC Symposium: Besides the Surgery - How to Make VAD Patients Successful
SYMPOSIUM 02: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors
SYMPOSIUM 03: Primary Graft Dysfunction (PGD) and Vasoplegia After Heart Transplantation: Sink or Swim
SYMPOSIUM 04: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation
SYMPOSIUM 05: Joint ISHLT/PHA Symposium: PH and Transplant: Where Do We Go From Here?
SYMPOSIUM 06: The Failing Fontan - Where Do We Go From Here?
SYMPOSIUM 07: Joint ISHLT/ESCMID Symposium: Ongoing Challenges in Transplant Infectious Diseases
OPENING PLENARY SESSION
ORAL SESSION 01: Too Thick or Too Thin? Bleeding and Thrombosis in MCS
ORAL SESSION 02: Engineering for Perfection in MCS
ORAL SESSION 03: Moving DCD Forward: Thinking Inside the Box
ORAL SESSION 04: Donor Lung Allocation Strategies
ORAL SESSION 05: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes
ORAL SESSION 06: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk
ORAL SESSION 07: Cutting Edge Updates in Infectious Diseases
ORAL SESSION 08: Bugs and Devices: A Bad Combination
ORAL SESSION 09: MCS Surgery: Does Nuance Make a Master?
ORAL SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies
ORAL SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction
ORAL SESSION 12: Innovation in Pediatric MCS
SYMPOSIUM 08: ECMO in Pre-Capillary PH: What is the Best Option for My Patient?
SYMPOSIUM 09: JHLT at ISHLT: The Year in a Capsule

THURSDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 06, 2017

SUNRISE SYMPOSIUM 01: Walk With Me: Exercise Physiology in the LVAD Patient
SUNRISE SYMPOSIUM 02: Chagasic Cardiomyopathy: Lessons To Be Learned
SUNRISE SYMPOSIUM 03: Lifecycle Journey of Thrombosis in Mechanical Circulatory Support Patients
SUNRISE SYMPOSIUM 04: Completing the Picture: Patient Reported Outcomes (PROs) as an Essential Source of Information in Evaluating Transplantation Outcomes
SUNRISE SYMPOSIUM 05: Upcoming Opportunities and Challenges in Pediatric Lung Transplantation
SUNRISE SYMPOSIUM 06: "Those Darn CARVs": Community Acquired Respiratory Viruses in Lung Transplant
SYMPOSIUM 10: Antibodies in Mechanical Circulatory Support: The Phantom Menace
SYMPOSIUM 11: Not CAVing to CLADtastrophe: Emerging Mechanisms of Chronic Heart and Lung Allograft Disease
SYMPOSIUM 12: A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients
SYMPOSIUM 13: Lung Allocation Scores (LAS): Making the Complex Simple, or Just the Simple Complex?
SYMPOSIUM 14: Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Current Controversies and New Directions
SYMPOSIUM 15: HLA, AMR and DSA - Approaching Antibodies in Kids
SYMPOSIUM 16: "Around the World in 80 Days": Infectious Challenges in Cardiothoracic Transplantation
PLENARY SESSION
ORAL SESSION 13: Contemporary LVAD Trials - Same Old Song or New Tune?
ORAL SESSION 14: Measure for Measure: In- and Ex-Vivo Cellular and Molecular Approaches for Thoracic Organ Tailoring
ORAL SESSION 15: Therapies and Monitoring After Heart Transplantation
ORAL SESSION 16: The Rise of the Machines: ECLS and EVLP in Lung Transplantation
ORAL SESSION 17: What's Up Next in Pulmonary Hypertension Research?
ORAL SESSION 18: Contemporary Challenges in Pediatric Heart Transplant
ORAL SESSION 19: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best
SYMPOSIUM 17: To Pulse or Not To Pulse? That is the Question

Saturday, April 8

SYMPOSIUM 18: Weeding Out Fact from Fiction - the Highs and Lows of Marijuana Use in Transplant
SYMPOSIUM 19: Cardiogenic Shock: Types, Teams and Tactics
SYMPOSIUM 20: ECMO in Lung Transplantation: Sensational Success or Fantastic Failure?
SYMPOSIUM 21: Cardiopulmonary Hemodynamics, the Right Ventricle, and the Kidney: Connecting All the Dots
SYMPOSIUM 22: Let's Get Personal! Precision Diagnostics in Thoracic Transplantation
SYMPOSIUM 23: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation

FRIDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 07, 2017

SUNRISE SYMPOSIUM 07: Getting to the Heart of Muscular Dystrophies
SUNRISE SYMPOSIUM 08: Live Long and Prosper: Thriving After Pediatric Transplantation
SUNRISE SYMPOSIUM 09: Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier
SUNRISE SYMPOSIUM 10: Contrasts and Similarities in Children and Adults: IPA, Portopulmonary Hypertension, and Perioperative Management
SUNRISE SYMPOSIUM 11: There is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation
SUNRISE SYMPOSIUM 12: HIV and Transplantation: It Isn't Going Away...
ORAL SESSION 20: New and Improving? Evolving Outcomes with MCS
ORAL SESSION 21: New Fixes for an Old Problem: Preventing, Diagnosing, and Treating Pump Thrombosis
ORAL SESSION 22: Does Risk Reap Reward? Expanding the Heart Donor Pool
ORAL SESSION 23: Choosing Right: Lung Recipient Selection and Management
ORAL SESSION 24: An Amalgamation of Support in Heart Failure
ORAL SESSION 25: Improving Outcomes in Pediatric Lung Transplantation
ORAL SESSION 26: Philip K. Caves Award Candidate Presentations
ORAL SESSION 27: The Leaking Gut - New Strategies for GI Bleeding in MCS
ORAL SESSION 28: The Heart of the Matter: Cardiac Substrate in MCS Therapy
ORAL SESSION 29: Donor Utilization and Allocation in Heart Transplantation: Lessons to Learn
ORAL SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction
ORAL SESSION 31: Saved by the Bell: Overcoming Adherence and Frailty
ORAL SESSION 32: The Tell Tale Heart: From Signals to Biomarkers
ORAL SESSION 33: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation
SYMPOSIUM 24: Aiming Off Target: Non-Cardiac Consequences of LVAD Support
SYMPOSIUM 25: Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver?
SYMPOSIUM 26: Making Every Heart Count
SYMPOSIUM 27: Bench to Bedside: How Advances in Immunology Shape the Care of Today's Lung Transplant Recipients
SYMPOSIUM 28: Great Debates in Pulmonary Hypertension
SYMPOSIUM 29: How to Mend a Broken Heart: Approaches for Cardiac Regeneration
SYMPOSIUM 30: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations?
ORAL SESSION 34: Short-Term MCS for Shock: New Paradigms
ORAL SESSION 35: Heart Failure in MCS
ORAL SESSION 36: CAV: New Insights to an Old Problem
ORAL SESSION 37: Impact of Donor Characteristics on Lung Transplant Outcomes
ORAL SESSION 38: The Nightmare of Primary Cardiac Allograft Dysfunction
ORAL SESSION 39: Early Career Scientist Award in Transplantation Finalist Presentations
ORAL SESSION 40: Drugs, Bleeding and Enzymes ... Oh My!

SATURDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 08, 2017

SUNRISE SYMPOSIUM 13: Mechanical Circulatory Support - The Interface of Design and Outcome
SUNRISE SYMPOSIUM 14: The Tsunami of Adult Congenital Heart Disease (ACHD) Patients Who Need Advanced Therapies: Are We Prepared?
SUNRISE SYMPOSIUM 15: Extracorporeal Photopheresis: Shedding Light on Rejection?
SUNRISE SYMPOSIUM 16: Pregnant - Scared? So Are We.... Management of Pregnancy in Our Complex Patients
SUNRISE SYMPOSIUM 17: Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation
ORAL SESSION 41: The Rhythm is Going to Get You: EP Issues in MCS
ORAL SESSION 42: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS
ORAL SESSION 43: In the Mix of Heart Failure
ORAL SESSION 44: Optimizing Early Outcomes after Lung Transplantation
ORAL SESSION 45: Heart Transplant in Special Populations

ORAL SESSION 46: Rogue One: A Graft Wars Story of Rejection and Tolerance

PLENARY SESSION

ORAL SESSION 47: Not the Usual Suspects: Driving Outcomes in MCS

ORAL SESSION 48: Seeing the Patient Beyond the Device

ORAL SESSION 49: Antibodies and Other Determinants of Cardiac Rejection: Let's ROCK and Rho

ORAL SESSION 50: Influencing Long-term Outcomes in Lung Transplantation

ORAL SESSION 51: Optimizing Outcomes After Heart Transplantation: Predictors and Risk Scores

ORAL SESSION 52: Does Size Matter? Center Volume, Urgency Status and Managing Complications

ORAL SESSION 53: Getting to the Heart of the Matter: Psychosocial Factors Predict Outcomes in Transplant and MCS

Wednesday, April 05, 2017

8:00 AM - 10:00 AM

SYMPOSIUM 01: Joint ISHLT/ICCAC Symposium: Besides the Surgery - How to Make VAD Patients Successful

Location:

Seaport A-E

Target Audience:

MCS, HF, HTX, NNSAH

Chairs:

Ivan Netuka, MD, PhD, and Thomas Schlöghofer, BSc

Session Summary: This session, supported by a collaborative effort with the International Consortium of Circulatory Assist Clinicians (ICCAC), is designed to discuss questions frequently asked by MCS Teams around the world regarding multidisciplinary program structure, practice guidelines, VAD education including simulation labs, cost-effectiveness and international aspects in care delivery from a program perspective, and with patients, families, and staff caring for them.

8:00 AM

Multidisciplinary Approaches to Optimize VAD Patient Management in High Volume Centers

Friedrich Kaufmann, MSc, German Heart Institute, Berlin, Germany

8:12 AM Q&A

8:17 AM

Caring for the Pediatric VAD Patient - They Aren't Just Small Adults

Jodie Lantz, MSN, RN, PCNS-BC, Children's Health Dallas, Dallas, TX, USA

8:29 AM Q&A

8:34 AM

Keep Them at Home: Interventions to Prevent Readmission

Lori Edwards, MSN, Inova Fairfax Hospital, Falls Church, VA, USA

8:46 AM Q&A

8:51 AM

Measuring and Managing Blood Pressure in CF-LVAD recipients

Brent C Lampert, DO, Ohio State University, Columbus, OH, USA

9:03 AM Q&A

9:08 AM

Echocardiography in LVAD Recipients: How and What to Measure?

Peter J Bergin, MBBS, FRACP, Alfred Hospital, Melbourne, Australia

9:20 AM Q&A

9:25 AM

Optimizing Unloading with Right Heart Catheterization Ramp Studies

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

9:37 AM Q&A

9:42 AM

Do We Need Antiplatelet Drugs and Anticoagulants to Manage LVAD Patients?

Haifa Lyster, MSc, Royal Brompton Harefield Hospital, Middlesex, United Kingdom

9:54 AM Q&A

Wednesday, April 5

8:00 AM - 10:00 AM

SYMPOSIUM 02: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors

Location:

Grand Hall A

Target Audience:

HTX, HF, MCS, NHSAAH

Chairs:

Lavanya Bellumkonda, MD, and Jane MacIver, RN, NP, PhD

Session Summary: This session will start by briefly reviewing the literature on psychosocial risk factors including: psychiatric illness, poor social support, medical non-adherence and substance abuse. The majority of the presentations will, however, focus on the interventions available to mitigate the risks associated with each variable and the efficacy of those interventions. Thus, the focus is how to use the psychosocial assessment as a means of problem identification for intervention rather than as a gate keeping function. A panel discussion with all speakers will conclude this session.

8:00 AM

The Impact of Psychiatric Risk Factors on Outcomes in Heart Failure, MCS and Cardiothoracic Transplant Patients

Heike Spaderna, PhD, University of Trier, Trier, Germany

8:15 AM

The Efficacy of Interventions for Psychiatric Risk Factors in Cardiothoracic Transplantation and MCS

Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

8:30 AM

It Takes a Village: Social Support and Social Determinants of Health in MCS and Cardiothoracic Transplantation as Potential Targets for Intervention

Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA

8:45 AM

When Do We Call It Quits: Intervention Strategies and Outcomes for Medical Non-Adherence

Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

9:00 AM

Are All Substances Made Equal?

Andrea DiMartini, MD, University of Pittsburgh, Pittsburgh, PA, USA

9:15 AM

Case Presentation (Part 1): The Good, The Bad And The Ugly

Jay Baumwol, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia

9:25 AM Q&A

9:30 AM

Case Presentation (Part 2): The Good, The Bad And The Ugly

Gillian Coult, BSW, Alfred Hospital, Melbourne, Australia

9:40 AM Q&A

9:45 AM Panel Discussion

8:00 AM - 10:00 AM

SYMPOSIUM 03: Primary Graft Dysfunction (PGD) and Vasoplegia After Heart Transplantation: Sink or Swim

Location:

Grand Hall B

Target Audience:

HTX, HF, MCS

Chairs:

Scott Silvestry, MD, and Hermann Reichenspurner, MD, PhD

Session Summary: The session goals are to review the existing and updated knowledge on primary graft dysfunction (PGD) and vasoplegia after heart transplantation. The presentations include: review of the published literature and ISHLT 2014 PGD definitions; the UK prospective PGD study; donor, recipient, and surgical risk factors; as well as experiences with post-transplant vasoplegia, with possible lessons learned from non-transplant heart surgery. There will be a 30-minute panel discussion at the end.

8:00 AM

Review of the Published Literature and the ISHLT 2014 PGD Definition

Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

8:15 AM

Review of Risk Factors for PGD: Donor, Recipient, and Surgical Procedure

Jennifer Cook, MD, University of Arizona, Tucson, AZ, USA

8:30 AM

First Prospective Observational Study on PGD: UK The Heart Evaluation and Retrieval for Transplantation Study

Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

8:45 AM

Vasoplegia after Adult Heart Transplantation and MCS Surgery

Maria M Patarroyo Aponte, MD, Allegheny General Hospital, Pittsburgh, PA, USA

9:00 AM

Severe PGD and Post-Operative Vasoplegia: Complications on the Same Spectrum or Different Entities?

Hiroo Takayama, MD, Columbia University, New York, NY, USA

9:15 AM

What Can We Learn from Non-Transplant Cardiac Surgery?

Paul J Mohacsi, MD, University Hospital, Bern, Switzerland

9:30 AM *Panel Discussion*

8:00 AM - 10:00 AM

SYMPOSIUM 04: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation

Location:

Grand Hall C

Target Audience:

LTX, BSTR, ID, NNSAH, PATH, PEDS, PHARM, PH

Chairs:

Adrian C Lawrence, MD, and Helen Whitford, MBBS, FRACP

Session Summary: Gastrointestinal complications, extra-pulmonary factors or concurrent systemic disorders may compromise long-term outcome following lung transplantation. This session highlights new paradigms of disease understanding, diagnosis, treatment, prevention and possibilities for investigational trial design.

8:00 AM

Gastro-Intestinal Dysmotility in Thoracic Organ Transplantation Revisited: Importance, Evaluation, Treatment

Frank D'Ovidio, MD, Columbia University, New York, NY, USA

8:20 AM Q&A

8:24 AM

Gastro-Intestinal Malignancies in Thoracic Organ Transplantation: Collateral Damage?

Monique Malouf, MD, St. Vincent's Hospital, Sydney, Australia

8:44 AM Q&A

8:48 AM

New Lungs - Old Sinuses: Friends or Foes?

Joseph M. Pilewski, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

9:08 AM Q&A

9:12 AM

Lung Transplantation in Systemic Disorders: Need for a Holistic Approach

Joseph P Lynch, MD, UCLA Medical Center, Los Angeles, CA, USA

9:32 AM Q&A

9:36 AM

Pregnancy After Thoracic Organ Transplantation: Unwanted But Unavoidable?

Mitesh Thakrar, MD, Alberta Lung Transplant Program, Calgary, AB, Canada

9:56 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 05: Joint ISHLT/PHA Symposium: PH and Transplant: Where Do We Go From Here?

Location:

Grand Hall D

Target Audience:

PH, HF, HTX, LTX, MCS, NNSAH, PEDS

Chairs:

Oksana A. Shlobin, MD, and Karen Fagan, MD

Session Summary: Lung transplantation is a viable treatment option for Group I pulmonary arterial hypertension (PAH). In addition, the presence of a secondary forms of PH (Group 2, or 3) in patients who require heart or lung transplant confers a high risk of complications. This symposium, supported by a collaborative effort with the Pulmonary Hypertension Association (PHA), will address various aspects of lung transplantation in adult and pediatric patients with different forms of PH.

8:00 AM

Transplantation for PH in the Era of LAS

Roham Zamanian, MD, Stanford University, Stanford, CA, USA

8:15 AM Q&A

8:20 AM

Effect of Non-Group 1 Pulmonary Hypertension on Lung Transplantation

Jorn Carlsen, MD, DMSc, Copenhagen University Hospital, Copenhagen, Denmark

8:35 AM Q&A

8:40 AM

Saving the Lung: Liver Transplant in Portopulmonary Hypertension

Sonja Bartolome, MD, UT Southwestern Medical Center, Dallas, TX, USA

8:55 AM Q&A

9:00 AM

Oops: Pregnancy in Pulmonary Hypertension

Valerie McLaughlin, MD, University of Michigan, Ann Arbor, MI, USA

9:15 AM Q&A

9:20 AM

Challenging Choices: Switching between IV and Oral Prostanoid Therapy

Joel Wirth, MD, Maine Medical Center, Portland, ME, USA

9:35 AM Q&A

9:40 AM

Quality of Life is Most Important: Patient Related Outcomes in PH

Mardi Gomberg-Maitland, MD, Inova Heart and Vascular Institute, Falls Church, VA, USA

9:55 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 06: The Failing Fontan - Where Do We Go From Here?

Location:

Seaport F-H

Target Audience:

PEDS, EEP, HF, HTX

Chairs:

Thomas Moller, MD, PhD, and Steven Kindel, MD

Session Summary: The aim is to discuss the care of the Fontan patient with heart failure across the spectrum, from pre-transplant medical management to mechanical support and heart transplantation. Timing of transplantation and listing, multi-organ transplantation and listing, and listing policies will all be discussed. Finally, a difficult case will be presented to the expert speaker panel at the end of the session.

8:00 AM

Sustainable Palliation: Optimizing Fontan Patients Prior to Heart Transplant

Jack Rychik, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

8:15 AM Q&A

8:20 AM

Call for Help! Surgical Options for End-Stage Fontan Failure

Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:35 AM Q&A

8:40 AM

Do You Want to List Too Early or Too Late? How to Determine When Fontan Patients Should be Listed for Transplant

Claire Irving, MBChB, MRCPCH, MD, Children's Hospital at Westmead, Sydney, Australia

8:55 AM Q&A

9:00 AM

It's Not JUST the Heart: Multi-Organ Transplantation in Fontan Patients

Daniel N Bernstein, MD, Stanford University, Stanford, CA, USA

9:15 AM Q&A

9:20 AM

Will Anybody Still Transplant My Patient? Programmatic Issues With Taking On Complex Fontan Patients

Richard Kirk, FRCP, FRCPCH, UT Southwestern Medical Center, Dallas, TX, USA

9:35 AM Q&A

9:40 AM

Case Presentation - The Failing Fontan Patient

Kathleen Simpson, MD, Washington University and Saint Louis Children's Hospital, St. Louis, MO, USA

9:50 AM Panel Discussion

8:00 AM - 10:00 AM

SYMPOSIUM 07: Joint ISHLT/ESCMID Symposium: Ongoing Challenges in Transplant Infectious Diseases

Location:

Coronado A-C

Target Audience:

ID, HTX, LTX, MCS, PHARM

Chairs:

Lara Danziger-Isakov, MD, MPH, and Oriol Manuel, MD

Session Summary: This session, supported by a collaborative effort with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), will provide important insight on relevant issues surrounding the care of thoracic organ transplant candidates and recipients and patients on mechanical circulatory support with infections.

8:00 AM

Non-Cultural Methods for Diagnosis and Prevention of Invasive Fungal Infections: Are We There Yet?

Barbara Alexander, MD, Duke University, Durham, NC, USA

8:15 AM Q&A

8:20 AM

Role of Inhaled Antimicrobials in the Era of Multidrug Resistance

Benoit Guery, MD, University Hospital Vaudois, Lausanne, Switzerland

8:35 AM Q&A

8:40 AM

Infection in Thoracic Organ Transplant Recipients on ECMO

Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland

8:55 AM Q&A

9:00 AM

Hepatitis C in Donor and Thoracic Organ Transplant Candidates and Recipients: A New Horizon

Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

9:15 AM Q&A

9:20 AM

Experience in HIV Infection in Thoracic Organ Transplantation and MCS

Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

9:35 AM Q&A

9:40 AM

EBV and Anellovirus Viremia as Markers of Risk of Infection in Lung Transplant Recipients

José Maria Aguado, MD, Hospital 12 de Octubre, Madrid, Spain

9:55 AM Q&A

10:30 AM - 12:30 PM
OPENING PLENARY SESSION

Location: Seaport A-E

Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Maryl R Johnson, MD

10:30 AM

Welcome/Program Chair Report

Jeffrey J Teuteberg, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

10:35 AM

Thoracic Registry Report

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

10:55 AM

MCSA Registry Reports

James K Kirklind, MD, University of Alabama, Birmingham, AL, USA

11:05 AM

President's Report

Maryl R Johnson, MD, University of Wisconsin School of Medicine, Madison, WI, USA

11:20 AM (1) *The Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation with the HeartWare Ventricular Assist Device: Results of the ENDURANCE Supplement Trial*; C. A. Milano¹, J. G.

Rogers¹, A. J. Tatroles², G. Bhat³, M. S. Slaughter⁴, E. J. Birks⁴, N. A. Mokadam⁵, C. Mahr⁵, J. S. Miller⁶, V. Jeevanandam⁷, K. Leadley⁸, K. D. Aaronson⁹, F. D. Pagani⁹. ¹Duke University Medical Center, Durham, NC, ²Advocate Christ Medical Center, Downers Grove, IL, ³Advocate Health Care, Oak Lawn, IL, ⁴University of Louisville, Louisville, KY, ⁵University of Washington, Seattle, WA, ⁶Emory Healthcare, Atlanta, GA, ⁷University of Chicago, Chicago, IL, ⁸HeartWare, Framingham, MA, ⁹University of Michigan Medical Center, Ann Arbor, IL

11:35 AM

Interactive Discussant

Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

11:40 AM (2) *The Impact of Age, Sex, Therapeutic Intent and Severity of Advanced Heart Failure on Outcomes in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial*; D. Goldstein¹, M. R. Mehra², Y. Naka³, C. T. Salerno⁴, N. Uriel⁵, D. Dean⁶, A.

Itoh⁷, F. D. Pagani⁸, E. R. Skipper⁹, G. Bhat¹⁰, N. Raval¹¹, B. A. Bruckner¹², J. Estep¹², R. Cogswell¹³, C. A. Milano¹⁴, L. Fendelander¹⁵, J. B. O'Connell¹⁶, J. Cleveland¹⁷. ¹Montefiore Medical Center, Bronx, NY, ²Brigham and Women's Hospital, Boston, MA, ³Columbia University Medical Center, New York, NY, ⁴St. Vincents Hospital, Indianapolis, IN, ⁵University of Chicago Medical Center, Chicago, IL, ⁶Piedmont Hospital, Atlanta, GA, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Michigan Medical Center, Ann Arbor, MI, ⁹Carolinas Medical Center, Charlotte, NC, ¹⁰Advocate Christ Medical Center, Chicago, IL, ¹¹Florida Hospital, Orlando, FL, ¹²Houston Methodist Hospital, Houston, TX, ¹³University of Minnesota Medical Center, Minneapolis, MN, ¹⁴Duke University Medical Center, Durham, NC, ¹⁵St. Jude Medical, Burlington, MA, ¹⁶St. Jude Medical, Pleasanton, CA, ¹⁷University of Colorado Medical Center, Denver, CO

11:55 AM

Interactive Discussant

Jan D Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

12:00 PM

Pioneer Award Recipient Lecture: Standing on the Shoulders of Giants

Stuart W Jamieson, MB, FRCS, UC San Diego Health System, La Jolla, CA, USA

2:30 PM - 4:00 PM

ORAL SESSION 01: Too Thick or Too Thin? Bleeding and Thrombosis in MCS

Location:

Seaport A-E

Target Audience:

MCS, HF, NHSAH, PHARM

Chairs:

Antonio Loforte, MD, and Nahush A. Mokadam, MD

2:30 PM (3) Plasma Free Hemoglobin Activates Platelets and Protects Von Willebrand Factor from Degradation: Clinical and In Vitro Evidence That LVAD Hemolysis Causes LVAD Thrombosis; S. Hennessy-Strahs, D. Zhang, J. Kang, E. Krause, G. Redline, J. Howard, M. Acker, P. Atluri, C. Bermudez, C. R. Bartoli. *University of Pennsylvania, Philadelphia, PA, PA*

2:45 PM (4) The Effect of Pre-Existing Hypercoagulable Disorders on Outcomes in Patients with LVADs; S. Adatya¹, G. Egnaczyk², J. N. Katz³, A. Brieke⁴, J. Stulak⁵, S. Nathan⁶, J. D. Rich⁷, S. Emani⁸, A. Kilic⁹, J. Ransom¹⁰, E. C. DePasquale¹¹, D. Crandall¹², D. J. Farrar¹², K. Sundareswaran¹², N. Uriel¹³. ¹*Advanced Heart Failure, Transplant and Mechanical Support, University of Chicago Medical Center, Chicago, IL*, ²*Christ Hospital, Cincinnati, OH*, ³*Division of Cardiology, University of North Carolina, Chapel Hill, NC*, ⁴*University of Colorado School of Medicine, Denver, CO*, ⁵*Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN*, ⁶*Memorial Hermann – Texas Medical Center, Houston, TX*, ⁷*Northwestern University Feinberg School of Medicine, Chicago, IL*, ⁸*Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH*, ⁹*Division of Cardiac Surgery, Ohio State University Medical Center, Columbus, OH*, ¹⁰*Baptist Health Heart and Transplant Institute, Little Rock, AR*, ¹¹*Ronald Reagan UCLA Medical Center, Los Angeles, CA*, ¹²*St. Jude Medical, Pleasanton, CA*, ¹³*University of Chicago Medical Center, Chicago, IL*

3:00 PM (5) Standard Dose Doxycycline Does Not Alter von Willebrand Factor Degradation in Patients with CF LVAD; M. E. Keebler, N. Haglund, S. Zalawadiya, M. Djunaidi, G. Baxter, A. Shah, D. Gailani, J. Lindenfeld. *Vanderbilt University Medical Center, Nashville, TN*

3:15 PM (6) Platelet Membrane-Related Morphologic Alterations: An Early Marker of Supra-Physiologic Shear-Mediated Platelet Activation Associated with VADs; A. Dimasi¹, M. Rasponi¹, F. Consolo¹, A. Redaelli¹, M. Slepian². ¹*Politecnico di Milano, Milano, Italy*, ²*University of Arizona, Tucson, AZ*

3:30 PM (7) Novel Analysis of High-Molecular-Weight Von Willebrand Factor Multimers Predicts Bleeding Events; S. Hennessy-Strahs, E. Bansal, J. Kang, E. Krause, M. Acker, P. Atluri, C. Bermudez, C. R. Bartoli. *University of Pennsylvania, Philadelphia, PA, PA*

3:45 PM (8) Managing Anticoagulation in LVAD Patients: The Harefield Experience; R. Hards, G. Edwards, C. Kavanagh, M. Hedger, A. R. Simon. *Transplant and Mechanical Circulatory Support, Harefield Hospital, Uxbridge, United Kingdom*

2:30 PM - 4:00 PM

ORAL SESSION 02: Engineering for Perfection in MCS

Location:

Grand Hall A

Target Audience:

MCS, HF, NHSAA

Chairs:

Shashank S Desai, MD, and Sanem Nalbantgil, MD

2:30 PM (9) Mechano-Acoustic Detection of Dysfunction in Continuous Flow VADs Utilizing Stretchable Electronic Systems; Y. Liu¹, K. R. Ammann², J. A. Rogers¹, M. J. Slepian². ¹University of Illinois, Urbana-Champaign, IL, ²University of Arizona, Tucson, AZ

2:45 PM (10) Virtual Implantation of the Infant Jarvik 2015 for Eligibility Criteria Establishment; J. R. Ryan¹, J. Teal², S. Pophal³, J. Nigro³, I. Adachi⁴, R. Jaquiss⁵, D. Frakes⁶, R. Jarvik², T. Baldwin⁷. ¹Cardiac 3D Print Lab, Phoenix Children's Hospital, Phoenix, AZ, ²Jarvik Heart, New York, NY, ³Phoenix Children's Hospital, Phoenix, AZ, ⁴Texas Children's Hospital, Phoenix/Houston, TX, ⁵Duke University School of Medicine, Durham, NC, ⁶Arizona State University, Tempe, AZ, ⁷National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

3:00 PM (11) A Novel, Implantable Device for Right-Side Mechanical Circulatory Support; J. R. Stanfield¹, J. W. Long². ¹University of Utah, Oklahoma City, OK, ²INTEGRIS, Oklahoma City, OK

3:15 PM (12) Pulsatile Outflow in Cows Supported Long-Term with the BiVACOR Rotary TAH; W. E. Cohn¹, F. Arabia², D. L. Timms³, N. Greatrex³, M. Kleinheyer³, F. Nestler³, S. Diab¹, O. Frazier¹. ¹Texas Heart Institute, Houston, TX, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³BiVACOR Inc., Houston, TX

3:30 PM (13) Primary Biventricular Durable Ventricular Assist Devices from Experience North American Centers: A Cautionary Tale; P. Shah¹, R. Ha², R. Singh³, E. Adler⁴, M. Brambatti⁴, S. Kidambi², D. Banerjee⁵, V. D. Pretorius⁶. ¹Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, ²Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ³Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, ⁴Cardiovascular Medicine, University of California San Diego, La Jolla, CA, ⁵Cardiovascular Medicine, Stanford University, Palo Alto, CA, ⁶Cardiothoracic Surgery, University of California San Diego, La Jolla, CA

3:45 PM (14) Is ICD Implantation Necessary in Patients with Left Ventricular Assist Device Therapy?; A. Uribarri, S. V. Rojas, J. S. Hanke, M. Avsar, G. Dogan, E. Deniz, M. Ricklefs, A. Haverich, J. D. Schmitto. Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany

2:30 PM - 4:00 PM

ORAL SESSION 03: Moving DCD Forward: Thinking Inside the Box

Location:

Grand Hall B

Target Audience:

HTX, BSTR, MCS

Chairs:

Maryjane Farr, MD, and Kumud K Dhital, MD, PhD

2:30 PM (15) 12 Hour Hypothermic Oxygenated Machine Perfusion Preserves the Quality of Donor Hearts: A Biomarker Analysis; S. G. Michel¹, M. L. Madariaga², S. M. Labbe³, E. Dupre³, L. M. Anderson⁴, K. Shanmugarajah⁵.

¹Cardiac Surgery, Ludwig Maximilian University, Muenchen, Germany, ²Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ³IPS Therapeutique, Sherbrooke, QC, Canada, ⁴Paragonix Technologies, Inc., Braintree, MA, ⁵Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom

2:45 PM (16) Excellent Early Outcomes Following Heart Transplantation from Circulatory Dead Donors; S. Messer,

A. Page, R. Axell, S. Colah, J. Hernandez-Sanchez, B. Parizkova, K. Valchanov, J. Dunning, J. Parameshwar, C. Lewis, Y. Abu Omar, S. Pettit, A. Kydd, D. Jenkins, C. Sudarshan, P. Catarino, M. Berman, M. Findlay, A. Ali, S. Tsui, S. R. Large. *Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom*

3:00 PM (17) Rapid Retrieval and Ex Situ Portable Machine Perfusion Allows Successful Cardiac Transplantation with Donor Hearts from Controlled Donation After Circulatory Death; K. K. Dhital, M. Connellan, H. C. Chew, A. Iyer,

C. Soto, A. Dinale, E. Granger, P. Jansz, C. Hayward, A. Jabbour, A. Keogh, E. Kotlyar, P. Spratt, P. Macdonald. *Cardiothoracic Surgery, St Vincent's Hospital, Sydney, NSW, Australia*

3:15 PM (18) Donor Circulatory Death Heart Transplantation with Adverse Donor and Recipient Risk Profile; D. García Sáez,

C. T. Bowles, O. K. Maunz, B. Zych, P. N. Mohite, O. Ananiadou, N. Marczin, A. Hurtado Doce, B. Raj, F. De Robertis, S. Rahman-Haley, N. R. Banner, A. R. Simon. *Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom*

3:30 PM (19) Does the Assessment of DCD Donor Hearts on the Organ Care System Using Lactate Need

Redefining?; A. Page, S. Messer, R. Axell, V. Naruka, S. Colah, S. Fakelman, C. Ellis, Y. Abu-Omar, A. Ali, M. Berman, P. Catarino, J. Dunning, D. Jenkins, C. Sudarshan, S. Tsui, S. Large. *Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom*

3:45 PM (20) Midterm Follow up of Heart Transplantation with Routine Ex-Vivo Normothermic Preservation with

Adverse Donor - Recipient Risk Profile; D. García Sáez, B. Zych, P. Mohite, F. De Robertis, C. T. Bowles, A. Sabashnikov, O. Ananiadou, B. Schmack, O. K. Maunz, A. Popov, T. Bahrami, N. R. Banner, A. R. Simon. *Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital NHS Trust, Harefield, London, United Kingdom*

2:30 PM - 4:00 PM

ORAL SESSION 04: Donor Lung Allocation Strategies

Location:

Grand Hall C

Target Audience:

LTX, EEP, NNSAH

Chairs:

Dirk E Van Raemdonck, MD, and Laveena Chhatwani, MD

2:30 PM (21) *What Effect Does Rate of Change in LAS Have on Lung Transplant Outcomes?*; A. Aretakis¹, C. Towe², M. Schechter², D. L. Morales¹, R. Bryant, III¹, F. Zafar¹. ¹*Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, ²*Pulmonology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

2:45 PM (22) *Lung Allocation Score Implementation Narrowed Racial/Ethnic Disparities in Adult Lung Transplantation Outcomes*; B. Lim, J. Lasky, C. Schaufler, Y. Suzuki, D. Malle, M. Molina, C. A. Bermudez, J. M. Diamond, J. D. Christie, E. Cantu. *University of Pennsylvania Perelman School of Medicine, Philadelphia, PA*

3:00 PM (23) *Objective Donor Scoring System for Lung Transplantation*; W. M. Whited, J. R. Trivedi, V. H. van Berkel, M. P. Fox. *Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

3:15 PM (24) *Is There a Rationale for an "Old-for-Old" Program in Lung Transplantation? A Comparative Study Using the International Society of Heart and Lung Transplantation Database*; A. M. Bernhardt¹, A. P. Levin², J. Stehlik³, C. Benden⁴, L. Edwards⁵, F. M. Wagner¹, H. Reichenspurner¹. ¹*Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany*, ²*Columbia University Medical Center, New York City, NY*, ³*University of Utah School of Medicine, Salt Lake City, UT*, ⁴*University Hospital Zurich, Zurich, Switzerland*, ⁵*United Network for Organ Sharing, Richmond, VA*

3:30 PM (25) *Are Donors with Pulmonary Arterial Embolism the Better Donors for Lung Transplantation?*; W. Sommer¹, H. Kirschner², F. Ius¹, J. Salman¹, T. Siemeni¹, M. Avsar¹, C. Kuehn¹, M. Kaufmann², M. Greer³, J. Gottlieb³, A. Rahmel⁴, T. Welte³, A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹*Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany*, ²*Deutsche Stiftung Organtransplantation, Region Nord, Germany*, ³*Respiratory Medicine, Hannover Medical School, Hannover, Germany*, ⁴*Deutsche Stiftung Organtransplantation, Frankfurt, Germany*

3:45 PM (26) *Use of Drug Intoxicated Donors for Lung Transplant: Impact on Survival Outcomes*; W. M. Whited, J. R. Trivedi, M. P. Fox, V. H. van Berkel. *Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

2:30 PM - 4:00 PM

ORAL SESSION 05: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes

Location: Grand Hall D

Target Audience: PH, HF, HTX, LTX, NNSAH, PEDS, PHARM

Chairs: Ioana R Preston, MD, and Tanya J. McWilliams, MD, PhD

2:30 PM (27) Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients; R. L. Benza¹, C. G. Elliott², H. W. Farber³, A. J. Foreman⁴, A. E. Frost⁵, M. Gombert-Maitland⁶, M. D. McGoon⁷, D. J. Pasta⁴, M. Selej⁸, R. P. Frantz⁷. ¹Allegheny General Hospital, Pittsburgh, PA, ²Intermountain Medical Center and the University of Utah, Salt Lake City, UT, ³Boston University School of Medicine, Boston, MA, ⁴ICON Clinical Research, San Francisco, CA, ⁵Houston Methodist Lung Center, Weill-Cornell, Institute for Academic Medicine, Houston, TX, ⁶Inova Fairfax Hospital, Falls Church, VA, ⁷Mayo Clinic, Rochester, MN, ⁸Actelion Pharmaceuticals US, Inc., South San Francisco, CA

2:45 PM (28) Preliminary Data from the USA CTEPH Registry; K. M. Kerr¹, W. R. Auger¹, R. L. Benza², R. N. Channick³, K. Chin⁴, R. D. Davis⁵, C. G. Elliott⁶, A. Z. LaCroix¹, M. M. Madani¹, V. V. McLaughlin⁷, M. H. Park⁸, V. F. Tapson⁹. ¹Univ California San Diego, La Jolla, CA, ²University of Pittsburgh, Pittsburgh, PA, ³Massachusetts General Hospital, Boston, MA, ⁴University of Texas Southwestern, Dallas, TX, ⁵Florida Hospital, Orlando, FL, ⁶Intermountain Healthcare, Salt Lake City, UT, ⁷University of Michigan, Ann Arbor, MI, ⁸Houston Methodist Hospital, Houston, TX, ⁹Cedars-Sinai Medical Center, Los Angeles, CA

3:00 PM (29) REVEAL Risk Score in Patients with Chronic Thromboembolic Pulmonary Hypertension Receiving Riociguat; R. L. Benza¹, H. W. Farber², A. Frost³, E. Grünig⁴, M. Hoeper⁵, D. Busse⁶, C. Meier⁷, S. Nikkho⁸, H. Ghofrani⁹. ¹Allegheny Gen Hosp, Pittsburgh, PA, ²Pulmonary Center, Boston University School of Medicine, Boston, MA, ³Houston Methodist Hospital Lung Center and Institute of Academic Medicine, Houston, TX, ⁴Centre for Pulmonary Hypertension, Thoraxclinic at the University Hospital Heidelberg, Heidelberg, Germany, ⁵Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, ⁶Chrestos Concept GmbH & Co, Essen, Germany, ⁷Global Medical Affairs, Bayer Pharma AG, Berlin, Germany, ⁸Global Clinical Development, Bayer Pharma AG, Berlin, Germany, ⁹University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, Member of the German Center, University Hospital Giessen and Marburg, Giessen, Germany

3:15 PM (30) OPUS Registry: Safety and Tolerability of Macitentan in a Real-World Setting; N. H. Kim¹, M. Brand², K. M. Chin³, R. N. Channick⁴, M. Selej⁵, V. V. McLaughlin⁶. ¹University of California, San Diego, La Jolla, CA, ²Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ³UT Southwestern Medical Center, Dallas, TX, ⁴Massachusetts General Hospital, Boston, MA, ⁵Actelion Pharmaceuticals US Inc, South San Francisco, CA, ⁶University of Michigan, Ann Arbor, MI

3:30 PM (31) Orthotopic Heart Lung Transplantation Improving Outcomes Over Time; E. Nagy¹, L. B. Edwards², A. Y. Kucheryavaya³, J. Stehlik⁴, R. D. Yusen⁵, L. H. Lund¹. ¹Dept. of Cardiology, Karolinska University Hospital; Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Research Department, United Network for Organ Sharing, Richmond, VA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas., Dallas, TX, ³Research Department, United Network for Organ Sharing, Richmond, VA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas, USA., Dallas, TX, ⁴University of Utah School of Medicine, Division of Cardiovascular Medicine, Salt Lake City, Utah, USA, Salt Lake City, UT, ⁵Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA., St. Louis, MO

3:45 PM (32) Orthotopic Heart-Lung Transplantation: Outcomes and Predictors of Outcomes in Recipients with Eisenmenger Syndrome, Other Congenital Etiologies, and Idiopathic Pulmonary Arterial Hypertension; E. Nagy¹, L. B. Edwards², A. Y. Kucheryavaya², J. Stehlik³, R. D. Yusen⁴, L. H. Lund¹. ¹Department of Cardiology, Karolinska University Hospital, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Research Department, United Network for Organ Sharing, Richmond, VA, USA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas, USA, Dallas, TX, ³University of Utah School of Medicine, Division of Cardiovascular Medicine, Salt Lake City, Utah, USA., Salt Lake City, UT, ⁴Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA., St. Louis, MO

2:30 PM - 4:00 PM

ORAL SESSION 06: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk

Location: Seaport F-H

Target Audience: PEDS, HF, HTX

Chairs: Ashwin K Lal, MD, and Shigetoyo Kogaki, MD

2:30 PM (33) Distinct Disease Mechanisms Govern the Progression of Pediatric and Adult Dilated

Cardiomyopathy; M. Patel¹, C. Schneider², J. Mohan², C. Canter¹, T. Jeffrey³, K. J. Lavine². ¹Pediatrics, Washington University, St Louis, MO, ²Cardiology, Washington University, St Louis, MO, ³Pediatrics, University of Tennessee Health Center, Memphis, TN

2:45 PM (34) Diagnostic Errors at First Presentation of Heart Failure in Children; K. Puri¹, H. Singh², S. W. Denfield¹, A. G. Cabrera¹, W. J. Dreyer¹, J. F. Price¹. ¹Cardiology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Medicine Health Services Research, Baylor College of Medicine, Houston, TX

3:00 PM (35) Hemodynamics of the Pediatric Failing Fontan; J. C. Dykes¹, D. B. McElhinney², D. Bernstein¹, M. R. Chrisant³, S. Chen¹, K. P. Daly⁴, R. K. Ameduri⁵, K. R. Knecht⁶, M. E. Richmond⁷, K. Y. Lin⁸, S. Urschel⁹, J. Simmonds¹⁰, K. E. Simpson¹¹, C. S. Almond¹, S. Chen¹. ¹Pediatrics, Stanford University, Palo Alto, CA, ²Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ³Pediatrics, Joe DiMaggio Children's Hospital, Fort Lauderdale, FL, ⁴Pediatrics, Harvard University, Boston, MA, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Pediatrics, University of Arkansas for Medical Sciences, Arkansas, AR, ⁷Pediatrics, Columbia University Medical Center, New York, NY, ⁸Pediatrics, University of Pennsylvania, Philadelphia, PA, ⁹Pediatrics, University of Alberta, Edmonton, AB, Canada, ¹⁰Pediatrics, Great Ormond Street Hospital, London, United Kingdom, ¹¹Pediatrics, Washington University School of Medicine, St. Louis, MO

3:15 PM (36) Assist Device Therapy for Myocarditis - Analysis from the German Multi-Centre Prospective

Myocarditis Registry in Pediatric Patients: "Mykke"; S. Schubert¹, F. Degener², B. Opgen-Rhein³, F. Schmidt⁴, A. Weigelt⁵, R. Wagner⁶, T. Mir⁷, A. Rentzsch⁸, E. z. Knyphausen⁹, K. Papkostas¹⁰, G. Wiegand¹¹, B. Ruf¹², T. Hannes¹³, K. Reineker¹⁴, D. Kiskj¹⁵, M. Khalil¹⁶, M. Steinmetz¹⁷, G. Fischer¹⁸, T. Pickardt¹⁹, D. Messroghli²⁰, O. O. MYKKE Consortium²¹. ¹Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin and DZHK, Berlin, Germany, ²Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, ³Pediatric Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Pediatric Cardiology, Medizinische Hochschule Hannover, Hannover, Germany, ⁵Pediatric Cardiology, Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Pediatric Cardiology, Herzzentrum Leipzig, Leipzig, Germany, ⁷Pediatric Cardiology, Universitäres Herzzentrum Hamburg, Hamburg, Germany, ⁸Pediatric Cardiology, Universitätsklinikum des Saarlandes, Homburg, Germany, ⁹Congenital Heart Disease, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, ¹⁰Structural Heart Disease/Pediatric Cardiology, Klinikum Links der Weser, Bremen, Germany, ¹¹Pediatric Cardiology, Universitätsklinikum Tübingen, Tübingen, Germany, ¹²Congenital Heart Disease/Pediatric Cardiology, ¹²Deutsches Herzzentrum und Technische Universität München, München, Germany, ¹³Pediatric Cardiology, Uniklinik Köln, Cologne, Germany, ¹⁴Congenital Heart Disease/Pediatric Cardiology, Universitäts-Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany, ¹⁵Pediatric Cardiology, Universitätsklinikum Münster, Münster, Germany, ¹⁶Pediatric Cardiology, Universitätsklinik Gießen, Giessen, Germany, ¹⁷Pediatric Cardiology and Intensive Care, Universitätsmedizin und Kinderherzklinik Göttingen, Göttingen, Germany, ¹⁸Clinic for Pediatric Cardiology, Universitätsklinikum Schleswig-Holstein, Kiel, Germany, ¹⁹Kompetenznetz für angeborene Herzfehler, Berlin, Germany, ²⁰Cardiology, Deutsches Herzzentrum Berlin & DZHK, Berlin, Germany, ²¹Multicenter, Germany, Germany

3:30 PM (37) Renal Dysfunction as a Relative Contraindication to Pediatric Heart Transplantation; I. Wilmot, R.

Rizwan, F. Zafar, D. Hooper, T. D. Ryan, C. Chin. Cardiology, Cincinnati Children's Hospital All Children 's Hospital, Cincinnati, OH

3:45 PM (38) The Impact of Tracheostomy on Pediatric Heart Transplant Outcomes: A Multi-Institutional Analysis;

J. A. Spinner¹, S. W. Denfield¹, K. Puri¹, S. A. Morris¹, B. S. Moffett², J. F. Price¹, W. J. Dreyer¹, A. G. Cabrera¹.

¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Pain Medicine, Texas Children's Hospital, Houston, TX

2:30 PM - 4:00 PM

ORAL SESSION 07: Cutting Edge Updates in Infectious Diseases

Location:

Coronado A-C

Target Audience:

ID, ALL

Chairs:

Karen Doucette, MD, MSc, and Stephanie M Pouch, MD

2:30 PM (39) Clinical Risk Factors for Invasive Aspergillosis in Lung Transplant Recipients: Results of an International Cohort Study; C. Aguilar¹, B. Hamandi², C. Fegbeutel³, F. P. Silveira⁴, E. A. Verschuuren⁵, P. Ussetti⁶, P. V. Chin-Hong⁷, A. Sole⁸, C. Holmes-Liew⁹, E. M. Billaud¹⁰, P. A. Grossi¹¹, O. Manuel¹², D. J. Levine¹³, R. G. Barbers¹⁴, D. Hadjiliadis¹⁵, L. Singer¹⁶, S. Husain¹. ¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Department of Pharmacy, University Health Network, Toronto, ON, Canada, ³Hannover Medical School, Hannover, Germany, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁶Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ⁷University of California, San Francisco, San Francisco, CA, ⁸University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain, ⁹Royal Adelaide Hospital, Adelaide, Australia, ¹⁰APHP Hopital Européen G Pompidou, Paris, France, ¹¹University of Insubria, Varese, Italy, ¹²University Hospital of Lausanne, Lausanne, Switzerland, ¹³University of Texas Health Science Center San Antonio, San Antonio, TX, ¹⁴KECK Medical Center of University of Southern California, Los Angeles, CA, ¹⁵University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, ¹⁶Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

2:45 PM (40) Aspergillus Galactomannan Detection in Exhaled Breath Condensate for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients; A. Bhimji¹, A. Bhaskaran¹, L. G. Singer², D. Kumar¹, A. Humar¹, R. Pavan¹, C. Rotstein¹, S. Keshavjee², T. Mazzulli³, S. Husain¹. ¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada

3:00 PM (41) Impact of Cytomegalovirus and Its Prevention Strategies on Survival in Thoracic Transplant Recipients; J. K. Preiksaitis, C. A. Mabilangan, C. Cervera. Medicine, University of Alberta, Edmonton, AB, Canada

3:15 PM (42) Invasive Mycobacterium abscessus Infection in Heart Transplant Recipients; E. K. Maziarz¹, A. W. Baker¹, C. B. Patel², P. Patel², C. A. Milano³, J. N. Schroder³, M. A. Daneshmand³, B. D. Alexander¹, C. R. Wolfe¹. ¹Division of Infectious Diseases and International Health, Duke University, Durham, NC, ²Division of Cardiology, Duke University, Durham, NC, ³Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC

3:30 PM (43) Clinical and Microbiologic Characteristics of Infections in Left Ventricular Assist Device Recipients; M. Bradbury¹, S. Phillips¹, J. Stulak², K. Abdullah¹, C. T. Salerno³, S. Maltais², S. M. Dunlay², T. F. Dardas⁴, K. Aaronson⁵, F. D. Pagani⁵, J. A. Cowger³, P. Shah¹. ¹Inova Heart and Vascular Institute, Falls Church, VA, ²Mayo Clinic, Rochester, MN, ³St. Vincent Heart Center of Indiana, Indianapolis, IN, ⁴University of Washington, Seattle, WA, ⁵University of Michigan Health System, Ann Arbor, MI

3:45 PM (44) Potential Posaconazole Sequestration During Extracorporeal Membrane Oxygenation: Results from an Ex-Vivo Experiment; H. Lyster¹, T. Pitt¹, O. Maunz¹, D. Garcia Saez¹, J. Tiller¹, N. Leaver¹, J. Roberts², K. Shekar³, D. Brown⁴, J. Mills⁴, M. Carby¹, A. Simon¹, A. Reed¹. ¹Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, ²The University of Queensland, Brisbane, Australia, ³The Prince Charles Hospital, Brisbane, Australia, ⁴University of Portsmouth, Portsmouth, United Kingdom

4:30 PM - 6:00 PM

ORAL SESSION 08: Bugs and Devices: A Bad Combination

Location:

Seaport A-E

Target Audience:

MCS, ID, NNSAH, PHARM

Chairs:

Simon Maltais, MD, PhD, and Orla Morrissey, MD

4:30 PM (45) *Epidemiology of Bloodstream Infections in MCSD Recipients in the IMACS Registry*; S. Aslam¹, R. Xie², V. Chu³, J. Cowger⁴, S. Schueler⁵, T. de By⁶, K. Gould⁵, O. Morrissey⁷, L. Lund⁸, S. Martin⁹, D. Goldstein¹⁰, M. Hannan¹¹. ¹Univ. of CA, San Diego, San Diego, CA, ²Univ. of Alabama, Birmingham, AL, ³Duke University, Durham, NC, ⁴St Vincent Heart Center of Indiana, Indianapolis, IN, ⁵Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Euromacs, Berlin, Germany, ⁷Alfred Hospital, Melbourne, Australia, ⁸Karolinska Institute, Stockholm, Sweden, ⁹Geisinger Health System, Danville, PA, ¹⁰Montefiore Medical Center, New York, NY, ¹¹Mater Misericordiae University Hospital, Dublin, Ireland

4:45 PM (46) *The Epidemiology of Infection in MCS from the IMACS Database: January 2013 to December 2015*; M. M. Hannan¹, R. Xie², J. A. Cowger³, S. Schueler⁴, T. M. de By⁵, A. I. Dipchand⁶, V. H. Chu⁷, R. S. Cantor², C. Koval⁸, T. Krabatsch⁹, C. Hayward¹⁰, J. K. Kirklin². ¹Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, ²The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO), UAB, Birmingham, AL, ³St Vincent Heart Center of Indiana, Indianapolis, IN, ⁴Newcastle Freeman Hospital, UK, Newcastle, United Kingdom, ⁵EUROMACS, Berlin, Germany, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Division of Infectious Diseases, Duke University Medical Center, Durham, NC, ⁸Cleveland Clinic, Cleveland, OH, ⁹Deutsches Herzzentrum, Berlin, Germany, ¹⁰St Vincent's Hospital, Sydney, Australia

5:00 PM (47) *Epidemiology of Fungal Infections (FI) in Mechanical Circulatory Support Device (MCSD) Recipients: Analysis of IMACS Registry 2013-2015*; O. Morrissey¹, R. Xie², J. Schaenman³, S. Husain⁴, M. Mooney⁵, T. Nakatani⁶, R. Kormos⁷, M. Gómez-Bueno⁸, S. Aslam⁹, Y. Pya¹⁰, M. Hannan¹¹. ¹Infectious Diseases, Alfred Health, Melbourne, Australia, ²The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO/UAB), Birmingham, AL, ³Medicine, University of California, Los Angeles, Los Angeles, CA, ⁴Infectious Diseases, University Health Network, Toronto, ON, Canada, ⁵Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, ⁶Maki Hospital, Osaka, Japan, ⁷Surgery, University of Pittsburgh, Pittsburgh, PA, ⁸Cardiology, Hospital Univ. Puerta de Hierro. Majadahonda, Madrid, Spain, ⁹Infectious Diseases, University of California, San Diego, San Diego, CA, ¹⁰National Research Cardiac Surgery Center, Astana, Kazakhstan, ¹¹Microbiology, Mater Misericordiae University Hospital, Dublin, Ireland

5:15 PM (48) *Risk Factors and Mortality for Sepsis in Left Ventricular Assist Device Recipients*; P. S. Joy¹, G. Kumar², J. K. Bhamra¹, L. M. Cadaret¹. ¹University of Iowa, Iowa City, IA, ²Northeast Georgia Health System, Gainesville, GA

5:30 PM (49) *Supporting Imaging Modalities for Improving Diagnosis of Infection in Patients on CF-LVAD: A Single-Center Experience Including 61 Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomographies*; A. M. Dell'Aquila¹, N. Avramovic², A. Motekallemi¹, M. Scherer¹, J. R. Sindermann¹, C. Wenning¹. ¹Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Münster, Germany, ²Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

5:45 PM (50) *Hepatitis C Virus Infection Does Not Impact Survival Following Continuous-Flow Left Ventricular Assist Device Implantation*; A. Pendyal, J. M. Gelow. Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR

4:30 PM - 6:00 PM

ORAL SESSION 09: MCS Surgery: Does Nuance Make a Master?

Location:

Grand Hall A

Target Audience:

MCS, HF, NNSAH

Chairs:

Nader Moazami, MD, and Diyar Saeed, MD

4:30 PM (51) A Novel Technique of Temporary Right Ventricular Assist Device (RVAD) Placement During Durable Left Ventricular Assist Device (LVAD) Implant to Allow Early Ambulation and Bedside Percutaneous Removal; G. Zanotti¹, T. B. Reece¹, D. Fullerton¹, J. Cleveland¹, A. Babu². ¹Cardiothoracic Surgery, University of Colorado, Aurora, CO, ²Cardiothoracic Surgery, ST. Thomas Hospital, Nashville, TN

4:45 PM (52) Pre-Implant Left Ventricular Apex Position Predicts Risk of HeartMate II Pump Thrombosis; L. T. Yarboro, R. B. Hawkins, J. Mehaffey, G. Ailawadi, I. L. Kron, J. A. Kern, R. K. Ghanta. University of Virginia, Charlottesville, VA

5:00 PM (53) Surgical Strategy to Support Right Ventricle with HVAD RVAD: Right Atrial vs Right Ventricular Diaphragmatic Surface Cannulation; Y. Shudo, R. V. Ha, O. Reinhartz, J. Woo, J. Boyd, C. Almond, D. N. Rosenthal, S. Chen, K. Maeda. Stanford University, Stanford, CA

5:15 PM (54) Should Prophylactic Tricuspid Valve Surgery Be Considered in Patients with Atrial Fibrillation Undergoing LVAD Implantation?; S. Maltais¹, V. Tchantchaleishvili¹, R. C. Daly¹, D. L. Joyce¹, L. D. Joyce¹, S. S. Kushwaha², J. M. Stulak¹. ¹Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

5:30 PM (55) Outcomes of Multiple Concomitant Valve Procedures in Patients Receiving Continuous-Flow Left Ventricular Assist Device; J. Han¹, H. Takayama¹, P. A. Kurlansky¹, A. R. Garan², M. Yuzefpolskaya², V. K. Topkara², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Columbia University Medical Center, New York, NY

5:45 PM (56) First-in-Human (FIH) Experience with the Intravascular Ventricular Assist System iVAS a Novel Approach to Mechanical Circulatory Support; V. Jeevanandam¹, D. Onsager¹, T. Song¹, T. Ota¹, C. Juricek¹, T. Lammy¹, V. Kagan¹, H. Costantini¹, G. Sayer², S. Adatya², G. Kim², N. Uriel². ¹CT Surgery, University of Chicago, Chicago, IL, ²Cardiology, University of Chicago, Chicago, IL

4:30 PM - 6:00 PM

ORAL SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies

Location:

Grand Hall B

Target Audience:

HTX, EEP, MCS, NHSAH

Chairs:

Mark J Zucker, MD, and Tahir Yagdi, MD

4:30 PM (57) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged by Left Ventricular Assist Device (LVAD) Type; A. Salimbangon¹, J. A. Cowger², D. Vucicevic¹, L. Honoris¹, A. Iyengar¹, S. Shah¹, E. Moreno¹, A. Chang¹, L. Reardon¹, K. Pandya³, M. C. Deng¹, A. Ardehali¹, E. C. DePasquale¹. ¹UCLA, Los Angeles, CA, ²St Vincent Heart Center, Indianapolis, IN, ³UC Davis, Sacramento, CA

4:45 PM (58) Left Ventricular Assist Device Is Protective Against Cardiac Transplant Delisting for Medical Unsuitability ; R. Cogswell¹, S. Duval¹, J. Schultz¹, C. Martin¹, K. Liao², R. John². ¹Cardiology, University of Minnesota, Minneapolis, MN, ²Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

5:00 PM (59) Age Dependent Risk of LVAD Used as a Bridge to Transplant and of Comorbidities on Post-Transplant Survival: An Analysis of ISHLT Registry; M. Masetti¹, A. R. Wilk², F. Grigioni¹, A. Russo¹, L. B. Edwards², L. H. Lund³, J. Stehlik⁴, L. Potena¹. ¹Heart Transplant Program, DIMEC, S.Orsola Hospital, University of Bologna, Bologna, Italy, ²United Network for Organ Sharing, Richmond, VA, ³Karolinska Institutet, Department of Medicine, and Karolinska University Hospital, Department of Cardiology, Stockholm, Sweden, ⁴Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, University of Utah School of Medicine, Salt Lake City, UT

5:15 PM (60) Impact of Sensitization and 4S Prioritization on Heart Transplantation Waiting Times in Canada; N. Aleksova¹, H. J. Ross², L. M. Mielniczuk¹, R. A. Davies¹, E. Stadnick¹, S. Chih¹. ¹University of Ottawa Heart Institute, Ottawa, ON, Canada, ²University Health Network, Toronto, ON, Canada

5:30 PM (61) Revealing a New Mode of Sensitization Induced by Mechanical Circulatory Support Devices (MCS): Impact of Anti-AT1R Antibodies; X. Zhang¹, J. Mirocha², T. Aintablian³, J. Moriguchi⁴, F. Arabia⁵, J. A. Kobashigawa⁴, N. L. Reinsmoen¹. ¹HLA and Immunogenetics Laboratory, Cedars-Sinai Health System, Los Angeles, CA, ²Biostatic Core, Cedars-Sinai Health System, Los Angeles, CA, ³California Heart Center, Los Angeles, CA, ⁴Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cardiovascular Surgery, Cedar Sinai Medical Center, Los Angeles, CA

5:45 PM (62) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged with Mechanical Circulatory Support (MCS); E. C. DePasquale¹, J. A. Cowger², L. Honoris¹, D. Vucicevic¹, S. Shah¹, A. Iyengar¹, A. Salimbangon¹, E. Moreno¹, A. Chang¹, L. Reardon¹, K. Pandya³, M. Deng¹, A. Ardehali¹. ¹UCLA, Los Angeles, CA, ²St Vincent Heart Center, Indianapolis, IN, ³UC Davis, Sacramento, CA

4:30 PM - 6:00 PM

ORAL SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction

Location:

Grand Hall C

Target Audience:

LTX, BSTR, EEP, ID, NNSAH, PATH, PHARM

Chairs:

Ramsey R Hachem, MD, and Erika D Lease, MD

4:30 PM (63) Correlation Between Microbial Diversity, Lung Inflammation, and Chronic Lung Allograft

Dysfunction; L. Levy¹, A. Tigert², T. Saito³, K. Boonstra², J. Prescod⁴, D. Hwang², S. Keshavjee², S. Juvet², B. Coburn⁴, T. Martinu². ¹Toronto Lung Transplant Program, Toronto, ON, Canada, ²Toronto General Hospital, University Health Network, Toronto, ON, Canada, ³Kansai Medical University, Hirakara, Japan, ⁴Toronto General Research Institute, Toronto, ON, Canada

4:45 PM (64) Lung Bile Acid Correlation with Inflammation, Infection, CLAD and Survival; M. Ahmed¹, R. Zamel², D.

Nakajima², W. Klement³, M. Cypel², J. Todd⁴, S. Weigt⁵, M. Liu², L. Singer¹, S. Keshavjee², T. Martinu¹. ¹Medicine, Toronto Lung Transplant Program, Toronto, ON, Canada, ²Thoracic Surgery, Toronto Lung Transplant Program, Toronto, ON, Canada, ³Toronto Lung Transplant Program, Toronto, ON, Canada, ⁴Medicine, Duke University, Durham, NC, ⁵Medicine, UCLA, Los Angeles, CA

5:00 PM (65) Matrix Metalloproteinase-7 May Be a Biomarker of Early Chronic Lung Rejection; J. Jaffar¹, T. Phan¹,

M. Stewart², B. Levey², M. Paraskeva², G. Snell², G. Westall¹. ¹The Alfred Hospital/Monash University, Melbourne, Australia, ²The Alfred Hospital, Melbourne, Australia

5:15 PM (66) The Impact of De Novo Donor-Specific Antibodies on Bronchiolitis Obliterans Syndrome and

Restrictive Allograft Syndrome; E. Miyamoto, T. Martinu, W. Klement, S. Juvet, S. Keshavjee, K. Tinckam, J. Tikkanen. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

5:30 PM (67) Role of Complement-Binding Anti-HLA Antibodies Detection as Early Predictor of Chronic Lung

Dysfunction After Lung Transplantation; O. Brugière¹, A. Roux², J. Le Pavec³, D. Sroussi¹, F. Parquin², P. Pradère³, C. Dupin¹, V. Bunel¹, G. Mourin¹, G. Jebrak¹, G. Thabut¹, G. Dauriat¹, Y. Castier¹, P. Mordant¹, B. Lortat Jacob¹, S. Jean-Baptiste¹, H. Mal¹, C. Suberbielle¹, J. Taupin¹. ¹Hôpital Bichat, Paris, France, ²Hôpital Foch, Suresnes, France, ³Hôpital Marie Lannelongue, Le Plessis Robinson, France

5:45 PM (68) Immunophenotyping Pre Total Lymphoid Irradiation for BOS After Lung Transplantation May Predict

Response to Therapy; B. Schmack¹, F. Cano Romero², J. Hester², V. Durrant³, S. Soresi⁴, D. Garcia Saez¹, B. Zych¹, O. Ananiadou¹, A. R. Simon¹, M. Carby⁴, A. Reed⁴, J. Smith³. ¹Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, ²Nuffield Department of Surgical Science, University of Oxford, Oxford, United Kingdom, ³Tissue Typing Service, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, ⁴Department of Respiratory and Transplant Medicine, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom

4:30 PM - 6:00 PM

ORAL SESSION 12: Innovation in Pediatric MCS

Location:

Seaport F-H

Target Audience:

PEDS, MCS

Chairs:

Kristine J Guleserian, MD, and Oliver Miera, MD

4:30 PM (69) Reverse Remodeling After Placement of Pulsatile and Continuous Flow Left Ventricular Assist Device in Children with End-Stage Idiopathic Dilated Cardiomyopathy; J. Kasten¹, P. Punjwani², S. Zhang³, D. Rakheja¹, B. B. Das². ¹Department of Pathology, UT Southwestern Med Ctr, Dallas, TX, ²Division of Pediatric Cardiology, UT Southwestern Med Ctr, Dallas, TX, ³Department of Clinical Science Research, UT Southwestern Med Ctr, Dallas, TX

4:45 PM (70) Are Implantable Cardioverter-Defibrillators Indicated in Pediatric Ventricular Assist Device Patients?; A. Bulic, S. Ceresnak, J. C. Dykes, S. Chen, K. Motonaga, D. N. Rosenthal, C. S. Almond, B. D. Kaufman, S. A. Hollander, K. Maeda, N. A. Laroussi, D. Hanisch, A. V. Trela, J. M. Murray, A. M. Dubin. *Division of Pediatric Cardiology, Stanford University, Palo Alto, CA*

5:00 PM (71) Post-Transplant Outcomes in Pediatric VAD Patients: A Pedimacs-PHTS Linkage Study; D. L. Sutcliffe¹, E. Pruitt², R. S. Cantor², J. Godown³, J. Lane⁴, M. W. Turrentine⁵, S. P. Law⁶, J. L. Lantz⁷, D. C. Naftel², J. K. Kirklin², D. Bernstein⁸, E. D. Blume⁹. ¹Pediatric Cardiology, Children's Health Dallas, UT Southwestern, Dallas, TX, ²Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ⁴Pediatric Critical Care, Phoenix Children's Hospital, Phoenix, AZ, ⁵Cardiac Surgery, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Cardiology, Columbia University-Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY, ⁷Pediatric Cardiology, Children's Health Dallas, Dallas, TX, ⁸Pediatric Cardiology, Lucile Packard Children's Hospital at Stanford, Palo Alto, CA, ⁹Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA

5:15 PM (72) In Vitro Examination of the VentriFlo™ True Pulse Pump for Failing Fontan Support; P. M. Trusty¹, M. Tree², D. Vincent³, J. P. Naber³, K. Maher⁴, A. P. Yoganathan¹, S. Deshpande⁴. ¹BME, Georgia Institute of Technology, Atlanta, GA, ²ME, Georgia Institute of Technology, Atlanta, GA, ³Design Mentor, Pelham, NH, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

5:30 PM (73) Outcome of a Continuous Flow Pump (Jarvik 2000) as Bridge to Transplantation or Destination Therapy in Pediatric Patients; G. Perri¹, S. Filippelli¹, G. Testa¹, F. Iodice¹, R. Adorisio¹, R. Iacobelli¹, A. Di Molfetta¹, M. Massetti², A. Amodeo¹. ¹Bambino Gesù Children Hospital, Rome, Italy, ²Catholic University of Sacred Heart, Rome, Italy

5:45 PM (74) Compassionate Deactivation of Ventricular Assist Devices in Children: A Survey of Pediatric VAD Clinicians' Perspectives and Practices; B. D. Kaufman¹, S. A. Hollander¹, S. H. Chen¹, D. Bernstein¹, D. N. Rosenthal¹, C. Almond¹, J. M. Murray¹, A. M. Burgart², H. J. Cohen¹, J. N. Kirkpatrick³, E. D. Blume⁴. ¹Pediatrics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, ²Pediatric Anesthesia, Biomedical Ethics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, ³Bioethics and Humanities, Medicine, University of Washington Medical Center, Seattle, WA, ⁴Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA

4:30 PM - 6:00 PM

SYMPOSIUM 08: ECMO in Pre-Capillary PH: What is the Best Option for My Patient?

Location:

Grand Hall D

Target Audience:

PH, HF, LTX, PEDS, PH

Chairs:

Ellie Fadel, MD, and Corey E Ventetuolo, MD

Session Summary: ECMO options in patients with pre-capillary PH are multiple. They include peripheral VA ECMO through the lower or upper body, central ECMO, VV ECMO, or the new option of oxyRVAD. The indications depend on the patient conditions and underlying cause of PH. This symposium presents an overview of the different options and their application according to the sub-group of patients. There will be a focus on pediatric patients with PAH, adult patients with PAH, IPF-PH patients, and CTEPH patients. A panel discussion with all speakers will conclude this session.

4:30 PM

Peripheral vs. Central: ECMO in PAH Patients

Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France

4:50 PM

OxyRVAD: Who is a Candidate?

Charles Hoopes, MD, University of Alabama, Birmingham, AL, USA

5:10 PM

ECMO in Pediatric Patients with PAH: What are the Particularities?

Pirooz Eghtesady, MD, St. Louis Children's Hospital, St Louis, MO, USA

5:30 PM

ECMO in Non-PAH Pulmonary Hypertension: Clots and Scars

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

5:50 PM

Panel Discussion

4:30 PM - 6:00 PM

SYMPOSIUM 09: JHLT at ISHLT: The Year in a Capsule

Location:

Coronado A-C

Target Audience:

ALL

Chairs:

Duane Davis, MD, MBA, and Martin Schweiger, MD, PhD

Session Summary: This session will highlight the most impactful publications in JHLT over the past year. Following the presentation of each publication by a member of the Junior Faculty and Trainee Council a senior editorial consultant of the JHLT will relate the presented articles to the greater body of published literature and discuss how they advance our understanding of the field.

4:30 PM

Introduction and Recognition of Top Papers of the Year

Patricia Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

4:40 PM

Highlights of Heart Transplantation and Mechanical Circulatory Support

Agneszka Ciarka, MD, Catholic University of Leuven, Leuven, Belgium

4:55 PM

Senior Editor Perspective: Heart Transplantation and Mechanical Circulatory Support

Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

5:00 PM

Highlights of Lung Transplantation and Pulmonary Hypertension

Hrishikesh S Kulkarni, MD, Washington University School of Medicine, St. Louis, MO, USA

5:15 PM

Senior Editor Perspective: Lung Transplantation and Pulmonary Hypertension

Andrew J Fisher, FRCP, PhD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:20 PM

Highlights of Pediatric Heart and Lung Transplantation

Erin Albers, MD, Seattle Children's Hospital, Seattle, WA, USA

5:35 PM

Senior Editor Perspective: Pediatric Heart and Lung Transplantation

Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada

5:40 PM

Highlights of Infectious Diseases

Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

5:55 PM

Senior Editor Perspective: Infectious Diseases

Margaret Hannan, MD, Mater Misericordiae University Hospital, Dublin, Ireland

Thursday, April 06, 2017

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 01: Walk With Me: Exercise Physiology in the LVAD Patient

Location:

Grand Hall A

Target Audience:

MCS, ALL

Chairs:

Christopher S Hayward, MD, and Jorge Silva Enciso, MD

Session Summary: Ventricular assist devices improve functional class and quality of life due to its impact on exercise capacity. Long-term LVAD support is associated with improved central hemodynamics and exercise performance. Although, the maximal effects on functional performance continue to be marginal, pump flow changes and cardiac output augmentation does occur during exercise. Understanding the basis of exercise physiology in LVAD patients may allow for future interventions to enhance exercise performance.

7:00 AM

Invasive Exercise Hemodynamic Evaluation in LVAD Patients

David M Kaye, MD, PhD, Alfred Hospital, Melbourne, Australia

7:10 AM Q&A

7:15 AM

Factors Influencing Exercise Performance in LVAD Patients

Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

7:25 AM Q&A

7:30 AM

Pulsatility and Exercise Performance in Continuous vs. Pulsatile Flow

Christopher S Hayward, MD, St. Vincent's Hospital, Sydney, Australia

7:40 AM Q&A

7:45 AM

Right Ventricular Function During Exercise in LVAD Patients

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 02: Chagasic Cardiomyopathy: Lessons To Be Learned

Location:

Grand Hall B

Target Audience:

HF, HTX, ID, MCS

Chairs:

Alejandro M Bertolotti, MD, and Stanley Martin, MD

Session Summary: The cardiac form of Chronic Chagas Disease is responsible for inability to work, low quality of life and death among infected individuals. Chagas disease currently affects approximately 8 – 11 million people in South America, Central America and Mexico, and approximately 80 million people are at risk for contracting the illness. Although an estimated 300,000 persons with Chagas disease live in the USA, little is known about the burden of Chagasic heart disease. A 12-minute panel discussion with all speakers will conclude this session.

7:00 AM

Chronic Chagas Disease and Chagasic Cardiomyopathy

Anna K Sa, MD, Pro Cardiac Hospital, Rio de Janeiro, Brazil

7:12 AM

Arrhythmic Storm as the First and Last Manifestation of Chagas Disease

Fabiana G Marcondes-Braga, MD, PhD, Heart Institute, Sao Paulo, Brazil

7:24 AM

Heart Transplant in Chagasic Cardiomyopathy: How to Manage Immunosuppression

Fernando Bacal, MD, PhD, University of Sao Paulo, Sao Paulo, Brazil

7:36 AM

Reactivation of Chagas Post-Transplant: Diagnosis and Pharmaceutical Management

Lisa Peters, PharmD, MedStar Washington Hospital Center, Washington, DC, USA

7:48 AM Panel Discussion

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 03: Lifecycle Journey of Thrombosis in Mechanical Circulatory Support Patients

Location:

Grand Hall C

Target Audience:

PHARM, HF, HTX, MCS, NNSAH

Chairs:

Stephan Schueler, MD, PhD, FRCS, and Christina T. Doligalski, PharmD, BCPS

Session Summary: This lifecycle journey is an enduring case with 3 defined points. The time points discussed include implantation and management strategies that influence thrombotic risk; management of anticoagulation including review of current therapy, potential novel therapies and appropriate monitoring; the anatomy of the clot and potential mechanisms of thrombosis in MCS.

7:00 AM

Lifecycle Journey Case Presentation

Christina T Doligalski, PharmD, BCPS, Tampa General Hospital, Tampa, FL, USA

7:03 AM

Influence of Surgical Techniques on Pump Thrombosis: How Physics Can Help Patient Management

Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

7:18 AM

Lifecycle Journey Case Update

Christina Doligalski

7:19 AM

Prevention of Thrombosis in Mechanical Support: Where are we going?

Ed Horn, PharmD, Allegheny General Hospital, Pittsburgh, PA, USA

7:34 AM

Lifecycle Journey Case Update

Christina Doligalski

7:35 AM

What Pathology Can Tell Us About Mechanisms of Thrombosis

Lisa Baumann Kreuziger, MD, Medical College of Wisconsin, Milwaukee, WI, USA

7:50 AM *Panel Discussion*

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 04: Completing the Picture: Patient Reported Outcomes (PROs) as an Essential Source of Information in Evaluating Transplantation Outcomes

Location:

Grand Hall D

Target Audience:

NHSAH, ALL

Chairs:

Maria R. Molina, MSN, CRNP, CCRN, and James Kirklin, MD

Session Summary: Patient Reported Outcomes (PRO) are increasingly used to capture the outcomes of transplant recipients and living donors and have become an inherent part of the evaluation of transplant programs' quality assessment and performance improvement. PROs drive patient centered outcomes research (PCOR). The aim of this session is to explain the concept of patient reported outcomes, how PROs measures are developed and how PROs are assessed to successfully perform PCOR. Further it will provide a number of examples on the use of PROs in clinical practice, research, and quality assessment and performance.

7:00 AM

The Crucial Importance of PROs for Transplant Evaluation from a Clinical, Research and Quality Assurance Perspective

Linda Ohler, MSN, FAAN, George Washington University, Washington, DC, USA

7:15 AM Q&A

7:20 AM

State of the Art Development of PRO Assessments for Patient Centered Outcomes Research (PCOR)

Sabina M De Geest, RN, PhD, University of Basel, Basel, Switzerland

7:35 AM Q&A

7:40 AM

PROs in Pediatric Transplant Patients: Special Issues

Kathleen L Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 05: Upcoming Opportunities and Challenges in Pediatric Lung Transplantation

Location:

Seaport F-H

Target Audience:

PEDS, HF, LTX, MCS, PEDS, PH

Chairs:

Marc G. Schechter, MD, and Christian Benden, MD, FCCP

Session Summary: Over recent years, outcomes after lung transplantation in children have improved. Against this background, new challenges arise and new opportunities come up. At this symposium, selection criteria and bridging strategies to lung transplantation for critically ill neonates are discussed, and overall changing indications for pediatric lung transplantation given the decreasing number of children with cystic fibrosis referred for it. In addition, alternative approaches to lung transplant such as Potts-shunts in children with severe pulmonary arterial hypertension are reviewed, and strategies debated to increase the donor pool, for example ABO incompatible lung transplantation in smaller children.

7:00 AM

Bridge over Troubled Water: ECMO for the Critically Ill Newborn as a Bridging Strategy to Transplantation - Who is the Right Candidate?

Stuart C Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

7:12 AM Q&A

7:15 AM

New Kids on the Block: Is There a Change of Indications for Pediatric Lung and Heart-Lung Transplantation?

Bart L. Rottier, MD, University Medical Center Groningen, Groningen, Netherlands

7:27 AM Q&A

7:30 AM

ABO Incompatible Lung Transplantation in Infants and Small Children to Expand the Donor Pool: Where is the Age Limit and What Has To Be Considered?

Melinda P. Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada

7:42 AM Q&A

7:45 AM

Potts-Shunt in Children with Severe PAH: A Promising Procedure To Avoid Lung Transplantation?

Maria C Gazzaneo, MD, Texas Children's Hospital, Houston, TX, USA

7:57 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 06: "Those Darn CARVs": Community Acquired Respiratory Viruses in Lung Transplant

Location:

Coronado A-C

Target Audience:

ID, LTX, PATH, PHARM

Chairs:

Pali Shah, MD, and Aric L Gregson, MD

Session Summary: Respiratory viruses following lung transplantation are a common occurrence and can range from the common cold to fulminant respiratory failure. Respiratory viruses have also been implicated in the development of Chronic Lung Allograft Dysfunction (CLAD), the most significant cause of mortality following lung transplantation. Available therapies are limited, however, as is the data supporting their use. Improved understanding of the host response to respiratory viruses may help contribute to the novel therapeutics.

7:00 AM

Respiratory Viruses and CLAD: Epidemiology and Clinical Data

Erika Lease, MD, University of Washington, Seattle, WA, USA

7:10 AM Q&A

7:15 AM

Respiratory Viruses and CLAD: Pathogenesis and Host Response

Tereza Martinu, MD, Toronto General Hosp/UHN, Toronto, ON, Canada

7:25 AM Q&A

7:30 AM

To Treat or Not to Treat: A Critical Review of Currently Available Therapies

Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

7:40 AM Q&A

7:45 AM

In the Pipeline: Novel Therapeutics

Christopher Ensor, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

7:55 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 10: Antibodies in Mechanical Circulatory Support: The Phantom Menace

Location:

Seaport A-E

Target Audience:

MCS, BSTR, HF, HTX, PEDS, PHARM

Chairs:

Jon A. Kobashigawa, MD, and Andreas Zuckermann, MD

Session Summary: As the number of patients requiring mechanical circulatory support (MCS) increases, allosensitization in this population presents a special challenge as it limits options for transplantation. This session will discuss the nature of sensitization in MCS patients, epidemiology, risk of the sensitized MCS patient, therapeutic options and post-transplant management. A 20-minute panel discussion with all speakers will conclude this session.

8:00 AM

Is the MCS Device Immunomodulatory?

Elaine F Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

8:20 AM

Sensitization in the Pediatric MCS Population

Francesco Parisi, MD, Bambino Gesù Pediatric Hospital, Rome, Italy

8:40 AM

Approach to the Sensitized MCS Patient: Desensitization and Other Strategies

Jignesh K. Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

9:00 AM

Epidemiology and Risk of the Sensitized MCS Patient

Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

9:20 AM

What Happens to the Antibodies After Heart Transplant?

Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

9:40 AM *Panel Discussion*

8:00 AM - 10:00 AM

SYMPOSIUM 11: Not CAVing to CLADtastrophe: Emerging Mechanisms of Chronic Heart and Lung Allograft Disease

Location:

Grand Hall A

Target Audience:

BSTR, HTX, LTX, PATH, PHARM

Chairs:

Elizabeth H Hammond, MD, and Christopher H. Wigfield, MD, FRCS

Session Summary: In this session, we will examine factors which have been recently implicated in coronary artery vasculopathy and chronic lung allograft dysfunction. Donor and recipient innate immune responses, autoimmune responses triggered by alloimmunity, and the pivotal role of endothelium and micro-vasculature will be explored. The goal of the session is to identify new pathologic and molecular targets for treatment in both Cardiac Allograft Vasculopathy (CAV) and Chronic Lung Allograft Dysfunction (CLAD). Importantly, this session will examine parallels between chronic processes in the transplanted heart and lung and bring together research and clinical experts in lung and heart transplantation.

8:00 AM

Pivotal Role of the Endothelium in CAV

Daniel Jane-Wit, MD, PhD, Yale School of Medicine, New Haven, CT, USA

8:15 AM Q&A

8:20 AM

Critical Effect of Airway Microvasculature on CLAD Development

Mark R. Nicolls, MD, Stanford University, Stanford, CA, USA

8:35 AM Q&A

8:40 AM

DAMPs, PAMPS and Innate Immunity in CAV

Joren C Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

8:55 AM Q&A

9:00 AM

DAMPs, PAMPS, and Innate Immunity in CLAD

Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA

9:15 AM Q&A

9:20 AM

Antibodies in CAV: the Role of Autoimmunity in Alloimmunity

Christine M Lin, MD, University of Colorado, Denver, CO, USA

9:35 AM Q&A

9:40 AM

Antibodies and B Cells in Pathogenesis of CLAD

Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

9:55 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 12: A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients

Location:

Grand Hall B

Target Audience:

HTX, ALL

Chairs:

Teresa De Marco, MD, and Jose Gonzalez-Costello, MD

Session Summary: This session will use a combination of lectures and debates to highlight treatment options for patients who have primary thoracic organ failure and secondary end-organ dysfunction. Appropriate selection and management of multi-organ recipients will be discussed. In addition, speakers will address unique challenges faced in multi-organ transplantation, including a review of the policies and ethical considerations in allocating multiple organs to a single individual. A 15-minute panel discussion will conclude this session.

8:00 AM

Heart-Lung Transplantation: How Bad Do The Ventricles Have To Be?

John J Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

8:15 AM

DEBATE (PRO): Heart Transplant Candidates with Vulnerable Kidneys Should Undergo Combined Heart-Kidney Transplantation

Eugene C DePasquale, MD, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

8:30 AM

DEBATE (CON): Heart Transplant Candidates with Vulnerable Kidneys Should Undergo Combined Heart-Kidney Transplantation

Marcelo Cantarovich, MD, McGill University Health Centre, Montreal, QC, Canada

8:45 AM

DEBATE (PRO): Heart Transplant Candidates with Bridging Fibrosis Should Undergo Combined Heart-Liver Transplantation

Sudhir S Kushwaha, MD, Mayo Clinic, Rochester, MN, USA

9:00 AM

DEBATE (CON): Heart Transplant Candidates with Bridging Fibrosis Should Undergo Combined Heart-Liver Transplantation

Charles E. Canter, MD, St Louis Children's Hospital, St. Louis, MO, USA

9:15 AM

Thoracic and Abdominal Tug of War: Management of the Multi-Organ Transplant Recipient

Richard C Daly, MD, Mayo Clinic, Rochester, MN, USA

9:30 AM

Ethical Principles in Allocating Multiple Organs to One Recipient

Heather J Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

9:45 AM *Panel Discussion*

8:00 AM - 10:00 AM

SYMPOSIUM 13: Lung Allocation Scores (LAS): Making the Complex Simple, or Just the Simple Complex?

Location:

Grand Hall C

Target Audience:

LTX, ALL

Chairs:

Kevin M. Chan, MD, and Allan Glanville, MBBS, MD, FRACP

Session Summary: This symposium highlights the lung allocation systems employed worldwide, describes changes in US lung allocation since the implementation of the LAS, reviews the results of the LAS by Eurotransplant, describes early results of the LAS revision, and discusses controversies on allocation equality raised by the LAS.

8:00 AM

Who Needs LAS Anyway? Lung Allocation Around the World

Are Martin Holm, MD, Oslo University Hospital, Oslo, Norway

8:20 AM Q&A

8:24 AM

Lung Allocation Score: the Changing Landscape of Lung Transplantation in the USA

Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC, USA

8:44 AM Q&A

8:48 AM

Modification of the USA LAS Model 2015: Early Results

Kevin M Chan, MD, University of Michigan, Ann Arbor, MI, USA

9:08 AM Q&A

9:12 AM

LAS in Eurotransplant: Towards a Uniform Approach?

Jacqueline Smits, MD, PhD, Eurotransplant International Foundation, Leiden, Netherlands

9:32 AM Q&A

9:36 AM

LAS Controversies: Improving Equity in Organ Allocation?

Selim Arcasoy, MD, MPH, Columbia University, New York, NY, USA

9:56 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 14: Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Current Controversies and New Directions

Location:

Grand Hall D

Target Audience:

PH

Chairs:

William Auger, MD, and C. Dario Vizza, MD

Session Summary: This symposium will review some of the key questions and controversial topics in patients with CTEPH in the preoperative and postoperative period.

8:00 AM

Out-of-Proportion Pulmonary Vascular Resistance (PVR): Operative Suitability and Perioperative Considerations

Marc de Perrot, MD, University of Toronto, Toronto, ON, Canada

8:15 AM Q&A

8:20 AM

Medical Therapy for CTEPH as "Bridge" to Surgery: Right or Wrong?

Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

8:35 AM Q&A

8:40 AM

The Right Ventricular (RV) in CTEPH: How to Assess Before and After Pulmonary Endarterectomy

Paul Forfia, MD, Temple University, Philadelphia, PA, USA

8:55 AM Q&A

9:00 AM

Chronic Thromboembolic Disease Without PH at Rest: Treat or Not?

John Granton, MD, University of Toronto, Toronto, ON, Canada

9:15 AM Q&A

9:40 AM

Is Balloon Pulmonary Angioplasty (BPA) an Alternative or Complementary to PEA?

Hiromi Matsubara, MD, PhD, Okayama Medical Center, Okayama, Japan

9:55 AM Q&A

8:00 AM - 10:00 AM

SYMPOSIUM 15: HLA, AMR and DSA - Approaching Antibodies in Kids

Location:

Seaport F-H

Target Audience:

ALL

Chairs:

Steven A. Webber, MBChB, and Robert G. Weintraub, FRACP, FACC

Session Summary: The goal of this symposia is to educate transplant clinicians in the use of antibody testing in the assessment of patients who are candidates for transplant, and for assessment and treatment of Antibody Mediated Rejection (AMR) after transplant. The session will start with basic science background principles in HLA antibodies, and end with a case of an allosensitized patient, with a forum discussion by the experts.

8:00 AM

Back to the Basics: HLA Antibodies, Donor-Specific Antibodies, and How to Measure Them

Anat Roitberg-Tambur, DMD/PhD, Northwestern University, Chicago, IL, USA

8:15 AM Q&A

8:20 AM

Before Transplant: Why the PRA Matters

Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

8:35 AM Q&A

8:40 AM

Before Transplant: Why the PRA Doesn't Matter Anymore

Brian Feingold, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

8:55 AM Q&A

9:00 AM

After Transplant: What To Do With New DSA?

Matthew Fenton, MRCPCH, Great Ormond Street Hospital for Children, London, United Kingdom

9:15 AM Q&A

9:20 AM

After Transplant: How to Diagnose and Treat AMR in Kids

Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA

9:35 AM Q&A

9:40 AM

Case Presentation: Managing an Allosensitized Patient to Transplant

Ching Kit Chen, MBBS, MRCPCH, KK Women's and Children's Hospital, Singapore, Singapore

9:50 AM Panel Discussion

8:00 AM - 10:00 AM

SYMPOSIUM 16: "Around the World in 80 Days": Infectious Challenges in Cardiothoracic Transplantation

Location:

Coronado A-C

Target Audience:

ID, HF, HTX, LTX

Chairs:

Saima Aslam, MD, MS, and Shahid Husain, MD, MS

Session Summary: The rise of cardiothoracic (CT) transplantation in emerging countries has led to unique infectious challenges. The goal of the symposium is to understand the impact of locally endemic infections such as Zika virus, hepatitis B, and tuberculosis on CT transplant recipients in different areas of the world. The presentations will cover the scope of the problem, management strategies, outcomes and travel advice.

8:00 AM

Perspective on Zika Virus and Other Emerging Infections from Latin America

Silvia V Campos, MD, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil

8:20 AM Q&A

8:24 AM

Hepatitis B and Thoracic Transplantation

Emily A Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

8:44 AM Q&A

8:48 AM

Screening and Management of Latent Tuberculosis

Subramanian Swaminathan, MD, MNAMS, Global Hospitals, Chennai/Bengaluru, India

9:08 AM Q&A

9:12 AM

Treatment of Tuberculosis

Amparo Sole, MD, PhD, Hospital Universitario la Fe, Valencia, Spain

9:32 AM Q&A

9:36 AM

Travel Advice for the Immunocompromised Traveler: Prophylaxis, Vaccination, and Other Preventive Measures

Stephanie Pouch, MD, The Ohio State University, Columbus, OH, USA

9:56 AM Q&A

10:30 AM - 12:30 PM
PLENARY SESSION

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Hermann Reichenspurner, MD, PhD, and David O. Taylor, MD

10:30 AM
Putting an End to Transplantation? Translating the Promise of Stem Cell Therapy into Practice
Brenda Ogle, PhD, University of Minnesota, Minneapolis, MN, USA

10:50 AM (147) *Impella RP Post Approval Study: First Multi-Center, Prospective Post Market Approval Results for the Impella RP in Patients with Right Ventricular Failure*; M. Anderson¹, L. Morris¹, D. Tang², G. Batsides³, A. Kirtane⁴, I. Hanson⁵, P. Meraj⁶, N. Kapur⁷, W. O'Neill⁸. ¹Einstein Healthcare Network, Philadelphia, PA, ²Virginia Commonwealth University, Richmond, VA, ³Rutgers / Robert Wood Johnson, New Brunswick, NJ, ⁴Columbia Presbyterian University Hospital, New York, NY, ⁵William Beaumont, Royal Oak, MI, ⁶Northwell Health, Manhasset, NY, ⁷Tufts University, Boston, MA, ⁸Henry Ford, Detroit, MI

11:05 AM
Interactive Discussant
Martin Strueber, MD, MSU College of Human Medicine, East Lansing, MI, USA

11:10 AM
Tweets, Texts, and Posts: Does Social Media Improve or Complicate Communication in Medicine?
Dorry Segev, MD, PhD, Johns Hopkins School of Medicine, Baltimore, MD, USA

11:30 AM
Share and Share Alike: Optimizing Organ Allocation in an Era of Increasing Need
Sommer Gentry, PhD, USA Naval Academy, Annapolis, MD, USA

11:50 AM (148) *Early Graft Injury Measured by Donor-Derived Cell-Free DNA Predicts Early Mortality in Lung Transplant Recipients*; S. Agbor-Enoh¹, I. Tunc², I. De Vlaminc³, A. Davis¹, S. Gorham¹, M. Jang¹, K. Cuttin¹, U. Fideli¹, A. Marishta¹, J. Wylie⁴, H. Luikart⁵, K. Khush⁴, H. Valantine¹. ¹Laboratory of Transplant Genomics, National Heart, Lung and Blood Institute, Bethesda, MD, ²Informatics and Computation Biology Core, National Heart, Lung and Blood Institute, Bethesda, MD, ³Cornell University, Ithaca, NY, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Laboratory of Transplant Genomics, Stanford University School of Medicine, Palo Alto, CA

12:05 PM
Interactive Discussant
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

12:10 PM
Metabolomics: New Tools to Understand Rejection
Brendan Keating, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

2:00 PM - 3:30 PM

ORAL SESSION 13: Contemporary LVAD Trials - Same Old Song or New Tune?

Location: Seaport A-E

Target Audience: MCS, HF, HTX, NHSAH

Chairs: Jeffrey J Teuteberg, MD, and Francis D Pagani, MD, PhD

2:00 PM (149) Hemocompatibility Related Outcomes in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial; N. Uriel¹, P. C. Colombo², J. Cleveland³, J. Long⁴, C. T. Salerno⁵, D. Goldstein⁶, C. Patel⁷, G. Ewald⁸, A. J. Tatoes⁹, S. Silvestry¹⁰, R. John¹¹, C. Caldeira¹², V. Jeevanandam¹, A. J. Boyle¹³, K. S. Sundareswaran¹⁴, P. Sood¹⁵, M. R. Mehra¹⁶. ¹University of Chicago Medical Center, Chicago, IL, ²Columbia University Medical Center, New York, NY, ³University of Colorado Medical Center, Denver, CO, ⁴Integris Baptist Medical Center, Oklahoma City, OK, ⁵St. Vincents Hospital, Indianapolis, IN, ⁶Montefiore Medical Center, Bronx, NY, ⁷Duke University Medical Center, Durham, NC, ⁸Washington University School of Medicine, St. Louis, MO, ⁹Advocate Christ Medical Center, Chicago, IL, ¹⁰Florida Hospital, Orlando, FL, ¹¹University of Minnesota Medical Center, Minneapolis, MN, ¹²Tampa General Hospital, Tampa, FL, ¹³Thomas Jefferson University, Philadelphia, PA, ¹⁴St. Jude Medical, Pleasanton, CA, ¹⁵St. Jude Medical, Burlington, MA, ¹⁶Brigham and Women's Hospital, Boston, MA

2:15 PM (150) ENDURANCE Destination Therapy Trial Outcomes as Stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Classification; S. V. Pamboukian¹, F. D. Pagani², J. J. Teuteberg³, R. L. Kormos³, C. C. Caldeira⁴, C. H. Selzmann⁵, J. K. Kirklin¹, B. B. Reid⁶, E. C. McGee⁷, C. A. Milano⁸, J. G. Rogers⁸. ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Michigan Medical Center, Ann Arbor, MI, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Tampa General Hospital, Tampa, FL, ⁵University of Utah, Salt Lake City, UT, ⁶Intermountain Heart Institute, Murray, UT, ⁷Loyola University Medical Center, Maywood, IL, ⁸Duke University Medical Center, Durham, NC

2:30 PM (151) HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure - CE Mark Study 2-Year Results; J. D. Schmitto¹, Y. Pya², D. Zimpfer³, T. Krabatsch⁴, J. Garbade⁵, V. Rao⁶, M. Morshuis⁷, F. Beyersdorf⁸, S. Marasco⁹, P. Sood¹⁰, L. Damme¹⁰, I. Netuka¹¹. ¹Hannover Medical School, Hannover, Germany, ²National Research Cardiac Surgery Center, Astana, Kazakhstan, ³University of Vienna, Vienna, Austria, ⁴German Heart Center, Berlin, Germany, ⁵Heart Center Leipzig, Leipzig, Germany, ⁶Toronto General Hospital, Toronto, ON, Canada, ⁷Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany, ⁸University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany, ⁹The Alfred Hospital, Melbourne, Australia, ¹⁰St. Jude Medical Inc., St. Paul, MN, ¹¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic

2:45 PM (152) A Prospective, Controlled, Un-Blinded, Multi-Center Clinical Trial to Evaluate the Thoracotomy Implant Technique of the HVAD System in Patients with Advanced Heart Failure: Results of the LATERAL Trial; M. R. Danter¹, E. C. McGee², M. Strueber³, S. Maltais⁴, N. A. Mokadam⁵, G. M. Weisenthaler⁶, K. Leadley⁷, S. W. Boyce⁸, A. Cheung⁹. ¹Vanderbilt University Medical Center, Nashville, TN, ²Loyola University Medical Center, Maywood, IL, ³Spectrum Health, Grand Rapids, MI, ⁴Mayo Clinic, Rochester, MN, ⁵University of Washington, Seattle, WA, ⁶University of California San Francisco, San Francisco, CA, ⁷HeartWare, Framingham, MA, ⁸MedStar Health, Washington, DC, ⁹University of British Columbia, Vancouver, BC, Canada

3:00 PM (153) Quality of Life and Functional Capacity Assessment in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3(Momentum 3) Pivotal Trial; J. A. Cowger¹, Y. Naka², K. Aaronson³, D. Horstmannshoff⁴, S. Gulati⁵, D. Rinde-Hoffman⁶, S. Pinney⁷, S. Adaty⁸, D. J. Farrar⁹, U. P. Jorde¹⁰. ¹St. Vincents Hospital, Indianapolis, IN, ²Columbia University Medical Center, New York, NY, ³University of Michigan Medical Center, Ann Arbor, MI, ⁴Integris Baptist Medical Center, Oklahoma City, OK, ⁵Carolinas Medical Center, Charlotte, NC, ⁶Tampa General Hospital, Tampa, FL, ⁷Mt. Sinai Hospital, New York, NY, ⁸University of Chicago Medical Center, Chicago, IL, ⁹St. Jude Medical, Pleasanton, CA, ¹⁰Montefiore Medical Center, Bronx, NY

3:15 PM (154) Impact of Adherence to Standard Practice Guidelines for Patients Receiving a Left Ventricular Assist Device - Insights from the PREVENT Study; J. N. Katz¹, S. Emami², G. Egnaczyk³, E. Adler⁴, J. Chin⁵, P. Shah⁶, A. Brieke⁷, M. Keebler⁸, S. Nathan⁹, I. Gregoric⁹, D. Crandall¹⁰, D. J. Farrar¹⁰, K. S. Sundareswaran¹⁰, S. Maltais¹¹. ¹Division of Cardiology, University of North Carolina, Chapel Hill, NC, ²Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH, ³Christ Hospital, Cincinnati, OH, ⁴Division of Cardiovascular Medicine, University of California - San Diego, San Diego, CA, ⁵Sutter Medical Center, Sacramento, CA, ⁶Inova Heart and Vascular Institute, Falls Church, VA, ⁷University of Colorado School of Medicine, Denver, CO, ⁸Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN, ⁹Memorial Hermann – Texas Medical Center, Houston, TX, ¹⁰St. Jude Medical, Pleasanton, CA, ¹¹Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN

2:00 PM - 3:30 PM

ORAL SESSION 14: Measure for Measure: In- and Ex-Vivo Cellular and Molecular Approaches for Thoracic Organ Tailoring

Location:

Grand Hall A

Target Audience:

BSTR, HF, HTX, LTX, MCS, NNSAH, PATH, PEDS, PHARM

Chairs:

Simon Pecha, MD, and Lori J West, MD, DPhil

2:00 PM (155) *Advanced Theranostics in Ex-Vivo Lung Bioengineering*; B. A. Guenthart¹, J. D. O'Neill², J. Kim², G. Vunjak-Novakovic³, M. Bacchetta¹. ¹Thoracic Surgery, Columbia University, New York, NY, ²Biomedical Engineering, Columbia University, New York, NY, ³Biomedical Engineering & Medicine, Columbia University, New York, NY

2:15 PM (156) *Mesenchymal Stem Cell Therapy for Ex Vivo Repair of Ischemic Injury in Pig Donor Lungs*; D. Nakajima¹, Y. Watanabe¹, A. Ohsumi¹, M. Pipkin¹, M. Chen¹, P. Mordant¹, T. Kanou¹, G. Zehong¹, R. Lam¹, R. Coutinho¹, L. Caldarone¹, R. K. Lyer², J. E. Davies², T. K. Waddell¹, M. Cypel¹, M. Liu¹, S. Keshavjee¹. ¹Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Tissue Regeneration Therapeutics Inc, Toronto, ON, Canada

2:30 PM (157) *Hypoxia Inducible Factor 1 Alpha Mediates Apoptotic Cell Death in the DCD Heart Following Prolonged Exposure to Warm Ischemia*; A. A. Ali¹, P. Downey², A. Zalewski², K. J. Clerkin², I. George³, P. C. Colombo², S. Messer¹, S. R. Large¹, Z. A. Ali². ¹Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom, ²Cardiology, Columbia University, New York, NY, ³Cardiothoracic Surgery, Columbia University, New York, NY

2:45 PM (158) *Extending the Boundaries of DCD Heart Transplantation: Improved Functional Recovery of DCD Hearts Exposed to Prolonged Warm Ischemia by Inhibition of Histone Deacetylase*; A. A. Ali¹, P. Downey², A. Zalewski², K. J. Clerkin², I. George³, P. C. Colombo², S. Messer¹, S. Large¹, Z. A. Ali². ¹Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom, ²Cardiology, Columbia University, New York, NY, ³Cardiothoracic Surgery, Columbia University, New York, NY

3:00 PM (159) *Donor Organ Pretreatment with a Gap and Tight Junction Stabilizing Peptide Prevents IRI in a Mouse Lung Transplant Model*; Q. Cheng¹, K. Patel¹, P. Zhu², L. Rucker¹, P. Allen¹, C. Vasu¹, S. Nadig¹, C. Atkinson¹. ¹Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, ²Department of Surgery, Tongji Hospital, Wuhan, China

3:15 PM (160) *Normothermic Donor Lung Preservation Using the Organ Care System Significantly Reduces Ischemia/Reperfusion Injury by Promoting Cytokine Antagonists*; B. Wiegmann¹, C. Falk², M. Seyda², C. Neudoerfl², C. Kühn¹, I. Tudorache¹, M. Avsar¹, A. Haverich¹, G. Warnecke¹. ¹Dpt. for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

2:00 PM - 3:30 PM

ORAL SESSION 15: Therapies and Monitoring After Heart Transplantation

Location:

Grand Hall B

Target Audience:

HTX, BSTR, NNSAH, PHARM

Chairs:

Todd F Dardas, MD, and Mustafa Toma, MD

2:00 PM (165) *Metformin Treatment After Heart Transplantation Is Associated with Reduced Malignancy Rate*; Y. Peled¹, J. Lavee¹, E. Raichlin², M. Katz¹, M. Arad¹, Y. Shemesh¹, Y. Kassif¹, E. Asher¹, D. Elia¹, Y. Har-Zahav¹, N. Shlomo¹, D. Freimark¹, I. Goldenberg¹, R. Klempfner¹. ¹Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, ²University of Nebraska Medical Center, Omaha, NE

2:15 PM (162) *High Sensitivity Troponin Assays Can Decrease the Frequency of Endomyocardial Biopsy After Heart Transplantation*; S. Fitzsimons¹, J. Parameshwar¹, N. Mills², S. Pettit¹. ¹Transplant Unit, Papworth Hospital, Papworth, United Kingdom, ²BHF Centre for Cardiovascular Sciences, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

2:30 PM (163) *Cluster Analysis and Dynamic Phenomapping to Guide Clinical Management After Heart Transplantation*; M. Bakir, N. Jackson, S. Han, C. Tseng, E. Chang, T. Khuu, A. Bui, Q. Zhang, E. Reed, D. Liem, B. Kubak, J. Schaenman, A. Ardehali, R. Ardehali, A. Baas, A. Nsair, D. Cruz, M. Kwon, E. DePasquale, M. Deng, M. Cadeiras. *Cardiology, UCLA, Los Angeles, CA*

2:45 PM (164) *Effect of Donor Simvastatin Treatment on Cardiac Allograft Ischemia-Reperfusion Injury - 30-Day Analysis of a Randomized Prospective Single-Center Clinical Trial*; A. I. Nykanen¹, E. Holmström², S. Syrjälä², J. Jokinen¹, R. Krebs², K. B. Lemström¹. ¹Cardiac Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland

3:00 PM (161) *Analysis of Donor-Derived Cell-Free DNA with 3-Year Outcomes in Heart Transplant Recipients*; M. Crespo-Leiro¹, D. Hiller², R. Woodward², M. Grskovic², C. Marchis², M. Song², J. Collins², A. Zuckermann³. ¹Hospital Universitario de A Coruña, La Coruña, Spain, ²CareDx, Brisbane, CA, ³Medical University of Vienna, Vienna, Austria

3:15 PM (166) *Does Induction Therapy for Heart Transplant Recipients on Tacrolimus/Mycophenolate/Prednisone Improve Survival in the Current Allocation Era?*; A. A. Amin¹, V. K. Ariyamuthu², M. A. Urey¹, F. G. Araj¹, M. H. Drazner¹, P. P. Mammen¹, B. Tanriover². ¹Cardiology, UT Southwestern, Dallas, TX, ²Nephrology, UT Southwestern, Dallas, TX

2:00 PM - 3:30 PM

ORAL SESSION 16: The Rise of the Machines: ECLS and EVLP in Lung Transplantation

Location:

Grand Hall C

Target Audience:

LTX, BSTR, EEP, ID, LTX, MCS, NNSAH, PATH, PHARM

Chairs:

Goran Dellgren, MD, PhD, and Marc De Perrot, MD

2:00 PM (167) *ECLS Bridge to Lung Transplantation: A Review of Our Institutional Experience*; A. Benazzo, G. Tukora, S. Schwarz, K. Hoetzenecker, B. Moser, J. Matilla Sigueenza, S. Taghavi, P. Jaksch, W. Klepetko, G. Lang. *Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

2:15 PM (168) *ECMO Prior to Lung Transplantation Does Not Impact Health-Related Quality of Life (HRQL) After Transplant*; N. A. Kolaitis, D. Huang, A. Soong, P. Shrestha, J. Golden, L. E. Leard, R. J. Shah, M. E. Kleinhenz, J. R. Greenland, P. P. Katz, P. D. Blanc, S. R. Hays, J. Kukreja, J. P. Singer. *University of California, San Francisco, San Francisco, CA*

2:30 PM (169) *Enhanced Organ Procurement with Resuscitation of Highly Marginal Donors with the Vivoline Ex Vivo Lung Perfusion System*; C. Divithotawela, D. C. Chambers, S. Yerkovich, P. Hopkins. *Queensland Lung Transplant Service, The Prince Charles Hospital, Chermside, Australia*

2:45 PM (170) *Treatment of Hepatitis C in Donor Lungs Using Ex Vivo Lung Perfusion*; M. Galasso, M. Pipkin, Y. Watanabe, D. Nakajima, C. Summers, R. Qaquis, A. Ali, A. Ohsumi, A. Gazzalle, T. K. Waddell, M. Liu, S. Keshavjee, M. Cypel. *Latner Thoracic Surgery Laboratories, University Health Network, Toronto, ON, Canada*

3:00 PM (171) *Improved Outcomes with Negative Pressure Ventilation (NPV) During Normothermic Ex Vivo Lung Perfusion*; N. Aboelnazar¹, S. Himmat¹, S. Hatami¹, C. W. White², D. H. Freed³, J. Nagendran³. ¹*Experimental Surgery, University of Alberta, Edmonton, AB, Canada*, ²*Cardiac Surgery Resident, University of Alberta, Edmonton, AB, Canada*, ³*Division of Cardiac Surgery, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada*

3:15 PM (172) *High Levels of Cytokines in the Perfusate During Ex-Vivo Lung Perfusion Correlates with Persistence of Poor Graft Function After Lung Transplantation Using Reconditioned Grafts*; M. Boffini, V. Fanelli, E. Simonato, D. Ricci, P. Solidoro, P. Lausi, C. Barbero, L. Brazzi, M. Rinaldi. *Surgical Sciences Department, University of Turin, Turin, Italy*

2:00 PM - 3:30 PM

ORAL SESSION 17: What's Up Next in Pulmonary Hypertension Research?

Location:

Grand Hall D

Target Audience:

PH, BSTR, HF, LTX

Chairs:

Dana P McGlothlin, MD, and David L Joyce, MD

2:00 PM (173) Human Right Ventricular Myofilaments Exhibit Directionally Opposite Changes in Maximal Force and Calcium Sensitivity in Systemic Sclerosis-Associated versus Idiopathic Pulmonary Arterial Hypertension; S. Hsu¹, J. A. Kirk², C. J. Mullin³, M. Mukherjee¹, T. M. Kolb³, R. L. Damico³, S. C. Mathai³, A. A. Shah⁴, F. M. Wigley⁴, K. B. Margulies⁵, P. M. Hassoun³, R. J. Tedford¹, D. A. Kass¹. ¹Cardiology, Johns Hopkins University, Baltimore, MD, ²Cell and Molecular Physiology, Loyola University Chicago Stritch School of Medicine, Chicago, IL, ³Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA

2:15 PM (174) In-Vivo Study of a Novel Long-Term Lung Support Device for PAH, Bridge-to-Transplant and Bridge-to-Candidacy; R. Borchardt¹, S. Sonntag¹, P. Ritter¹, F. Boehning¹, S. Groß-Hardt¹, F. Hesselmann¹, U. Steinseifer², T. Verbelen³, B. Meyns³, T. Kaufmann¹. ¹enmodes GmbH, Aachen, Germany, ²Dept. of Cardiovascular Engineering, Institute of Applied Medical Engineering, RWTH Aachen University, Aachen, Germany, ³Dept. of Cardiovascular Science, KU Leuven, Leuven, Belgium

2:30 PM (175) Lung Allocation Score Is Not Predictive of Post-Transplant Survival Among Pulmonary Hypertension Lung Transplant Recipients; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

2:45 PM (176) Surgical Series of 370 Cases of Pulmonary Thromboendarterectomy: Experience from the Indian Subcontinent; V. Shetty, J. Punnen, D. P. Shetty. Cardiac Surgery, Narayana Institute of Cardiac Sciences, Bangalore, India

3:00 PM (177) Implications of PAP Changes from Right Heart Catheterization to Lung Transplantation; S. Biswas Roy¹, R. Panchanathan², E. Todd¹, P. Kang³, R. Walia¹, R. M. Bremner¹, M. A. Smith⁴. ¹Norton Thoracic Institute; St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²University of Arizona Medical School, Phoenix, AZ, ³University of Arizona College of Public Health, Phoenix, AZ, ⁴Norton Thoracic Institute, Phoenix, AZ

3:15 PM (178) Incremental Benefit of Cardiopulmonary Exercise Testing for the Prediction of Outcome in Stable Prevalent Pulmonary Arterial Hypertension Patients; R. Badagliacca¹, S. Papa¹, R. Poscia¹, G. Valli¹, B. Pezzuto¹, G. Manzi¹, P. Palange², F. Fedele¹, C. D. Vizza¹. ¹Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, ²Clinical Medicine, Sapienza University of Rome, Rome, Italy

2:00 PM - 3:30 PM

ORAL SESSION 18: Contemporary Challenges in Pediatric Heart Transplant

Location:

Seaport F-H

Target Audience:

PEDS, HTX, PATH

Chairs:

Steven C Greenway, MD, and Tajinder P Singh, MD, MSc

2:00 PM (179) Pediatric Marginal Donor Hearts: National Use and Center-Specific Variability; A. K. Morrison¹, D. Tumin², D. Hayes, Jr.³, C. Phelps¹, J. Tobias², R. J. Gajarski¹, D. Nandi¹. ¹The Heart Center, Nationwide Children's Hospital, Columbus, OH, ²Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, ³Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH

2:15 PM (180) Hearts Transplanted After Circulatory Death in Children: Analysis of the International Society for Heart and Lung Transplantation Registry; J. Kleinmahon¹, S. Patel¹, S. Auerbach¹, J. Stehlik², J. Rossano³, M. Everitt¹. ¹Cardiology, Children's Hospital Colorado, Denver, CO, ²Cardiology, University of Utah Hospital, Salt Lake City, UT, ³Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA

2:30 PM (181) Use of Decellularized Cryopreserved Allografts During Single Ventricle Reconstruction Results in Lower HLA Sensitization Than Standard Allograft; H. M. Lim¹, J. Friedland-Little², S. Yu¹, R. E. Lowery¹, R. J. Gajarski³, R. G. Ohye⁴, K. R. Schumacher¹. ¹Department of Pediatric Cardiology, University of Michigan, C.S Mott Children's Hospital, Ann Arbor, MI, ²Department of Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, ³Department of Pediatric Cardiology, Nationwide Children's Hospital, Columbus, OH, ⁴Department of Cardiac Surgery, University of Michigan, C.S Mott Children's Hospital, Ann Arbor, MI

2:45 PM (182) Impact of Newly Detected Donor Specific Anti-HLA Antibody in the First Year After Pediatric Heart Transplantation; A. I. Dipchand¹, S. Webber², K. Much³, B. Feingold⁴, C. Bentelejewski⁵, E. D. Blume⁶, R. Shaddy⁷, C. Canter⁸, J. Lamour⁹, W. Mahle¹⁰, W. Zuckerman¹¹, H. Diop¹², Y. Morrison¹³, B. Armstrong³, D. Ikle³, J. Odum¹³, A. Zeevi¹⁴, T. CTOTC-04 Investigators¹³. ¹Hosp for Sick Children, Toronto, ON, Canada, ²Vanderbilt Univ, Nashville, TN, ³Rho, Chapel Hill, NC, ⁴Children's Hospital of Pittsburgh, Pittsburgh, PA, Canada, ⁵Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁶Children's Hospital Boston, Boston, MA, Canada, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸St Louis Children's Hospital, St Louis, MO, ⁹Montefiore Children's Hospital, New York, NY, ¹⁰Children's Healthcare of Atlanta, Atlanta, GA, ¹¹Children's Hospital of New York, New York, NY, ¹²NIAID, Bethesda, MD, Canada, ¹³NIAID, Bethesda, MD, ¹⁴Univ of Pittsburgh, Pittsburgh, PA

3:00 PM (183) HLA Eplet Mismatching Is Associated with Increased Risk of Graft Loss in Pediatric Heart Transplant Recipients; E. Albers¹, N. Jorgensen², J. Friedland-Little¹, B. Hong¹, M. Kemna¹, P. Warner³, Y. Law¹. ¹Seattle Children's Hospital, Seattle, WA, ²University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA

3:15 PM (184) Predicting Cardiac Allograft Vasculopathy Using Circulating Vascular Endothelial Growth Factor in Pediatric Heart Transplant Recipients; K. Watanabe, S. D. Miyamoto, S. J. Nakano. School of Medicine, University of Colorado Denver, Aurora, CO

2:00 PM - 3:30 PM

ORAL SESSION 19: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best

Location: Coronado A-C

Target Audience: ALL

Chairs: Duane Davis, MD, MBA, and Hirsch S Mehta, MD

2:00 PM (185) *Driving an Electric Car Before You're Old Enough To Get A Licence*; D. S. Burstein¹, D. Nandi², J. W. Gaynor¹, J. W. Rossano¹. ¹*Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA*, ²*Pediatric Cardiology, Nationwide Children's Hospital, Columbus, OH*

2:05 PM *Expert Senior Discussant (Pediatric Transplantation)*

Elfriede Pahl, MD, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

2:09 PM *Moderated Discussion*

2:15 PM (186) *Doing Your Best to Keep the Germs Away*; T. Sam¹, S. Wada², S. M. Joseph³, J. F. Trotter¹, S. K. Asrani¹, B. Lima³, G. Gonzalez-Stawinski³, S. A. Hall³, R. L. Gottlieb³. ¹*Baylor Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Dallas, TX*, ²*Transplant Infectious Diseases, Baylor University Medical Center, Dallas, Dallas, TX*, ³*Baylor Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Dallas, TX*

2:20 PM *Expert Senior Discussant (Infectious Diseases)*

Stanley I. Martin, MD, Geisinger Health System, Danville, PA, USA

2:24 PM *Moderated Discussion*

2:30 PM (187) *When Phoning It In Becomes the New Normal*; R. J. Cogswell¹, T. B. Freitag¹, C. A. Lilla², R. John³. ¹*Cardiology, University of Minnesota, Minneapolis, MN*, ²*Nursing, Fairview - University of Minnesota Medical Center, Minneapolis, MN*, ³*Cardiovascular Surgery, University of Minnesota, Minneapolis, MN*

2:35 PM *Expert Senior Discussant (Mechanical Circulatory Support)*

Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

2:39 PM *Moderated Discussion*

2:45 PM (188) *The Logistics of Staffing Clinic From Home*; S. Airhart¹, C. Walters¹, N. Verlinden¹, P. Correa¹, V. Franco², A. Raina¹, R. Benza¹. ¹*Allegheny General Hospital, Pittsburgh, PA*, ²*Ohio State University, Columbus, OH*

2:50 PM *Expert Senior Discussant (Pulmonary Hypertension)*

Myung H. Park, MD, Houston Methodist, Houston, TX, USA

2:54 PM *Moderated Discussion*

3:00 PM (189) *Safety During a Transition of Power*; Y. Peled, Y. Har-Zahav, Y. Kassif, Y. Shemesh, D. Freimark, J. Lavee. *Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel*

3:05 PM *Expert Senior Discussant (Heart Failure/Transplantation)*

Steven SL Tsui, MD, FRCS, Papworth Hosp NHS Trust, Cambridge, United Kingdom

3:09 PM *Moderated Discussion*

3:15 PM (190) *How It Feels to Get Rejected Quickly*; G. L. Calligaro¹, N. Watson², M. Malouf¹, M. Plit¹, M. R. Qiu³, T. Shein³, M. Benzimra¹, A. Rigby¹, A. R. Glanville¹, A. Havryk¹. ¹*Lung Transplantation, St. Vincent's Hospital, Sydney, Australia*, ²*Tissue Typing Laboratory, Australian Red Cross, Sydney, Australia*, ³*Anatomical Pathology, St. Vincent's Hospital, Sydney, Australia*

3:20 PM *Expert Senior Discussant (Lung Failure/Transplantation)*

Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

3:24 PM *Moderated Discussion*

4:00 PM - 6:00 PM
SYMPOSIUM 17: To Pulse or Not To Pulse? That is the Question

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Paolo Colombo, MD, and Bart Meyns, MD, PhD

Session Summary: Human evolution has favored a pulsatile heart pump as the optimal way for organ perfusion. CF-LVAD physiology, with low to no pulsatility, has challenged that widely accepted notion. Although the present technology had been rapidly adapted, we are still hampered by morbidities that limit the expansion into the less sick group. Are we missing the pulse? Thus, methods to generate pulsatility and possibly create a hybrid between the man-made and mankind are presently being explored. A 15-minute panel discussion with all speakers will conclude this session.

4:00 PM
Physiologic and Clinical Impact of Pulsatile vs. Nonpulsatile Flow on Blood Vessels and Vital Organs
Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

4:15 PM
Physiologic and Clinical Impact of Pulsatile vs. Nonpulsatile Flow on the Brain
William K Cornwell, MD, University of Colorado, Denver, CO, USA

4:30 PM
Best Strategies to Measure Arterial Pulsatility and Tissue Perfusion in CF-LVAD Patients
Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

4:45 PM
Design and Rationale for New Pulsatile Technology
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

5:00 PM
Hemodynamic Effects of Counterpulsation
Navin K Kapur, MD, Tufts Medical Center, Boston, MA, USA

5:15 PM
Long-term Ambulatory Counterpulsation Using iVAS
Val Jeevanandam, MD, University of Chicago Medicine, Chicago, IL, USA

5:30 PM
The Pulse of Life - A Scientific and Existential Perspective
Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital / Harvard Medical School, Boston, MA, USA

5:45 PM *Panel Discussion*

4:00 PM - 6:00 PM

SYMPOSIUM 18: Weeding Out Fact from Fiction - the Highs and Lows of Marijuana Use in Transplant

Location:

Grand Hall A

Target Audience:

PHARM, ALL

Chairs:

Adam Cochrane, PharmD, and Vincent G. Valentine, MD

Session Summary: Increasing prevalence of medicinal and recreational cannabis use among transplant recipients has sparked discussion on the legal and safety ramifications of cannabis use in this patient population. This symposium will discuss the pharmacology of cannabis as well as explore the data surrounding the legal ramifications and risk/benefits of cannabis use in transplantation.

4:00 PM

The Pharmacology of a Weed: Clinical Pharmacology of Cannabis and Cannabinoids

Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

4:15 PM Q&A

4:20 PM

Cannabis: Wonder-Drug or Devil's Weed? The Psychosocial Impact of Cannabis Use Post-Transplant

Patrick Smith, PhD, Duke University Medical Center, Durham, NC, USA

4:35 PM Q&A

4:40 PM

Cannabis Use and Graft Function: What Do We Know?

Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada

4:55 PM Q&A

5:00 PM

But the Government Says I Can't; Regulatory Implications of Legalizing Cannabis

Lorriana E Leard, MD, UCSF Medical Center, San Francisco, CA, USA

5:15 PM Q&A

5:20 PM

DEBATE (PRO): Cannabis Use Pre-Transplant - Don't Judge Me!

Martin Zamora, MD, University of Colorado, Denver, CO, USA

5:35 PM

DEBATE (CON): Cannabis Use Pre-Transplant - Don't Judge Me!

Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

5:50 PM

DEBATE REBUTTAL (PRO)

Martin Zamora

5:55 PM

DEBATE REBUTTAL (CON)

Erik Am Verschuuren

4:00 PM - 6:00 PM

SYMPOSIUM 19: Cardiogenic Shock: Types, Teams and Tactics

Location:

Grand Hall B

Target Audience:

HF, HTX, MCS

Chairs:

Lynn R Punnoose, MD, and Marian Urban, MD

Session Summary: Cardiogenic shock encompasses a broad clinical spectrum, including acute MI, primary RV failure and biventricular failure. This session will incorporate individual presentations describing (1) the spectrum and prevalence of cardiogenic shock subtypes, (2) national and international approaches to management and temporary mechanical support selection, and (3) the interdisciplinary approach to device management involving heart failure, interventional, critical care and imaging cardiologists.

4:00 PM

Phenotypes of Cardiogenic Shock: How to Move Beyond Anecdotes to Estimate Subtype Prevalence

Shelley A. Hall, MD, Baylor University Medical Center, Dallas, TX, USA

4:15 PM Q&A

4:20 PM

Hemodynamics of Temporary MCS: Do They Help Guide Device Selection? What If You Don't Have Them?

Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

4:35 PM Q&A

4:40 PM

The Use of SHOCK Teams in Hospitals with Advanced Heart Failure Care

Jose N Nativi, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

4:55 PM Q&A

5:00 PM

Refractory Ventricular Tachycardia (VT) with Hemodynamic Compromise: Temporary Device Choice and Ablative Options

A Reshad Garan, MD, Columbia University, New York, NY, USA

5:15 PM Q&A

5:20 PM

Weaning Temporary Mechanical Circulatory Support: Echocardiographic vs. Hemodynamic Parameters - This Is How We Do It

Jamie L Kennedy, MD, University of Virginia Health System, Charlottesville, VA, USA

5:35 PM Q&A

5:40 PM

Weaning Temporary Mechanical Circulatory Support: Echocardiographic vs. Hemodynamic Parameters - This Is How WE Do It

Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

5:55 PM Q&A

4:00 PM - 6:00 PM

SYMPOSIUM 20: ECMO in Lung Transplantation: Sensational Success or Fantastic Failure?

Location:

Grand Hall C

Target Audience:

LTX, ALL

Chairs:

Erika Berman Rosenzweig, MD, and Reda E. Girgis, MD

Session Summary: This symposium gives a state-of-the art overview of current ECMO technology, including cannulation strategies, patient selection, peri-operative and program management.

4:00 PM

ECMO Technique: Configuration, Cannulae, Complications

Martin Strueber, MD, Michigan State University College of Human Medicine, East Lansing, MI, USA

4:20 PM Q&A

4:24 PM

ECMO Candidate Selection for Elective ECMO

Clemens Aigner, MD, Universität Duisburg-Essen, Essen, Germany

4:44 PM Q&A

4:48 PM

ECMO as Urgent Bridge to Transplant

Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

5:08 PM Q&A

5:12 PM

Post-Operative ECMO for Rescue Therapy

Göran Dellgren, MD, Sahlgrenska University Hospital, Göteborg, Sweden

5:32 PM Q&A

5:36 PM

ECMO Program Management: Bridge over Troubled Water?

David Michael McMullan, MD, Seattle Children's Hospital, Seattle, WA, USA

5:56 PM Q&A

4:00 PM - 6:00 PM

SYMPOSIUM 21: Cardiopulmonary Hemodynamics, the Right Ventricle, and the Kidney: Connecting All the Dots

Location:

Grand Hall D

Target Audience:

PH, HF, HTX, LTX, MCS

Chairs:

Ryan J Tedford, MD, and Marco Guazzi, MD, PhD

Session Summary: This symposium reviews hot topics in hemodynamic assessment and management of patients with pulmonary hypertension including measures of pulmonary vascular compliance, the emerging role of right ventricular reserve assessment, and the interaction between right heart and kidney function. In the final two talks, the speakers debate the need for provocative testing in patients meeting hemodynamic criteria for Group I PAH but who have all least some phenotypic characteristics of group II PH. A panel discussion with all speakers will conclude this session.

4:00 PM

Forget About Pulmonary Vascular Resistance (PVR), Only Pulmonary Vascular Compliance Matters

Kurt Prins, MD, University of Minnesota, Minneapolis, MN, USA

4:20 PM

No Time to Rest: The Importance of Right Ventricular Reserve in Pulmonary Hypertension

Ryan J. Tedford, MD, Johns Hopkins, Baltimore, MD, USA

4:40 PM

The Cardiorenal Syndrome in Right Heart Failure: Just Central Venous Pressure (CVP) or More to the Story?

Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

5:00 PM

Case Presentation: Age >65, mPAP>25mmHg, Borderline Pulmonary Artery Wedge Pressure (PAWP)

Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

5:05 PM

DEBATE (PRO): It is Essential to Unmask PH due to Left Heart Disease (LHD) with Volume Loading and/or Exercise Testing

Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

5:25 PM

DEBATE (CON): It is Essential to Unmask PH due to Left Heart Disease (LHD) with Volume Loading and/or Exercise Testing

Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada

5:45 PM *Panel Discussion*

4:00 PM - 6:00 PM

SYMPOSIUM 22: Let's Get Personal! Precision Diagnostics in Thoracic Transplantation

Location:

Seaport F-H

Target Audience:

PATH, ALL

Chairs:

Patrick Bruneval, MD, and Sean Agbor-Enoh, MD

Session Summary: In recent years, methodologies of precision medicine have been applied to the study of post-transplant pathobiology. Basic molecular mechanisms involved in acute and chronic allograft rejection have been uncovered, and novel molecular tools for the non-invasive monitoring of heart and lung transplantation have been discovered. This symposium brings together state-of-the-art scientific speakers who lead the field as we make a transition to personalized transplant care.

4:00 PM

Precision Medicine: Applying Circulating Cell-Free DNA to Monitor Transplant Health Outcomes

Hannah Valantine, MD, National Institutes of Health, Bethesda, MD, USA

4:15 PM Q&A

4:20 PM

How to Use the Virome to Monitor Post-Transplant Immune Status

Iwijn De Vlaminck, PhD, Cornell University, Ithaca, NY, USA

4:35 PM Q&A

4:40 PM

Tissue and Circulating Long-Noncoding RNA and MicroRNA in Thoracic Transplantation

Howard J Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, USA

4:55 PM Q&A

5:00 PM

Transcriptomic Analysis of Endomyocardial Biopsies for Precision Diagnosis

Jean-Paul Duong Van Huyen, MD, Hospital Necker, Paris, France

5:15 PM Q&A

5:20 PM

Next Generation Sequencing and Signatures: Applications in Transplant Diagnostics

Bruce McManus, MD, PhD, St. Paul's Hospital, Vancouver, BC, Canada

5:35 PM Q&A

5:40 PM

The Future of Precision Medicine: Genome Editing Using CRISPR/Cas9 Technology

Christof Fellmann, PhD, University of California, Berkeley, CA, USA

5:55 PM Q&A

4:00 PM - 6:00 PM

SYMPOSIUM 23: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation

Location:

Coronado A-C

Target Audience:

ID, ALL

Chairs:

Jens Gottlieb, MD, and Me-Linh Luong, MD

Session Summary: Mycobacterium abscessus is increasingly isolated pre- and post-lung transplant (LT). It causes a wide spectrum of infection including disseminated post-LT. Pre-LT isolation is a risk for post-LT infection and patient-to-patient transmission may occur. It is resistant to many antibiotics. Prolonged combination therapy is required and side-effects are frequent. Thus, many centers consider M. abscessus a contra-indication to LT. Good outcomes appear linked to aggressive peri-operative management. A 10-minute panel discussion with all speakers will conclude this session.

4:00 PM

Epidemiology and Modes of Transmission

Cameron Wolfe, MD, Duke University, Durham, NC, USA

4:15 PM Q&A

4:20 PM

Clinical Manifestations, Diagnosis and Antimicrobial Susceptibility

Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

4:35 PM Q&A

4:40 PM

Management of M. Abscessus in the Lung Transplant Candidate: Preparation for Transplantation

Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

4:55 PM Q&A

5:00 PM

Antimicrobial Therapy of M. Abscessus: Current and Novel Agents

Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

5:15 PM Q&A

5:20 PM

DEBATE (PRO): Patients with M. Abscessus Can Be Safely Transplanted

Gregory I Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

5:35 PM

DEBATE (CON): Patients with M. Abscessus Can Be Safely Transplanted

Paul Corris, MB FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:50 PM Panel Discussion

Friday, April 07, 2017

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 07: Getting to the Heart of Muscular Dystrophies

Location:

Grand Hall A

Target Audience:

ALL

Chairs:

Forum Kamdar, MD, PhD, and Takeshi Nakatani, MD, PhD

Session Summary: Neuromuscular disorders result in significant skeletal muscle weakness and increasingly severe cardiomyopathy. The objectives of this session are to identify cardiomyopathy as a common sequela of neuromuscular disorders, review current medical therapies for treating heart failure in this unique population, and discuss the use of advanced heart failure therapies such as cardiac transplantation and LVADs for pediatric and adult patients with end-staged neuromuscular cardiomyopathy.

7:00 AM

Heart Failure in Muscular Dystrophies: No Longer Just a Skeletal Muscle Disorder

Forum Kamdar, MD, PhD, University of Minnesota Medical Center, Minneapolis, MN, USA

7:10 AM Q&A

7:15 AM

Heart Failure Medical Treatment for Muscular Dystrophy: When and How to Treat

Denis Duboc, MD, CHU Paris Centre, Hospital Cochin, Paris, France

7:25 AM Q&A

7:30 AM

Mechanical Circulatory Support in Muscular Dystrophy Cardiomyopathy

Antonio Amodio, MD, Bambino Gesù Pediatric Hospital, Rome, Italy

7:40 AM Q&A

7:45 AM

Cardiac Transplantation in Muscular Dystrophies

Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 08: Live Long and Prosper: Thriving After Pediatric Transplantation

Location:

Grand Hall B

Target Audience:

PEDS, EEP, HF, HTX, LTX, MCS, NNSAH, PHARM

Chairs:

Caron L Burch, MSN, and Estela Azeka, MD

Session Summary: The session will focus on the psychosocial, behavioral challenges as well as communication and developmental issues in pediatric transplant patients. Specific attention will be given to adolescence and models for transition.

7:00 AM

Neurodevelopmental Outcomes after Pediatric Cardiothoracic Transplant

Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

7:10 AM Q&A

7:15 AM

Keep Moving! Physical Exercise and Competitive Sports After Pediatric Transplantation

Kari Nytroen, PhD, Oslo University Hospital Rikshospitalet, Oslo, Norway

7:25 AM Q&A

7:30 AM

Nobody Understands Me! Communication Strategies to Reach Teenagers and Young Adults

Melissa Cousino, PhD, University of Michigan Transplant Center, Ann Arbor, MI, USA

7:40 AM Q&A

7:45 AM

Transitioning to Adult Care: Does Anything Work?

Jonathan N Johnson, MD, Mayo Clinic, Rochester, MN, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 09: Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier

Location:

Grand Hall C

Target Audience:

PATH, BSTR, HF, HTX

Chairs:

Gerald J. Berry, MD, and Marny Fedrigo, MD, PhD

Session Summary: Cellular rejection and antibody mediated rejection are well-characterized. These two forms of rejection are most often considered separately, if not mutually exclusive. Increasingly, an overlap in features of these two rejection patterns is being noted (coined "mixed rejection"). Insights into the immune mechanisms of rejection may be gleaned from a better understanding of mixed rejection. A panel discussion with all speakers will conclude this session.

7:00 AM

T- and B-cell Immunity in Mixed Rejection: Time to Tango

Anne Halpin, MSc, University of Alberta, Edmonton, AB, Canada

7:15 AM

Is the Pathology of Mixed Rejection More Than Just ACR + AMR? See for Yourself

Dylan Miller, MD, Intermountain Central Laboratory, Salt Lake City, UT, USA

7:30 AM

Clinical Insights into the Behavior of Mixed Rejection in Heart Transplantation

A. G Kfoury, MD, FACC, Intermountain Medical Center, Murray, UT, USA

7:45 AM *Panel Discussion*

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 10: Contrasts and Similarities in Children and Adults: IPAH, Portopulmonary Hypertension, and Perioperative Management

Location:

Grand Hall D

Target Audience:

PH, BSTR, HF, LTX, NNSAH, PEDS, PHARM

Chairs:

Jean-Luc Vachery, MD, and Brian Feingold, MD

Session Summary: This symposium will provide attendees with details on current management of pulmonary arterial hypertension (PAH) in adults and children. Three different clinical scenarios are discussed: idiopathic PAH, portopulmonary PAH, and perioperative PAH care. A panel discussion with all speakers will conclude this session.

7:00 AM

New Treatment Paradigms in IPAH Management in Children: How do we extrapolate data from Adults?

Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

7:15 AM

Challenges in Portopulmonary hypertension: Different in Children?

Michel De Pauw, MD, Ghent University Hospital, Ghent, Belgium

7:30 AM

Peri-operative Management of Infants, Children, and Adolescents with Pulmonary Vascular Disease: "Tried as an Adult"?

Ernestina Melicoff-Portillo, MD, Baylor College of Medicine, Houston, TX, USA

7:45 AM *Panel Discussion*

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 11: There is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation

Location:

Seaport F-H

Target Audience:

LTX, ID, NNSAH, PEDS

Chairs:

Rupal Shah, MD, and Daniel C. Chambers, MBBS, MRCP, FRACP, MD

Session Summary: Selection of lung transplant recipients is challenging, often due to limitations of current selection criteria. This sunrise symposium highlights cutting edge research and practical knowledge on physiologic factors, psychological features and non-standard, controversial or rare transplant indications to assist in selecting lung transplant recipients.

7:00 AM

Identifying the Right Candidate: Body Composition, Physiologic Frailty and Age

Jonathan P Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA

7:17 AM Q&A

7:20 AM

Psychological and Neurocognitive Frailty: Effect on Transplant Outcomes

James A Blumenthal, PhD, Duke University Medical Center, Durham, NC, USA

7:37 AM Q&A

7:40 AM

"Extended Criteria" Recipients: How Far Should We Go?

Jens Gottlieb, PhD, Hannover Medical School, Hannover, Germany

7:57 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 12: HIV and Transplantation: It Isn't Going Away...

Location:

Coronado A-C

Target Audience:

PHARM, HTX, ID, LTX, NNSAH, PEDS, PH

Chairs:

Patricia Uber, PharmD, and Joanna M. Schaenman, MD, PhD

Session Summary: This session will review end-stage heart and lung diseases associated with HIV and discuss key infectious diseases and pharmacotherapy management considerations in both the transplant and post-transplant phases of care. Lastly, HIV to HIV transplantation in the cardio-thoracic population will be discussed.

7:00 AM

The ART and Science of HIV Associated Cardiomyopathy

Marco Masetti, MD, Malpighi University Hospital, Bologna, Italy

7:10 AM Q&A

7:15 AM

HIV Associated Pulmonary Arterial Hypertension: True, True and Related

Robert Frantz, MD, Mayo Clinic, Minneapolis, MN, USA

7:25 AM Q&A

7:30 AM

HIV: the ID Perspective on the Donor and Recipient

Valentina Stosor, MD, Northwestern University, Chicago, IL, USA

7:40 AM Q&A

7:45 AM

A Delicate Balance: Management of Transplant Meds, HIV Meds, and ID Prophylaxis Meds

Christine Hui, PharmD, UCSF Medical Center, San Francisco, CA, USA

7:55 AM Q&A

8:00 AM - 9:30 AM

ORAL SESSION 20: New and Improving? Evolving Outcomes with MCS

Location:

Seaport A-E

Target Audience:

MCS, EEP, HF, HTX, NNSAH

Chairs:

Claudius Mahr, DO, and Patricia P Chang, MD

8:00 AM (263) *Clinical Outcomes with Heartmate 3 as Treatment for Advanced HF: First Data from the European ELEVATE Registry*; F. Gustafsson¹, M. Morshuis², D. Zimpfer³, J. Lavee⁴, T. Krabatsch⁵, S. Shaw⁶, D. Saeed⁷, L. Damme⁸, J. Garbade⁹. ¹Rigshospitalet, Copenhagen, Denmark, ²HDZ NRW, Bad Oeyenhausen, Germany, ³Medical University Vienna, Vienna, Austria, ⁴Sheba Medical Center, Ramat Aviv, Israel, ⁵Deutsches Herz Zentrum, Berlin, Germany, ⁶Wythenshawe Hospital, Manchester, United Kingdom, ⁷Heinrich-Heine Universität Düsseldorf, Dusseldorf, Germany, ⁸St Jude Medical, Zaventem, Belgium, ⁹Herzzentrum Leipzig GmbH, Leipzig, Germany

8:15 AM (264) *Bridging to Transplantation with Contemporary Continuous-Flow Left Ventricular Assist Devices: A Decade Experience*; L. K. Truby, R. Givens, A. R. Garan, M. Yuzefpolskaya, M. Flannery, H. Takayama, K. Takeda, J. Haythe, F. Latif, S. Restaino, M. Maurer, D. M. Mancini, Y. Naka, M. Farr, P. C. Colombo, V. K. Topkara. *Columbia University College of Physicians and Surgeons, New York, NY*

8:30 AM (265) *Five-Year Outcome in Patients Treated with Heart Transplantation with Advanced Age Donors versus Patients on Waiting List for Heart Transplantation Implanted with Left Ventricular Assist Device*; E. Ammirati, M. Cipriani, E. Perna, M. Varrenti, T. Colombo, A. Garascia, A. Cannata, G. Pedrazzini, F. Milazzo, F. Oliva, M. P. Gagliardone, C. F. Russo, M. Frigerio. *De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy*

8:45 AM (266) *Which INTERMACS 4-7 Patients Are at Low Risk for Mortality at One Year? Insights from the INTERMACS Database*; J. J. Teuteberg¹, A. D. Althouse¹, M. Shullo¹, N. Kunz¹, K. Lockard¹, E. Dunn¹, L. Lagazzi¹, C. Sciortino¹, J. Cowger², S. Joseph³, R. L. Kormos¹. ¹University of Pittsburgh, Pittsburgh, PA, ²St. Vincent, Indianapolis, IN, ³Baylor Medical Center, Houston, TX

9:00 AM (267) *Outcomes of Jarvik 2000 LVAD as a Bridge to Heart Transplantation: Data from the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS)*; H. Kohno¹, G. Matsumiya¹, Y. Sawa², M. Ono³, Y. Saiki⁴, A. Shiose⁵, K. Yamazaki⁶, Y. Matsui⁷, H. Niinami⁸, H. Matsuda⁹, S. Kitamura¹⁰, T. Nakatani¹¹, S. Kyo¹². ¹Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan, ²Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ³Cardiac Surgery, The University of Tokyo, Tokyo, Japan, ⁴Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁵Cardiovascular Surgery, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan, ⁶Cardiovascular Surgery, Tokyo Women's Medical University Hospital, Tokyo, Japan, ⁷Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁸Cardiovascular Surgery, Saitama Medical University International Medical Center, Hidaka, Japan, ⁹Higashi-Takarazuka Satoh Hospital, Takarazuka, Japan, ¹⁰National Cerebral and Cardiovascular Center, Osaka, Japan, ¹¹Maki Health Care Group, Maki Hospital, Osaka, Japan, ¹²Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan

9:15 AM (268) *Effects of Hospital Characteristics on In-Hospital Mortality and Hospitalization Costs for Mechanical Circulatory Support Device (MCS) Therapy: Results from the National (Nationwide) Inpatient Sample (NIS)*; L. Sridharan¹, R. Givens¹, A. R. Garan¹, M. Yuzefpolskaya¹, K. Takeda², F. Latif¹, S. Restaino¹, J. Haythe¹, M. Maurer¹, D. M. Mancini³, M. Farr¹, Y. Naka², P. C. Colombo¹, V. Topkara¹. ¹Cardiology, Columbia University, New York, NY, ²Cardiothoracic Surgery, Columbia University, New York, NY, ³Cardiology, Mount Sinai, New York, NY

8:00 AM - 9:30 AM

ORAL SESSION 21: New Fixes for an Old Problem: Preventing, Diagnosing, and Treating Pump Thrombosis

Location:

Grand Hall A

Target Audience:

MCS, HF, NNSAH, PHARM

Chairs:

Evgenij V Potapov, MD, PhD, and Allen Cheng, MD

8:00 AM (269) Management and Outcomes of LVAD Thrombosis: A Systematic Review and Meta-Analysis; V. Tchantchaleishvili¹, J. G. Luc², K. Phan³, S. M. Dunlay⁴, S. Maltais¹, J. M. Stulak¹. ¹Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ³Faculty of Medicine, University of Sydney, Sydney, Australia, ⁴Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

8:15 AM (270) Novel Techniques of Sound Wave Analysis Can Detect Ventricular Assist Device Thrombosis; M. Bran Pouyan¹, L. Blazquez Arroyo², S. Hersek¹, M. Janmohamed², T. De Marco², G. M. Wieselthaler³, V. N. Selby², O. T. Inan¹, L. Klein². ¹School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ²Cardiology, University of California, San Francisco, CA, ³Cardiac Surgery, University of California, San Francisco, CA

8:30 AM (271) Apixabanin Mechanical Circulatory Support - Evaluation in a Mock Circulatory Loop with Human Blood; S. Rao¹, D. Connor², N. Kerr³, J. Joseph⁴, P. Jansz¹, C. Hayward¹. ¹Heart Transplant, St Vincent's Hospital, Darlinghurst, Australia, ²St Vincent's Centre for Applied Medical Research, Darlinghurst, Australia, ³St Vincent's Hospital, Darlinghurst, Australia, ⁴Hematology, St Vincent's Hospital, Darlinghurst, Australia

8:45 AM (272) Left Atrial Appendage Occlusion Is Associated with Decreased Thromboembolic Events in LVAD Patients; A. Deshmukh, A. Bhatia, N. Sarswat, S. Adaty, G. Kim, G. Sayer, C. Ozcan, T. Ota, V. Jeevanandam, N. Uriel. University of Chicago, Chicago, IL

9:00 AM (273) Trends in Serum Lactate Dehydrogenase During HeartMate II Left Ventricular Assist Device Support and Its Relation to Clinical Outcomes: Insights from the PREVENT Study; T. Thenappan¹, J. Stulak², R. Agarwal³, S. Maltais², P. Shah⁴, P. Eckman⁵, S. Emani⁶, J. Katz⁷, I. Gregoric⁸, M. Keebler⁹, N. Uriel¹⁰, E. Adler¹¹, J. Chuang¹², D. Farrar¹², K. Sundareswaran¹², R. John¹. ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Allegheny General Hospital, Pittsburgh, PA, ⁴Inova Heart and Vascular Institute, Falls Church, VA, ⁵Minneapolis Heart Institute, Minneapolis, MN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷University of North Carolina, Chapel Hill, NC, ⁸Memorial Hermann - Texas Medical Center, Houston, TX, ⁹Vanderbilt University, Nashville, TN, ¹⁰University of Chicago Medical Center, Chicago, IL, ¹¹University of California San Diego Medical Center, La Jolla, CA, ¹²St. Jude Medical, Pleasanton, CA

9:15 AM (274) Sildenafil Reduces Risk of Ischemic Stroke and Pump Thrombosis with Ongoing Low Level Hemolysis During Heart Mate II Support; O. Saeed¹, S. Rangasamy¹, A. Luke¹, S. P. Patel¹, D. B. Sims¹, J. Shin¹, M. Reyes Gil², M. J. Slepian³, H. H. Billett², D. J. Goldstein⁴, U. P. Jorde¹. ¹Medicine (Cardiology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ²Medicine (Hematology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ³Medicine (Cardiology), University of Arizona, Tucson, AZ, ⁴Surgery (Cardiothoracic), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

8:00 AM - 9:30 AM

ORAL SESSION 22: Does Risk Reap Reward? Expanding the Heart Donor Pool

Location:

Grand Hall B

Target Audience:

HTX, BSTR

Chairs:

Mahazarin B Ginwalla, MD, and Paul Christian Schulze, MD, PhD

8:00 AM (275) Outcomes for Donor Hearts with Low Ejection Fraction That Improve During Donor Management; S. Madan¹, O. Saeed¹, P. Vlismas¹, I. Katsa², S. R. Patel¹, J. Shin¹, D. Sims¹, D. Goldstein³, U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, ²Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, New York, NY, ³Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

8:15 AM (276) Center for Disease Control High Risk Donor Use in Heart Transplantation: Current Trends; A. Iyengar¹, D. Vucicevic², E. Adams¹, C. Eisenring³, L. Reardon², M. Deng², A. Ardehali³, E. DePasquale². ¹David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, ²Department of Cardiology, University of California - Los Angeles, Los Angeles, CA, ³Department of Cardiac Surgery, University of California - Los Angeles, Los Angeles, CA

8:30 AM (277) Changing Dynamics of Donor Hearts: Impact of Drug Intoxicated Organs on Survival; J. R. Trivedi, M. Gallo, W. M. Whited, M. S. Slaughter. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

8:45 AM (278) Predicted Heart Mass Is the Optimal Metric for Size Matching in Heart Transplantation; E. Kransdorf, M. Kittleson, J. Patel, T. Aintablian, A. Velleca, E. Stimpson, D. Geft, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

9:00 AM (279) Close to the Heart: Increasing Geographic Distance from Transplanting Center Associated with Increased Incidence of Graft Failure and Mortality Following Heart Transplant; T. Khuu¹, B. Chen¹, M. Cadeiras². ¹UCLA, Los Angeles, CA, ²Medicine, UCLA, Los Angeles, CA

9:15 AM (280) Prediction of Waitlist Mortality in Adult Heart Transplant Candidates: The Candidate Risk Score; C. Jasseron¹, C. Legeai¹, C. Jacquelinet¹, P. Leprince², C. Cantrelle¹, B. Audry¹, R. Porcher³, O. Bastien¹, R. Dorent¹. ¹Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, ²Service de Chirurgie Cardio-Vasculaire, Hôpital de la Pitié Salpêtrière, Paris, France, ³Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Paris, France

8:00 AM - 9:30 AM

ORAL SESSION 23: Choosing Right: Lung Recipient Selection and Management

Location:

Grand Hall C

Target Audience:

LTX, BSTR, EEP, NNSAH, PHARM

Chairs:

Roger D. Yusen, MD, MPH, and Marie M Budev, DO, MPH

8:00 AM (281) *The Lung Transplant Risk Model - A Nationally Validated Tool for Pre-Transplant Risk Assessment*; E. Y. Chan¹, D. T. Nguyen², N. Sinha³, T. S. Kaleekal³, A. Goodarzi³, J. G. Youssef³, B. A. Bruckner⁴, E. E. Suarez⁴, S. A. Scheinin⁴, E. A. Graviss², A. O. Gaber⁵. ¹Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, TX, ²Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, ³Division of Transplant Pulmonology, Department of Medicine, Houston Methodist Hospital, Houston, TX, ⁴Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, ⁵Department of Surgery, Houston Methodist Hospital, Houston, TX

8:15 AM (282) *Underutilization of Lung Transplant Referral Among Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)*; L. Paoletti¹, S. Palmer², E. Yow³, M. L. Neely³, V. Gamerman⁴, T. Whelan¹. ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

8:30 AM (283) *Cost and Readmission of Single and Double Lung Transplantation in the U.S. Medicare Population*; F. McCarthy, D. Savino, D. Graves, T. Dibble, C. Brown, D. Spragan, C. Bermudez, E. Cantu, D. Nimesh. *Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA*

8:45 AM (284) *Technique and Outcomes of Less Invasive Lung Retransplantation*; W. Sommer¹, F. Ius¹, C. Kuehn¹, M. Avsar¹, J. Salman¹, T. Siemeni¹, J. Gottlieb², N. Schwerk³, A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, ²Respiratory Medicine, Hannover Medical School, Hannover, Germany, ³Pediatric Respiratory Medicine, Hannover Medical School, Hannover, Germany

9:00 AM (285) *Functions of Inverted Grafts Are Satisfactory Compared with Non-Inverted Grafts in Living-Donor Lobar Lung Transplantation*; H. Kayawake, T. F. Chen-Yoshikawa, Y. Goda, H. Oda, S. Ueda, H. Motoyama, M. Hamaji, K. Hijiya, A. Aoyama, H. Date. *Department of Thoracic Surgery, Kyoto University, Kyoto, Japan*

9:15 AM (286) *A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial*; N. Kim¹, J. G. Lee², S. Lee², K. S. Nam², J. W. Shu², H. C. Paik², Y. C. Yoo¹. ¹Anesthesiology, Yonsei University, Seoul, Korea, Republic of, ²Thoracic and Cardiovascular Surgery, Yonsei University, Seoul, Korea, Republic of

8:00 AM - 9:30 AM

ORAL SESSION 24: An Amalgamation of Support in Heart Failure

Location:

Grand Hall D

Target Audience:

HF, MCS, NNSAH, PHARM

Chairs:

Savitri Fedson, MD, and Navin K Kapur, MD

8:00 AM (287) *MitraClip Therapy for Patients with End-Stage Heart Failure: A Durable Option?*; D. Reichart, D. Kalbacher, N. Schofer, F. Deuschl, J. Schirmer, S. Blankenberg, H. Reichenspurner, U. Schäfer, E. Lubos, L. Conradi. *University Heart Center Hamburg, Hamburg, Germany*

8:15 AM (288) *Percutaneous Axillary Balloon Pumps: Outcomes of Extended Support*; D. A. Baran, K. Stelling, J. Pieretti, C. Gidea, S. Kapoor, M. J. Zucker, M. Cohen, T. Martin, B. Dinicola, M. Camacho. *Newark Beth Israel Medical Ctr, Newark, NJ*

8:30 AM (289) *Predictors of Hemodynamic Stabilization Following Intra-Aortic Balloon Pump Implantation for Cardiogenic Shock*; C. Juricek¹, T. Imamura², H. Costantini¹, V. Kagan¹, T. Song¹, D. Onsager¹, T. Ota¹, S. Adatya², G. Kim², N. Sarswat², G. Sayer², V. Jeevanandam¹, N. Uriel². ¹CT Surgery, *University of Chicago, Chicago, IL*, ²Cardiology, *University of Chicago, Chicago, IL*

8:45 AM (290) *The ASA Score - A Simple Way to Predict Outcome of Non-Transplant Eligible Patients Receiving Palliative Inotropic Therapy*; E. Achu¹, D. A. Baran¹, A. Harhash², M. J. Zucker¹, J. Crincoli¹, M. Rovner², M. Mody¹, Z. Port¹, A. Hussein², S. Kapoor¹, J. Pieretti¹, C. Gidea¹, M. Goldschmidt². ¹*Newark Beth Israel Medical Ctr, Newark, NJ*, ²*Morristown Medical Center, Morristown, NJ*

9:00 AM (291) *Tolerability of High Dose Continuous Outpatient Milrinone: Time to Re-Evaluate?*; A. Harhash¹, E. Achu², M. J. Zucker², M. Goldschmidt¹, M. Rovner¹, J. Crincoli², A. Hussein¹, J. Pieretti², C. Gidea², M. Mody², Z. Port², S. Kapoor², D. A. Baran². ¹*Morristown Medical Center, Morristown, NJ*, ²*Newark Beth Israel Medical Ctr, Newark, NJ*

9:15 AM (292) *Seattle Heart Failure Model Predicted One-Year Mortality of 20% or More Is Associated with a Poor Prognosis in Patients Referred for Heart Transplant Assessment*; P. Narayan, S. Drew, A. Bin Mohd Ghazi, C. Lewis, J. Parameshwar, S. J. Pettit. *Transplant Unit, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom*

8:00 AM - 9:30 AM

ORAL SESSION 25: Improving Outcomes in Pediatric Lung Transplantation

Location: Seaport F-H

Target Audience: PEDS, ID, LTX

Chairs: Carol K Conrad, MD, and Malcolm Brodlie, BSc (Hons), MB ChB, PhD, MRCPCH

8:00 AM (293) Long-Term Outcomes After Living-Donor Lobar Lung Transplantation Using a Single Donor; S. Ueda, T. F. Chen-Yoshikawa, H. Motoyama, M. Hamaji, K. Hijjiya, A. Aoyama, H. Date. *Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan*

8:15 AM (294) Respiratory Viral Infections in Pediatric Lung Transplant Recipients Are Not Associated with BOS, Retransplant or Death; S. C. Sweet¹, R. Buller¹, H. Chin², C. Conrad³, A. Faro⁴, S. Goldfarb⁵, D. Hayes⁶, P. Heeger⁷, D. Ikle², K. Kesler², E. Melicoff-Portillo⁸, T. Mohanakumar⁹, M. Schechter¹⁰, G. Storch¹, G. Visner¹¹, N. Williams¹², L. Danziger-Isakov¹⁰. ¹Washington University, St. Louis, MO, ²Rho, Inc., Chapel Hill, NC, ³Lucille Packard Children's Hospital, Palo Alto, CA, ⁴Cystic Fibrosis Foundation, Bethesda, MD, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Mount Sinai School of Medicine, New York, NY, ⁸Texas Children's Hospital, Houston, TX, ⁹St. Joseph's Hospital & Medical Center, Phoenix, AZ, ¹⁰Cincinnati Children's Hosp Med Ctr, Cincinnati, OH, ¹¹Boston Children's Hospital, Boston, MA, ¹²National Institutes of Health, Bethesda, MD

8:30 AM (295) Autotransplantation of the Left Lung for the Treatment of Recurrent Life Threatening Pulmonary Hemorrhage Related to Pulmonary Vascular Malformation: A Novel Treatment Approach & a Unique Chance to Study Ischemia/Reperfusion Injury; C. Falk¹, I. Tudorache², C. Mueller³, W. Sommer⁴, K. Daeman¹, J. Keil¹, C. Neudörf¹, G. Hansen³, A. Haverich⁴, G. Warnecke⁴, I. Tudorache⁴. ¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany, ²Cardiac-, Thoracic-, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ³Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁴Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

8:45 AM (296) Risk and Outcomes of Pulmonary Fungal Infection in Pediatric Lung Transplant; E. Ammerman¹, L. Danziger-Isakov¹, G. A. Storch², M. Fenchel¹, C. Conrad³, D. Hayes⁴, A. Faro², S. Goldfarb⁵, K. Kesler⁶, E. Melicoff-Portillo⁷, M. Schechter¹, G. Visner⁸, N. Williams⁹, S. C. Sweet². ¹Children's Hosp Med Ctr, Cincinnati, OH, ²Washington University/St. Louis Children's Hospital, St. Louis, MO, ³Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Rho, Inc, Chapel Hill, NC, ⁷Texas Children's Hospital, Houston, TX, ⁸Harvard Medical School/Boston Children's Hospital, Boston, MA, ⁹National Institute of Allergy and Infectious Diseases, Bethesda, MD

9:00 AM (297) Anellovirus Can Be Used to Predict Short- and Long-Term Outcomes in Pediatric Lung Transplant Recipients; J. Blatter¹, S. Sweet¹, C. Conrad², L. A. Danziger-Isakov³, A. Faro⁴, S. B. Goldfarb⁵, D. Hayes, Jr.⁶, E. Melicoff⁷, M. Schechter⁸, G. Storch¹, G. A. Visner⁹, N. M. Williams¹⁰, D. Wang¹¹. ¹Department of Pediatrics, Washington University School of Medicine in St. Louis, Saint Louis, MO, ²Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, ³Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cystic Fibrosis Foundation, Bethesda, MD, ⁵Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, ⁶Department of Pediatrics, The Ohio State University, Columbus, OH, ⁷Department of Pediatrics, Baylor College of Medicine, Houston, TX, ⁸Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ⁹Department of Pediatrics, Harvard Medical School, Boston, MA, ¹⁰National Institutes of Health, Bethesda, MD, ¹¹Department of Pathology and Immunology, Department of Molecular Biology, Washington University School of Medicine in St. Louis, Saint Louis, MO

9:15 AM (298) Extracorporeal Life Support in Pediatric Lung Transplant: A Single Center Experience; R. D. Vanderlaan¹, M. Cypel², H. Grassmann³, O. Honjo⁴, T. Hump⁵, C. A. Caldarone⁴, M. Solomon³, R. Casas³, S. Azad², A. Gueguerian⁶, S. Keshavjee². ¹Cardiac Surgery, University of Toronto, Toronto, ON, Canada, ²Thoracic Surgery, Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Respiratory Medicine, Lung Transplant Program, Hospital for Sick Children, Toronto, ON, Canada, ⁴Cardiovascular Surgery, Hospital for Sick Children, Toronto, ON, Canada, ⁵Cardiology, Hospital for Sick Children, Toronto, ON, Canada, ⁶Critical Care Medicine, Hospital for Sick Children, Toronto, ON, Canada

8:00 AM - 9:30 AM

ORAL SESSION 26: Philip K. Caves Award Candidate Presentations

Location:

Coronado A-C

Target Audience:

ALL

Chairs:

Stephan M. Ensminger, MD, DPhil, and Daniel Kreisel, MD, PhD

8:00 AM (299) Donor-Derived Non-Classical Monocytes Recruit Recipient Neutrophils and Mediate Primary Lung Allograft Dysfunction; S. Chiu¹, Z. Zheng¹, M. Akbarpour¹, R. Fernandez¹, A. McQuattie-Pimentel¹, P. Reyfman¹, K. Anekalla¹, D. Kreisel², H. Perlman¹, G. S. Budinger¹, A. Misharin¹, A. Bharat¹. ¹Northwestern University, Chicago, IL, ²Washington University, St. Louis, MO

8:15 AM (300) Extracorporeal Photopheresis Inhibits the Development of Obliterative Airway Disease and Promotes the Expansion of Intra-graft Retinoic Acid-Producing CD103⁺ Dendritic Cells and Tregs; Z. Liu¹, F. Liao¹, X. Lin¹, K. A. Toth¹, X. Wang², J. Zhu¹, D. Scozzi¹, A. S. Krupnick³, D. Kreisel¹, R. Hachem⁴, J. M. Green⁵, A. E. Gelman¹. ¹Department of Surgery, Washington University in St. Louis, St. Louis, MO, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Surgery, University of Virginia, Charlottesville, VA, ⁴Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, MO, ⁵Division of Biology and Biomedical Sciences, Washington University in St. Louis, St. Louis, MO

8:30 AM (301) Increased Tumor Necrosis Factor- α Levels in Patients with Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated with Higher Non-Surgical Bleeding; C. E. Tabit¹, M. Coplan¹, P. Chen¹, V. Jeevanandam², N. Uriel¹, J. K. Liao¹. ¹Cardiology, The University of Chicago Medical Center, Chicago, IL, ²Surgery, The University of Chicago Medical Center, Chicago, IL

8:45 AM (302) Induction of Persistent Lung Transplant Tolerance by IL-2 Complex-Stimulated Regulatory T Cells In Vivo; Y. Yamada¹, D. Impellizzieri², T. Maeyashiki¹, K. Brüstle¹, L. Dubs¹, J. Jang¹, U. Karakus², J. Woytschak², I. Inci¹, W. Weder¹, O. Boyman², W. Jungraithmayr¹. ¹Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²Department of Immunology, University Hospital Zurich, Zurich, Switzerland

9:00 AM (303) Ischaemic Reperfusion Injury and Allograft Rejection Following DCD Heart Transplantation: Early Results; A. Page, M. Goddard, S. Messer, J. Dunning, J. Parameshwar, C. Lewis, A. Kydd, S. Pettit, Y. Abu-Omar, M. Berman, A. Ali, S. Tsui, S. Large. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

9:15 AM (304) Utility of Droplet Digital PCR for the Detection of Aspergillus DNA in Bronchoalveolar Lavage and Exhaled Breath Condensate Samples from Lung Transplant Recipients; A. Bhimji¹, L. G. Singer², D. Kumar¹, A. Humar¹, C. Rotstein¹, S. Keshavjee², T. Mazzulli³, S. Husain¹. ¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada

10:00 AM - 11:30 AM

ORAL SESSION 27: The Leaking Gut - New Strategies for GI Bleeding in MCS

Location:

Seaport A-E

Target Audience:

MCS, HF, NHSAH, PHARM

Chairs:

Jan F Gummert, MD, PhD, and Sarah Schettle, PA-C

10:00 AM (305) Endoscopic Evaluation in Patients with CF-LVADs with Gastrointestinal Bleeding: Are We Ready for a Paradigm Shift to Improve Care?; J. Axelrad, A. Pinsino, C. Brooks, P. Trinh, B. Cagliostro, F. Castagna, V. K. Topkara, A. R. Garan, L. A. Effner, H. Takayama, K. Takeda, Y. Naka, P. C. Colombo, M. Yuzefpolskaya, T. Gonda. *New York Presbyterian Hospital - Columbia University Medical Center, New York, NY*

10:15 AM (306) Incidence and Risk Factors of Late Bleeding in Patients Enrolled in the PREVENT Study; R. John¹, M. Keebler², J. Stulak³, S. Emani⁴, C. Klodell⁵, S. Nathan⁶, A. Brieke⁷, N. Uriel⁸, J. Chin⁹, P. Eckman¹⁰, A. Nsair¹¹, R. Agarwal¹², T. Thenappan¹, R. Adamson¹³, J. Chuang¹⁴, D. Farrar¹⁴, K. Sundareswaran¹⁴, J. Katz¹⁵. ¹*University of Minnesota, Minneapolis, MN*, ²*Vanderbilt University, Nashville, TN*, ³*Mayo Clinic, Rochester, MN*, ⁴*Ohio State University Medical Center, Columbus, OH*, ⁵*University of Florida, Gainesville, FL*, ⁶*Memorial Hermann - Texas Medical Center, Houston, TX*, ⁷*University of Colorado School of Medicine, Denver, CO*, ⁸*University of Chicago Medical Center, Chicago, IL*, ⁹*Sutter Medical Center, Sacramento, CA*, ¹⁰*Minneapolis Heart Institute, Minneapolis, MN*, ¹¹*UCLA Medical Center, Santa Monica, CA*, ¹²*Allegheny General Hospital, Pittsburgh, PA*, ¹³*Sharp Memorial Hospital, San Diego, CA*, ¹⁴*St. Jude Medical, Pleasanton, CA*, ¹⁵*University of North Carolina, Chapel Hill, NC*

10:30 AM (307) Predicting Recurrent GI Bleeding in Patients with CF-LVADs Using Pre-Implant Data; L. C. Lohmueller¹, W. A. Alexander², J. F. Antaki¹. ¹*Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA*, ²*HEMA Biologics, LLC, Louisville, KY*

10:45 AM (308) Comparison of Gastrointestinal Bleeding Rates Between Axial Flow (HeartMate II) and Centrifugal (HeartWare) Flow Pumps at a Single Institution; M. Kawabori, C. Kurihara, T. Sugiura, L. Cunningham, A. B. Civitello, W. E. Cohn, O. H. Frazier, J. A. Morgan. *Texas Heart Institute, Baylor College of Medicine, Houston, TX*

11:00 AM (309) Octreotide Reduces the Reoccurrence of Ventricular Assist Device Related Gastrointestinal Bleeding; K. B. Shah¹, G. Sampath¹, S. Emani², M. K. Kanwar³, N. Uriel⁴, P. C. Colombo⁵, P. A. Uber¹, M. L. Sears¹, J. Chuang⁶, D. J. Farrar⁶, G. B. Smallfield¹. ¹*Virginia Commonwealth Univ, Richmond, VA*, ²*Ohio State University, Columbus, OH*, ³*Allegheny General Hospital, Pittsburgh, PA*, ⁴*University of Chicago, Chicago, IL*, ⁵*Columbia University, New York, NY*, ⁶*St. Jude Medical, St. Paul, MN*

11:15 AM (310) Pre-Implant Moderate-Severe Fibrosis on Liver Biopsy Predicts Adverse Outcomes After Mechanical Circulatory Support; R. Mohan, J. Neyer, J. Patel, M. Kittleson, T. Aintablian, R. Levine, D. Chang, L. Czer, J. Moriguchi, J. A. Kobashigawa, F. Arabia. *Cedars-Sinai Heart Institute, Los Angeles, CA*

10:00 AM - 11:30 AM

ORAL SESSION 28: The Heart of the Matter: Cardiac Substrate in MCS Therapy

Location:

Grand Hall A

Target Audience:

MCS, HF

Chairs:

Stuart D. Russell, MD, and Jennifer A Cowger, MD, MS

10:00 AM (311) Diurnal and Patient Activity Related Determinants of Aortic Valve Opening on Continuous Flow LVAD Support; R. Clifford¹, D. Robson¹, C. Gross², F. Moscato², H. Schima², P. S. Macdonald¹, P. Jansz¹, C. S. Hayward¹. ¹Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²Medical University of Vienna, Vienna, Austria

10:15 AM (312) Increased Aortic Vascular Fibrosis with Prolonged Continuous-Flow Left Ventricular Assist Device Support; E. Dobrinskikh, S. Purohit, R. Dodson, R. Shtofman, S. Al-Juboori, M. Aftab, T. Reece, W. Cornwell, A. V. Ambardekar. *U Colorado, Aurora, CO*

10:30 AM (313) Echocardiography Accurately Tracks Left Ventricular Unloading in Patients Supported with a HeartMate II LVAD Undergoing Ramp Testing; L. Letarte¹, J. Amione-Guerra², A. Bhimaraj¹, B. Trachtenberg¹, A. Guha¹, G. Torre-Amione¹, M. H. Park¹, J. D. Estep¹. ¹Advanced Heart Failure and Transplant Cardiology, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Hospital, Houston, TX

10:45 AM (314) 3D Echocardiography and Shape Analysis Changes Following Left Ventricular Assist Device Implantation: The Effect of Unloading on Reverse Remodeling; G. Sayer¹, D. Medvedofsky¹, S. Adatya¹, N. Sarswat¹, G. H. Kim¹, E. Kruse¹, T. Ota², V. Jeevanandam², D. Burkhoff³, R. Lang¹, N. Uriel¹. ¹Medicine, University of Chicago, Chicago, IL, ²Cardiothoracic Surgery, University of Chicago, Chicago, IL, ³Medicine, Columbia University, New York, NY

11:00 AM (315) Prevalence of Myocardial Fibrosis by LVAD Apical Core Biopsy and Correlation with Other Markers of Myocardial Recovery; J. N. Schultz¹, R. John², C. M. Martin³, M. Pritzker³, E. Missov³, T. Thenappan³, R. Cogswell³. ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN, ³Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

11:15 AM (316) Coronary Artery Remodeling and Fibrosis with Continuous-Flow Left Ventricular Assist Device Support; A. V. Ambardekar, M. Weiser-Evans, M. Li, M. Aftab, T. Reece, P. Buttrick, K. Moulton. *University of Colorado, Aurora, CO*

10:00 AM - 11:30 AM

ORAL SESSION 29: Donor Utilization and Allocation in Heart Transplantation: Lessons to Learn

Location:

Grand Hall B

Target Audience:

HTX, HF

Chairs:

Joseph G Rogers, MD, and Marta Farrero Torres, MD, PhD

10:00 AM (317) *Great Variability in Donor Heart Acceptance Practices Across the USA*; K. Khush, R. Ball. *Stanford University, Stanford, CA*

10:15 AM (318) *Supply and Demand: Disparities Across UNOS Regions*; D. A. Baran¹, H. Copeland², G. Katlaps³, B. Dharmaraj³, S. Kapoor¹, J. Pieretti¹, C. Gidea¹, M. J. Zucker¹, T. Martin¹, M. Camacho¹, J. Copeland³. ¹*Transplant Center, Newark Beth Israel Medical Ctr, Livingston, NJ*, ²*Dept of Cardiac Surgery, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA*, ³*McGuire VA Medical Center, Richmond, VA*

10:30 AM (319) *Is There an Optimal Acceptance Rate for Adult Transplant Centers?*; Y. Radzi¹, F. Zafar¹, R. Rizwan¹, C. Park¹, J. Tweddell¹, A. Simeone², L. Louis IV¹, D. Morales¹. ¹*Division of Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH*, ²*Division of Cardiac Surgery, University of Cincinnati, Cincinnati, OH*

10:45 AM (320) *Trends in Simultaneous Heart-Kidney Transplantation: An Analysis of UNOS/OPTN Data from 2000 to 2015*; R. C. Givens, V. K. Topkara, S. W. Restaino, F. Latif, Y. Naka, H. Takayama, K. Takeda, P. C. Colombo, M. A. Farr. *Medicine, Columbia University Medical Center, New York, NY*

11:00 AM (321) *The New Heart Allocation System: Implications on Patients with Restrictive Cardiomyopathy in the UNOS Registry*; L. Sridharan¹, R. Givens¹, K. Takeda², A. R. Garan¹, M. Yuzefpolskaya¹, F. Latif¹, S. Restaino¹, J. Haythe¹, J. Ginns¹, D. Mancini³, Y. Naka², P. Colombo¹, M. Maurer¹, H. Takayama², V. K. Topkara¹. ¹*Cardiology, Columbia University, New York, NY*, ²*Cardiothoracic Surgery, Columbia University, New York, NY*, ³*Cardiology, Mount Sinai, New York, NY*

11:15 AM (322) *Effect of Left Ventricular Dysfunction on Utilization of Donor Hearts*; D. Tryon¹, N. W. Hasaniya¹, L. L. Bailey¹, D. S. Juma², B. Jabo², A. J. Razzouk¹, D. G. Rabkin¹. ¹*Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA*, ²*School of Public Health, Research Consulting Group, Loma Linda University Medical Center, Loma Linda, CA*

10:00 AM - 11:30 AM

ORAL SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction

Location:

Grand Hall C

Target Audience:

LTX, BSTR, ID, PATH, PHARM

Chairs:

Mark Greer, MB Bch, and David Weill, MD

10:00 AM (323) *Decreased Donor PBMC and Allograft Telomere Length Are Associated with Shorter CLAD-Free Survival*; H. E. Faust¹, J. A. Golden², R. Rajalingam³, A. S. Wang³, G. Green², S. R. Hays², J. Kukreja³, J. P. Singer², P. J. Wolters², J. R. Greenland². ¹Medicine, Perelman School of Medicine, Philadelphia, PA, ²Medicine, U. California SF, San Francisco, CA, ³Surgery, U. California SF, San Francisco, CA

10:15 AM (324) *Novel Mechanism for the Increased Risk for Chronic Lung Allograft Dysfunction by Respiratory Viral Infections Following Human Lung Transplantation*; M. Gunasekaran¹, A. Limaye², M. Sharma¹, S. Bansal¹, R. Walia¹, M. Smith¹, R. M. Bremner¹, T. Mohanakumar¹. ¹St. Joseph's Hospital & Medical Center, Phoenix, AZ, ²University of Washington, Seattle, WA

10:30 AM (325) *The Role of the Mesothelium in rCLAD After Lung Transplantation*; A. Sacreas, S. E. Verleden, H. Bellon, E. Vandermeulen, T. Heigl, A. Van Herck, G. M. Verleden, R. Vos, B. M. Vanaudenaerde. *KU Leuven, Leuven, Belgium*

10:45 AM (326) *Antibodies to Human Leukocyte Antigen Class I and Lung Associated Self-Antigens, K-alpha-1 Tubulin and Collagen V Induces Exosomes Containing Self-Antigens from Human Primary Airway Epithelial and Endothelial Cells*; M. Gunasekaran¹, M. Sharma¹, S. Bansal¹, R. Walia¹, R. M. Bremner¹, M. Smith¹, T. Mohanakumar². ¹St. Joseph's Hospital & Medical Center, Phoenix, AZ, ²St. Joseph's, Phoenix, AZ

11:00 AM (327) *Exosomes Isolated from Lung Transplant Recipients Diagnosed with Bronchiolitis Obliterans Syndrome, But Not Stable, Can Induce Immune Responses to Lung Associated Self-Antigens, K-alpha-1 Tubulin and Collagen V*; M. Gunasekaran, M. Sharma, S. Bansal, R. Walia, M. Smith, R. M. Bremner, T. Mohanakumar. *St. Joseph's Hospital & Medical Center, Phoenix, AZ*

11:15 AM (328) *Increasing Frequency of CD127^{low} Regulatory T Cells Early After Lung Transplantation Is Associated with Freedom from Chronic Lung Allograft Rejection and Survival in 503 Patients*; F. Ius¹, J. Salman¹, A. Knöfel¹, T. Nakagiri¹, W. Sommer¹, T. Siemeni¹, C. Kühn¹, M. Avsar¹, D. Böthig¹, T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

10:00 AM - 11:30 AM

ORAL SESSION 31: Saved by the Bell: Overcoming Adherence and Frailty

Location:

Grand Hall D

Target Audience:

NHSAH, ALL

Chairs:

Meloneysa Hubbard, MSN, CRNP, CCTC, and Christiane Kugler, PhD

10:00 AM (329) *The Use of Transplant Medicines IT Tool in Supporting Patients' Knowledge of Immunosuppressant Medications*; L. Alsarraf¹, R. Betmouni¹, N. Bidad², A. Reed¹, O. Dar¹, A. Simon¹, H. Lyster¹.
¹Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, ²University College London, London, United Kingdom

10:15 AM (330) *Practice Patterns to Improve Pre- and Post-Transplant Medication Adherence in Heart Transplant Centers: A Secondary Data Analysis of the International Bright Study*; S. M. De Geest. *Public Health, University of Basel, Basel, Switzerland*

10:30 AM (331) *A Trajectory Analysis of Adherence to Recommended Exercise Following Lung Transplantation*; M. Alrawashdeh, J. Choi, A. DeVito Dabbs. *School of Nursing, University of Pittsburgh, Pittsburgh, PA*

(332) WITHDRAWN

10:45 AM (448) *FOCUS for Pediatric Heart Transplant: A Trauma-Informed, Family-Centered, Resilience Enhancing Intervention*; K. Wijesekera¹, N. D. Emerson¹, M. S. Cortez¹, J. Alejos², P. Lester¹. ¹*Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA*, ²*Pediatric Cardiology, UCLA, Los Angeles, CA*

11:00 AM (333) *Quadriceps Strength Predicts Estimates of Physical Activity Post-Heart Transplantation*; R. L. Kelly¹, J. R. Walsh¹, J. D. Paratz², S. T. Yerkovich³, S. McKenzie³, N. R. Morris². ¹*Physiotherapy Department, The Prince Charles Hospital, Chermside, Australia*, ²*School of Allied Health Sciences, Griffith University, Gold Coast, Australia*, ³*School of Medicine, The University of Queensland, Brisbane, Australia*

11:15 AM (334) *Increased Perceived Stress and Fatigue are Associated with Worse Quality of Life in Patients with a Left Ventricular Assist Device*; M. A. Abshire¹, P. M. Davidson¹, S. Desai², C. Budhathoki¹, S. D. Russell¹, C. Dennison Himmelfarb¹. ¹*Johns Hopkins University, Baltimore, MD*, ²*Inova Fairfax Hospital, Falls Church, VA*

10:00 AM - 11:30 AM

ORAL SESSION 32: The Tell Tale Heart: From Signals to Biomarkers

Location:

Seaport F-H

Target Audience:

BSTR, HF, HTX, MCS, NNSAH, PATH, PEDS, PH, PHARM

Chairs:

Kyung-Hee Kim, MD, and Tomoko S Kato, MD, PhD

10:00 AM (335) Complementary Intra-graft and Peripheral Blood Mononuclear Cell Gene Co-Expression Network Analysis of ISHLT Driven versus Unsupervised Molecular Classification; E. Chang¹, G. Fishbein¹, M. Bakir¹, D. Liem¹, S. Litovsky², J. Tallaj², G. Bondar¹, E. Reed¹, M. Deng¹, E. Tabak³, M. Cadeiras¹. ¹Medicine, UCLA, Los Angeles, CA, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Courant Institute of Mathematical Sciences, New York University, New York, NY

10:15 AM (336) Pre-Transplant Serum Exosome and Functional Analysis in Primary Graft Dysfunction; B. Fine¹, E. Zorn¹, E. Chen², G. Vunjak-Novakovic³, P. Colombo¹. ¹Medicine, Columbia University, New York, NY, ²Pharmacology, Columbia University, New York, NY, ³Biomedical Engineering, Columbia University, New York, NY

10:30 AM (337) Antibody Response to Non-Self Blood Group A-Antigen Is Dependent on CD4 T Cells and Co-Engagement with Foreign Protein; I. Adam¹, B. Motyka¹, J. Pearcey¹, K. Tao¹, P. J. Cowan², L. J. West¹. ¹Dept. Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ²Immunology Research Centre, St Vincent's Hospital, University of Melbourne, Melbourne, Australia

10:45 AM (338) Gene Expression in Pediatric Myocardium: Pulsatile- vs. Continuous-Flow VAD Support; I. Adachi¹, M. Zhang², S. Burki¹, D. L. Morales³, A. Jeewa⁴, D. Kearney⁵, L. Wadhwa¹, C. D. Fraser, Jr.¹, J. F. Martin⁶. ¹Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, ²Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, ³Congenital Heart Surgery, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Pediatric Cardiology, Texas Children's Hospital, Houston, TX, ⁵Pathology, Texas Children's Hospital, Houston, TX, ⁶Molecular Physiology and Biophysics and Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX

11:00 AM (339) PPARgamma Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells; L. Calvier¹, P. Chouvarine¹, M. M. Mozes², G. Hansmann¹. ¹Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany, ²Pathophysiology, Semmelweis University, Budapest, Hungary

11:15 AM (340) Voltage-Gated Ca²⁺ Influx into Coronary Artery Smooth Muscle Is Decreased in Ischemic versus Non-Ischemic Cardiomyopathy - The First Evidence from Human Transplant Cardiotomy Samples; R. J. Chen¹, M. Alloosh², J. K. Badin², M. Sturek², I. Wang¹, T. Wozniak¹, Z. A. Hashmi¹. ¹Cardiothoracic Transplantation Surgery, Indiana University - Methodist Hospital, Indianapolis, IN, ²Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN

10:00 AM - 11:30 AM

ORAL SESSION 33: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation

Location:

Coronado A-C

Target Audience:

PATH, BSTR, HTX, LTX, PEDS

Chairs:

Martin J Goddard, FRCS MRCPa, and Robert F. Padera, MD, PhD

10:00 AM (341) Widening of Alveolar Septa in Transbronchial Biopsies with Antibody-Mediated Rejection (AMR): Preliminary Data from Multicenter Pilot Study; F. Calabrese¹, S. Hirschi², M. Chenard², M. Montero-Fernandez³, D. Neil⁴, W. Timens⁵, E. Verbeken⁶, E. Perissinotto¹, F. Lunardi¹, E. Cozzi⁷, D. J. Levine⁸, M. Goddard⁹. ¹University of Padova, Padova, Italy, ²University of Strasbourg, Strasbourg, France, ³Royal Brompton & Harefield NHS, London, United Kingdom, ⁴Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁵University of Groningen, Groningen, Netherlands, ⁶University of Leuven, Leuven, Belgium, ⁷Padova University Hospital, Padova, Italy, ⁸University of Texas Health Science Center, San Antonio, TX, ⁹Papworth Hospital, Papworth, United Kingdom

10:15 AM (342) Prospective Study of Histopathologic Features of Cardiac Antibody-Mediated Rejection and Correlation with Donor Specific Antibodies and Graft Dysfunction; A. C. Roden¹, J. J. Maleszewski¹, P. Lin¹, S. M. Jenkins², M. Gandhi², N. Pereira², M. Aubry¹. ¹Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN

10:30 AM (343) Endothelial Cell Activation in a Mouse Model of Cardiac Antibody-Mediated Rejection; M. Racape¹, J. Duong Van Huyen¹, C. Chen², A. Loupy¹, O. Thauinat², P. Bruneval¹. ¹U970, INSERM-University Paris Descartes, Paris, France, ²U1111, INSERM-University Lyon 1 Claude Bernard, Lyon, France

10:45 AM (344) Liquid Biopsies: Non-Invasive Rejection Detection After Heart Transplantation; L. Hofste¹, A. Vink¹, J. van Kuik¹, E. Siera-de Koning¹, F. Ahmadi¹, N. de Jonge², R. de Weger¹, M. Huibers¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

11:00 AM (345) Changes in Myocardial Microvascularisation After Heart Transplantation and During Cardiac Allograft Vasculopathy ; M. Huibers¹, F. van Pijpen¹, H. Kirkels², N. de Jonge², A. Vink¹, R. de Weger¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

11:15 AM (346) Late Graft Dysfunction After Pediatric Heart Transplantation Is Associated with Fibrosis and Decreased Capillary Density by Automated, Whole-Slide Imaging; B. Feingold¹, J. Picarsic², A. Lesniak³, M. Wood-Trageser³, B. Popp³, A. J. Demetris³. ¹Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pathology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pathology, University of Pittsburgh, Pittsburgh, PA

1:30 PM - 3:30 PM

SYMPOSIUM 24: Aiming Off Target: Non-Cardiac Consequences of LVAD Support

Location:

Seaport A-E

Target Audience:

MCS, BSTR, HF

Chairs:

Mustafa Toma, MD, and Emma Birks, MD, PhD

Session Summary: The relevance of non-cardiac consequences of LVAD support is being increasingly recognized. Many of these “off-target-organ” effects have largely driven the morbidity and mortality of LVAD-supported patients, and these will become more relevant with the rise of the destination therapy population. In this symposium, each speaker will discuss alterations in a different organ system with LVAD support and future directions for research and technologic development to address these alterations.

1:30 PM

Continuous-Flow Effects on the Systemic Vasculature and Endothelium

Amrut V Ambardekar, MD, University of Colorado, Aurora, CO, USA

1:45 PM Q&A

1:50 PM

LVAD Effects on Skeletal Musculature and Exercise Capacity

Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

2:05 PM Q&A

2:10 PM

Renal Function with LVAD Support

Meredith A Brisco, MD MSCE, Temple University, Philadelphia, PA, USA

2:25 PM Q&A

2:30 PM

Hematologic Perturbations Caused by Mechanical Support

Anna L Meyer, MD, Leipzig Heart Center, Leipzig, Germany

2:45 PM Q&A

2:50 PM

Neuropsychological Function in Long-term LVAD Patients

Ralph Petrucci, MD, Drexel University College of Medicine, Philadelphia, PA, USA

3:05 PM Q&A

3:10 PM

Gastrointestinal Physiologic Changes Associated With Continuous-Flow Pumps

Brian Houston, MD, Medical University of South Carolina, Charleston, SC, USA

3:25 PM Q&A

1:30 PM - 3:30 PM

SYMPOSIUM 25: Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver?

Location:

Grand Hall A

Target Audience:

ALL

Chairs:

Michael Shullo, PharmD, and Luciano Potena, MD, PhD

Session Summary: This session will provide an overview of the current management strategies for sensitized patients pre- and post-transplant by discussing desensitization pharmacotherapy, long-term management and monitoring, key challenges and strategies, immunogenetic and non-HLA considerations, and possible downstream implications on target cells, incorporating the newest research-based evidence supplemented with experience from seasoned multidisciplinary clinicians.

1:30 PM

Overview of the Management of the Sensitized Heart Transplant Candidate and Recipient

Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA

1:45 PM Q&A

1:50 PM

Strategies for Desensitization of the Heart Transplant Candidate

Laura M. Lourenco, PharmD, University of Chicago Medicine, Chicago, IL, USA

2:05 PM Q&A

2:10 PM

Downstream Implications of Desensitization

Rajalingam Raja, PhD, UCSF Medical Center, San Francisco, CA, USA

2:25 PM Q&A

2:30 PM

DEBATE (PRO): No Time to Wait: Proceed to Heart Transplant with Low Level Donor Specific Antibodies

Barbara Pisani, MD, Wake Forest Medical Center, Winston-Salem, NC, USA

2:45 PM

DEBATE (CON): No Time to Wait: Proceed to Heart Transplant with Low Level Donor Specific Antibodies

Lee R. Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, USA

3:00 PM

DEBATE (PRO): Asymptomatic Donor Specific Antibodies After Transplant: Everyone Should Be Treated

Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

3:15 PM

DEBATE (CON): Asymptomatic Donor Specific Antibodies After Transplant: Everyone Should Be Treated

Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA

1:30 PM - 3:30 PM
SYMPOSIUM 26: Making Every Heart Count

Location:
Grand Hall B

Target Audience:
HTX, EEP, HF, HTX

Chairs:
Kiran K. Khush, MD, and Jason W Smith, MD

Session Summary: This symposium focuses on donor heart utilization, from use of expanded criteria donors to improved stewardship of donor hearts, reducing waste of potentially usable hearts and breaking open the doors of DCD heart procurement.

1:30 PM
Is The Expanded Criteria Donor the New Standard Criteria Donor?
Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

1:45 PM Q&A

1:50 PM
Can We Revive the DCD Heart?
Stephen Large, FRCS, Papworth Hospital, Cambridge, United Kingdom

2:05 PM Q&A

2:10 PM
Resource Stewardship in Donor Selection
Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, USA

2:25 PM Q&A

2:30 PM
The Public Health Service (PHS) Increased Risk Donor: What Is the Real Risk of Infection?
Michael Ison, MD, Northwestern University, Chicago, IL, USA

2:45 PM Q&A

2:50 PM
Evaluation of the Heart at Time of Donor Procurement
William E Stansfield, MD, Toronto General Hospital, Toronto, ON, Canada

3:05 PM Q&A

3:10 PM
Getting The Heart Home - How to Procure the Donor Heart
Hannah Copeland, MD, VA McGuire Medical Center/Virginia Commonwealth University, Richmond, VA, USA

3:25 PM Q&A

1:30 PM - 3:30 PM

SYMPOSIUM 27: Bench to Bedside: How Advances in Immunology Shape the Care of Today's Lung Transplant Recipients

Location:

Grand Hall C

Target Audience:

LTX, BSTR, HTX, ID, NNSAH, PATH, PEDS, PHARM

Chairs:

Ciara M Shaver, MD, and Andrew J Fisher, PhD FRCP

Session Summary: Recent advances in immunology have important implications for modern day clinical care. This session will highlight some important scientific advances in genomics and immunology with direct applicability to clinical issues including immunosuppression, graft surveillance, drug dosing, and antibody mediated rejection. This session will help to bridge the gap between translational immunology research and current clinical practice.

1:30 PM

The Immunobiology of Lung Transplantation: From Bench to Bedside

Rebecca A Shilling, MD, University of Chicago, Chicago, IL, USA

1:50 PM Q&A

1:54 PM

The Quest for Biomarkers for Acute and Chronic Lung Rejection: Where Are We Now?

John R Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

2:14 PM Q&A

2:18 PM

Tackling the Immune System: Novel Biologicals and Immunomodulators in Lung Transplant Recipients

Stephen Juvet, MD, PhD, Toronto General Research Institute, Toronto, ON, Canada

2:38 PM Q&A

2:42 PM

Antibody-Targeted Therapies in Lung Transplantation: When and How to Use?

Ramsey R Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

3:02 PM Q&A

3:06 PM

Targeting Non-Immune Cells: Novel Treatment Options in Lung Transplantation

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

3:26 PM Q&A

1:30 PM - 3:30 PM

SYMPOSIUM 28: Great Debates in Pulmonary Hypertension

Location:

Grand Hall D

Target Audience:

PH, ALL

Chairs:

Teresa De Marco, MD, FACC, and Paul A Corris, MB FRCP

Session Summary: The diagnosis and management of pulmonary hypertension is steadily being refined by ongoing investigations in the field. However, knowledge gaps and challenges still remain. This session will explore in case and debate format controversial diagnostic and management dilemmas beyond accepted practice. Topics include adding additional Pulmonary Arterial Hypertension (PAH) specific therapy in a stable patient, treatment of borderline pulmonary hypertension, and managing pulmonary hypertension complicated by Interstitial Lung Disease (ILD).

1:30 PM

Case Presentation: To Treat or Not To Treat...Interstitial Lung Disease (IDL)-PH

Christopher King, MD, FACP, FCCP, Inova Fairfax Hospital, Falls Church, VA, USA

1:35 PM

DEBATE (PRO): Pulmonary Hypertension Due to Lung Disease Should Be Treated with PAH Specific Therapies

Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

1:50 PM

DEBATE (CON): Pulmonary Hypertension Due to Lung Disease Should Be Treated with PAH Specific Therapies

Marius Hoepfer, MD, Hannover Medical School, Hannover, Germany

2:05 PM

Case Presentation: To Treat or Not To Treat...Borderline PAH

Kurt Prins, MD, University of Minnesota, Minneapolis, MN, USA

2:10 PM

DEBATE (PRO): "Borderline" PAH Should Be Treated with PAH Specific Therapy

Bradley Maron, MD, Brigham and Women's Hospital, Boston, MA, USA

2:25 PM

DEBATE (CON): "Borderline" PAH Should Be Treated with PAH Specific Therapy

Jean-Luc Vachiery, MD, Erasme University Hospital - ULB, Brussels, Belgium

2:40 PM

Case Presentation: "I'm doing fine Doc, do I really need another pill?"

Roberto Badagliacca, MD, University of Rome Sapienza, Rome, Italy

2:45 PM

DEBATE (PRO): My Patient with PAH is Clinically Stable on Monotherapy: I Should Escalate to Dual or Triple Therapy

Rogério Souza, MD, University of Sao Paulo, Sao Paulo, Brazil

3:00 PM

DEBATE (CON): My Patient with PAH is Clinically Stable on Monotherapy: I Should Escalate to Dual or Triple Therapy

Veronica Franco, MD, Ohio State University, Columbus, OH, USA

3:15 PM Panel Discussion

1:30 PM - 3:30 PM

SYMPOSIUM 29: How to Mend a Broken Heart: Approaches for Cardiac Regeneration

Location:

Seaport F-H

Target Audience:

BSTR, HF, HTX, PATH, PHARM

Chairs:

Lori West, MD, DPhil, and Daniel TS Reichart, MD

Session Summary: This session provides an overview of mechanisms of heart failure and different experimental approaches for cardiac regeneration. Implications for multipotent stem cell therapies are presented, followed by cell independent strategies to cardiac regeneration. Furthermore, the potential of pluripotent stem cells and stem cell-derived cardiomyocytes, as well as myocardial tissue engineering approaches, will be discussed.

1:30 PM

Mechanisms of Heart Failure and Experimental Therapeutic Options

Claudius Mahr, DO, University of Washington, Seattle, WA, USA

1:45 PM Q&A

1:50 PM

Multipotent Stem Cells and Cardiac Progenitors in Clinical Trials

Joshua Hare, MD, Miller School of Medicine, Miami, FL, USA

2:05 PM Q&A

2:10 PM

MicroRNAs and Cell Independent Strategies for Cardiac Regeneration

Pradeep Mammen, MD, UT Southwestern Medical Center, Dallas, TX, USA

2:25 PM Q&A

2:30 PM

Cardiac Cell Injection for Heart Failure: Pluripotent Stem Cells (PSC) and Stem Cell-Derived Cardiomyocytes

Tobias Deuse, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

2:45 PM Q&A

2:50 PM

Myocardial Tissue Engineering: Where Are We Now and Where Are We Heading?

Simon Pecha, MD, University Heart Centre Hamburg, Hamburg, Germany

3:05 PM Q&A

3:10 PM

Pluripotent Stem Cells: Hurdles and Perspectives on the Way to Clinical Application

Doris Taylor, MD, Texas Heart Institute, Houston, TX, USA

3:25 PM Q&A

1:30 PM - 3:30 PM

SYMPOSIUM 30: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations?

Location:

Coronado A-C

Target Audience:

NHSAH, ALL

Chairs:

Deborah Page, NP, and Steve Ivulich, PharmD

Session Summary: The purpose of this symposium is to discuss the state-of-the-art of e-health technology (telemedicine, telehealth and interactive health technology applications) in delivering care (e.g. long-distance care, self-management support) in end-stage organ disease, LVAD and transplantation. In addition, interactive communication options via social media for public involvement as well as research dissemination will be reviewed. Moreover the value of big data for transplantation will be explored.

1:30 PM

The Many Faces of E-health: An Overview

Fabienne Dobbels, MSc, PhD, University of Leuven, Leuven, Belgium

1:45 PM Q&A

1:50 PM

The Importance of Involving End-Users When Designing Interactive Health Technology Applications for Self-Management Support

Annette Devito-Dabbs, PhD, RN, ACNS-BC, FAAN, University of Pittsburgh School of Nursing, Pittsburgh, PA, USA

2:05 PM Q&A

2:10 PM

The ABCs of Social Media

Mary N. Walsh, MD, St. Vincent Hospital, Indianapolis, IN, USA

2:25 PM Q&A

2:30 PM

Closer to the Heart: The Impact of Distance to Care and Remote Care

Tam Khuu, PharmD, UCLA Medical Center, Los Angeles, CA, USA

2:45 PM Q&A

2:50 PM

Big Data: Big Impact

Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

3:05 PM Q&A

3:10 PM

New Ethical and Legal Challenges Surrounding E-health in Transplantation

JiYeon Choi, PhD, RN, University of Pittsburgh School of Nursing, Pittsburgh, PA, USA

3:25 PM Q&A

4:00 PM - 5:30 PM

ORAL SESSION 34: Short-Term MCS for Shock: New Paradigms

Location:

Seaport A-E

Target Audience:

MCS, HF, HTX, NNSAH

Chairs:

Ashish S. Shah, MD, and Pascal N. Leprince, MD, PhD

4:00 PM (347) *Extra Corporeal Membrane Oxygenation (ECMO) as a Bridge to Adult Heart Transplantation: Bridge to Bridge Strategy vs Direct ECMO Bridge Strategy (UNOS Analysis)*; [B. Hannawi](#)¹, J. Estep¹, D. Nguyen², E. Graviss², B. Trachtenberg¹, A. Bhimaraj¹, M. Park¹, B. A. Bruckner³, A. Guha¹. ¹Cardiovascular Disease, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Research Institute, Houston, TX, ³Houston Methodist Hospital, Houston, TX

4:15 PM (348) *Hemodynamic Effects and Clinical Response to Intra-Aortic Balloon Pump in Chronic Heart Failure Patients with Cardiogenic Shock*; [J. Fried](#), A. Nair, V. K. Topkara, A. Masoumi, K. Clerkin, P. C. Colombo, M. Yuzefpolskaya, K. Takeda, H. Takayama, Y. Naka, A. R. Garan. *Columbia University, New York, NY*

4:30 PM (349) *Incidence and Outcomes of Acute Circulatory Support Prior to Heart Transplantation*; D. Ouyang, G. Gulati, R. Ha, [D. Banerjee](#). *Medicine, Stanford, Palo Alto, CA*

4:45 PM (350) *Clinical Outcomes and Left Ventricular Unloading with Intra-Aortic Balloon Pump During Extracorporeal Life Support*; S. Tepper, M. F. Masood, M. Baltazar Garcia, M. Pisani, A. Ahmed, A. Khan, [A. Itoh](#). *Washington University School of Medicine in St. Louis, Saint Louis, MO*

5:00 PM (351) *Contemporary ECMO Therapy for Postcardiotomy Shock: From REgiSty for Cardiogenic Shock: Utility and Efficacy of Device Therapy (RESCUE)*; H. Takayama¹, J. Han¹, M. Baltazar-Garcia², M. Lucas³, M. Kai⁴, M. Camacho⁵, B. Sun⁶, D. Ranney⁷, M. A. Daneshmand⁷, [A. Itoh](#)². ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO, ³Department of Cardiothoracic Surgery, University of Colorado, Denver, CO, ⁴Department of Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, ⁵Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ, ⁶Minneapolis Heart Institute, Minneapolis, MN, ⁷Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC

5:15 PM (352) *Clinical Outcomes of Impella Microaxillary Pumps When Used in Patients with Cardiogenic Shock Bridged Successfully to Durable Mechanical Circulatory Support and Cardiac Transplantation*; [R. Cheng](#), D. Ramzy, B. Azarbal, F. Esmailian, D. Geft, D. H. Chang, E. Passano, L. Czer, J. A. Kobashigawa, J. Moriguchi, F. Arabia. *Cedars-Sinai Heart Institute, Los Angeles, CA*

4:00 PM - 5:30 PM

ORAL SESSION 35: Heart Failure in MCS

Location:

Grand Hall A

Target Audience:

MCS, HF, HTX, PH

Chairs:

Ahmet Kilic, MD, and Anna L Meyer, MD

4:00 PM (353) Does Inotrope Dependence Make a Difference in Outcome in Patients Receiving Left Ventricular Assist Device? Comparison Between INTERMACS Profiles 3 vs 4/5 from the INTERMACS Registry; S. M. Joseph¹, S. A. Hall¹, B. Lima¹, J. O. Robertson², D. C. Naftel³, S. Myers³, J. K. Kirklin⁴, S. C. Silvestry⁵. ¹Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, ²Washington University, St. Louis, MO, ³University of Alabama, Birmingham, AL, ⁴Surgery, University of Alabama, Birmingham, AL, ⁵Surgery, Florida Hospital Center, Orlando, FL

4:15 PM (354) Vasoactive-Inotropic Score Is Associated with In-Hospital Mortality in Continuous Flow Left Ventricular Assist Device Patients; J. Han¹, H. Takayama¹, P. A. Kurlansky¹, A. R. Garan², M. Yuzefpolskaya², V. K. Topkara², P. C. Colombo², Y. Naka¹, K. Takeda¹. ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Columbia University Medical Center, New York, NY

4:30 PM (355) The Duration of Inotropic Support and Survival After Left Ventricular Assist Device; E. Grandin¹, D. Mooney¹, K. Kennedy², M. S. Kiernan³, R. D. Kociol¹, J. J. Teuteberg⁴, F. D. Pagani⁵, A. C. Gaffey⁶, P. Atluri⁷, E. Y. Birati⁸, S. Myers⁹, D. Naftel⁹, G. Oliveira¹⁰, K. E. Simpson¹¹, R. W. Yeh¹, J. K. Kirklin¹², R. L. Kormos¹³, J. Rame⁸. ¹Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, ²Mid America Heart Institute, St. Luke's Hospital, Kansas City, MO, ³Division of Cardiovascular Medicine, Tufts Medical Center, Boston, MA, ⁴Division of Cardiovascular Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Cardiovascular Surgery, University of Michigan, Ann Arbor, MI, ⁶Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁷Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁸Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁹INTERMACS, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Cleveland, OH, ¹¹Division of Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO, ¹²Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Cardiovascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

4:45 PM (356) The Incidence of Early and Late Clinical Right Heart Failure and the Impact on Survival After Continuous Flow Mechanical Support: Insights from the New INTERMACS Definition of Right Heart Failure; J. J. Teuteberg¹, G. Studdard², F. Pagani³, M. Kiernan⁴, G. Oliveria⁵, E. Rame⁶, P. Alturi⁶, A. Gaffey⁶, E. W. Grandin⁷, J. Kirlin², S. Myers², C. Collum², R. L. Kormos¹. ¹University of Pittsburgh, Pittsburgh, PA, ²University of Alabama, Birmingham, Birmingham, AL, ³University of Michigan, Ann Arbor, MI, ⁴Tufts Medical Center, Boston, MA, ⁵Case Western, Cleveland, OH, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Beth Israel Deaconess, Boston, MA

5:00 PM (357) Normalization of Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure in Response to Speed Change Predicts Better Outcome in Patients with Left Ventricular Assist Devices; T. Imamura¹, G. Sayer¹, S. Adatya¹, G. Kim¹, J. Raikhelkar¹, T. Ota¹, T. Song¹, C. Juricek¹, V. Kagan¹, D. Rodgers¹, V. Jeevanandam¹, D. Burkhoff², N. Uriel¹. ¹University of Chicago, Chicago, IL, ²University of Columbia, New York, NY

5:15 PM (358) Effect of Transplant Rates on Benefit of Left Ventricular Assist Device versus Inotrope Support; J. C. Robertson¹, K. D. Aarsonson², A. Basu¹, L. Kessler¹, C. Mahr³, N. A. Mokadam⁴, T. Dardas³. ¹Health Services, University of Washington, Seattle, WA, ²Internal Medicine, University of Michigan, Ann Arbor, MI, ³Medicine, University of Washington, Seattle, WA, ⁴Surgery, University of Washington, Seattle, WA

4:00 PM - 5:30 PM

ORAL SESSION 36: CAV: New Insights to an Old Problem

Location:

Grand Hall B

Target Audience:

HTX, BSTR, PATH, PHARM

Chairs:

Randall C. Starling, MD, MPH, and Marco Masetti, MD

4:00 PM (359) Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study; R. Asleh, A. Briasoulis, J. Tilford, W. Choi, N. L. Pereira, B. S. Edwards, A. L. Clavell, L. D. Joyce, J. M. Stulak, S. Maltais, D. L. Joyce, R. C. Daly, A. Lerman, S. S. Kushwaha. *Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN*

4:15 PM (360) Early Aspirin Initiation Following Heart Transplantation Decreases the Risk of Allograft Vasculopathy During Long-Term Follow-Up; Y. Peled¹, J. Lavee¹, E. Raichlin², M. Katz¹, Y. Shemesh¹, Y. Kassif¹, E. Asher¹, D. Elian¹, Y. Har-Zahav¹, N. Shlomo¹, I. Goldenberg¹, D. Freimark¹, R. Klempfner¹. ¹Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, ²University of Nebraska Medical Center, Omaha, NE

4:30 PM (361) Atheroprotective Effect of IgM Anti-Phosphorylcholine Natural Antibodies in Heart Transplant Patients; C. A. Labarrere¹, J. W. Hardin², B. R. Jaeger³, D. L. Bhatt⁴, G. S. Kassab¹. ¹California Medical Innovations Institute, San Diego, CA, ²Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, ³Medical Care Center, Laboratory Dr. Stein and Colleagues, Mönchengladbach, Germany, ⁴Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

4:45 PM (362) IgM Anti-Phosphorylcholine, Inflammation and Thrombosis: Effects on Heart Transplant Outcomes; C. A. Labarrere¹, J. W. Hardin², B. R. Jaeger³, D. L. Bhatt⁴, G. S. Kassab¹. ¹California Medical Innovations Institute, San Diego, CA, ²Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, ³Medical Care Center, Laboratory Dr. Stein and Colleagues, Mönchengladbach, Germany, ⁴Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

5:00 PM (363) Early Changes in the Coronary Microstructure After Heart Transplantation: A Prospective Optical Coherence Tomography Study; T. S. Clemmensen¹, N. R. Holm¹, H. Eiskjær¹, B. B. Løgstrup¹, J. Dijkstra², C. J. Terkelsen¹, M. Maeng¹, E. H. Christiansen¹, S. H. Poulsen¹. ¹Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark, ²Division of Image Processing, Leiden University Medical Centre, Leiden, Netherlands

5:15 PM (364) Markers of Intermediate-Term Risk After Heart Transplant - Results of the CTOT-18 Study; J. Stehlik¹, B. Armstrong², D. A. Baran³, A. Chandraker⁴, N. D. Bridges⁵, T. DeMarco⁶, E. Feller⁷, M. Givertz⁴, R. Gordon⁸, P. S. Heeger⁹, A. Heroux¹⁰, J. Hunt¹¹, D. N. Ikle², A. G. Kfoury¹², J. C. Madsen¹³, Y. R. Morrison⁵, S. P. Pinney¹⁴, R. C. Starling¹⁵, .. for CTOT-18 Investigators¹. ¹University of Utah School of Medicine, Salt Lake City, UT, ²Rho Federal Systems Division, Chapel Hill, NC, ³Newark Beth Israel Medical Center, Newark, NJ, ⁴Brigham & Women's Hospital, Boston, MA, ⁵DAIT, NIAID, NIH, Bethesda, MD, ⁶UCSF, San Francisco, CA, ⁷University of Maryland, Baltimore, MD, ⁸Northwestern University, Chicago, IL, ⁹Mount Sinai School of Medicine, New York, NY, ¹⁰Loyola University School of Medicine, Maywood, IL, ¹¹Medical City Dallas Hospital, Dallas, TX, ¹²Intermountain Medical Center, Salt Lake City, UT, ¹³Massachusetts General Hospital, Boston, MA, ¹⁴Mount Sinai School of Medicine, Salt Lake City, UT, ¹⁵The Cleveland Clinic Foundation, Cleveland, OH

4:00 PM - 5:30 PM

ORAL SESSION 37: Impact of Donor Characteristics on Lung Transplant Outcomes

Location:

Grand Hall C

Target Audience:

LTX, BSTR, EEP, MCS, NNSAH

Chairs:

Arne Neyrinck, MD, PhD, and Cassie C Kennedy, MD

(365) WITHDRAWN

4:00 PM (409) Making a Case for EPLET Matching...Eplet Matching Is Associated with Improved Baseline Spirometry and Reduced Risk of CLAD Following Lung Transplantation; M. Paraskeva¹, D. C. Walton², S. J. Hiho², J. Fuller³, L. S. Cantwell², G. P. Westall¹, G. I. Snell¹. ¹Lung Transplant Service, Alfred Hospital, Melbourne, Australia, ²Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia, ³Monash University, Melbourne, Australia

4:15 PM (366) 10 Years Experience with Maastricht Category III Donation After Circulatory Death (DCD) in Lung Transplantation (LTx) - Analysis of Early and Long-Term Results in Large Single-Centre Cohort; B. Zych¹, D. Garcia-Saez¹, O. Ananiadou¹, P. N. Mohite¹, L. Fazekas¹, M. Husain¹, B. Schmack¹, F. De Robertis¹, A. F. Popov¹, T. Bahrami¹, N. Marczin², A. Reed¹, M. Carby¹, A. R. Simon¹. ¹Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital. Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, ²Department of Anaesthesia and Intensive Care, Harefield Hospital. Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom

4:30 PM (367) Extended Donation After Circulatory Death (DCD) Cat 3 Lung Donor Agonal and Post-Mortem Warm Ischemic Times (WIT) Do Not Affect Early Mortality; B. Levvey¹, L. Edwards², A. Robinson², S. Keshavjee³, M. Erasmus⁴, A. Glanville⁵, P. Hopkins⁶, M. Musk⁷, A. Patterson⁸, M. Hertz⁹, F. D'Ovidio¹⁰, K. McCurry¹¹, P. Camp¹², B. Carrico², J. Stehlik¹³, D. Van Raemdonck¹⁴, G. Snell¹. ¹Alfred Hospital, Melbourne, Australia, ²UNOS, Richmond, VA, ³Toronto General Hospital, Toronto, ON, Canada, ⁴Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁵St Vincent's Hospital, Sydney, Australia, ⁶Prince Charles Hospital, Brisbane, Australia, ⁷Lung Transplant Program, Fiona Stanley Hospital, Perth, Australia, ⁸Barnes-Jewish Hospital, St Louis, MO, ⁹Fairview Medical Centre-University of Minnesota, Minneapolis, MN, ¹⁰Columbia Presbyterian Medical Center, New York, NY, ¹¹The Cleveland Clinic Foundation, Cleveland, OH, ¹²Brigham and Womens Hospital, Boston, MA, ¹³University of Utah, Salt Lake City, UT, ¹⁴UZ Gasthuisberg Leuven, Leuven, Belgium

4:45 PM (368) Lessons Learned from the First Clinical Trial to Compare Outcomes of Lungs Transplanted from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) Assessed by Ex-Vivo Lung Perfusion (EVLP) and CT Scan and Lungs Transplanted from Conventional Donors (CONV); T. M. Egan¹, J. Blackwell¹, B. Haithcock¹, J. Long¹, K. Birchard², J. Lobo³, S. Masuodi¹, J. Requard III⁴, C. Thys⁵. ¹Surgery, U. North Carolina Sch Med, Chapel Hill, NC, ²Radiology, U. North Carolina Sch Med, Chapel Hill, NC, ³Medicine, U. North Carolina Sch Med, Chapel Hill, NC, ⁴Lung Banks of America, Chapel Hill, NC, ⁵Carolina Donor Services, Durham, NC

5:00 PM (369) An In Situ Donor Derived Panel of Innate Immune Transcripts Predicts Primary Graft Dysfunction in Lung Transplant Recipients; T. I. Carter¹, Y. Suzuki¹, J. Lasky¹, C. Schaufler¹, B. Lim¹, D. Mallem¹, C. A. Bermudez¹, J. M. Diamond², J. D. Christie³, X. Yu⁴, R. Feng⁴, E. Cantu¹. ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania, Philadelphia, PA, ³Pulmonary, Allergy, and Critical Care Division; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA

5:15 PM (370) Donor-Derived Cell-Free DNA Associates with Rejection in Lung Transplantation Using Clinical-Grade Targeted Next-Generation Sequencing; K. K. Khush¹, J. F. Beausang¹, R. N. Woodward², D. Lew², J. Sninsky², I. De Vlaminc³, C. Strehl⁴, H. Luikart¹, M. Nicolls¹, D. Weill⁵. ¹Stanford University, Stanford, CA, ²CareDx, Brisbane, CA, ³Cornell University, Ithaca, NY, ⁴Florida International University, Miami, FL, ⁵Weill Consulting Group, Palo Alto, CA

4:00 PM - 5:30 PM

ORAL SESSION 38: The Nightmare of Primary Cardiac Allograft Dysfunction

Location:

Grand Hall D

Target Audience:

HTX, MCS, PHARM

Chairs:

Feras Khaliel, MD, PhD, and Maria G Crespo-Leiro, MD

4:00 PM (371) Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome?; J. Patel, M. Kittleson, T. Aintablian, R. Levine, M. Curry, A. Hage, D. Geft, D. Chang, L. Czer, D. Ramzy, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

4:15 PM (372) The Incidence and Outcome of Primary Graft Dysfunction After Adult Heart Transplantation in the United Kingdom; S. Avtaar Singh¹, N. R. Banner², S. Rushton³, N. Al-Attar¹. ¹*Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom*, ²*Golden Jubilee National Hospital, Glasgow, United Kingdom*, ³*Statistics, National Health Service Blood and Transplant (NHSBT), Bristol, United Kingdom*

4:30 PM (373) Treatment of Primary Graft Dysfunction with Plasmapheresis Improves Outcome; D. H. Chang, M. Kittleson, J. Patel, T. Aintablian, R. Levine, D. Geft, E. Kransdorf, L. Czer, A. Trento, F. Esmailian, J. A. Kobashigawa. *Cedars-Sinai Heart Institute, Los Angeles, CA*

4:45 PM (374) Risk of Early Graft Failure Following Heart Transplantation with Durable Continuous Flow vs. Pulsatile Flow Mechanical Circulatory Support; K. J. Clerkin¹, D. M. Mancini², J. Stehlik³, M. A. Clark⁴, L. B. Edwards⁴, L. H. Lund⁵. ¹*Cardiology, Columbia University Medical Center, New York, NY*, ²*Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY*, ³*Cardiology, University of Utah School of Medicine, Salt Lake City, UT*, ⁴*United Network for Organ Sharing, Richmond, VA*, ⁵*Karolinska Institutet (Department of Medicine) and Karolinska University Hospital (Department of Cardiology), Stockholm, Sweden*

5:00 PM (375) Donor Predicted Heart Mass Is Superior to Total Body Weight in Predicting Primary Graft Dysfunction in Undersized Donors; T. A. Gong, G. Gonzalez-Stawinski, S. M. Joseph, P. P. Kale, J. C. MacHannaford, A. Rafael, G. Saracino, S. A. Hall, B. Lima. *Advanced Heart Failure and Transplant, Baylor University Medical Center, Dallas, TX*

5:15 PM (376) Assessing Risk of Primary Graft Dysfunction in Heart Transplantation (HT); S. Shah¹, D. Cruz², M. Deng², A. Ardehali², E. C. DePasquale². ¹*David Geffen School of Medicine, Los Angeles, CA*, ²*UCLA Department of Cardiology, Los Angeles, CA*

4:00 PM - 5:30 PM

ORAL SESSION 39: Early Career Scientist Award in Transplantation Finalist Presentations

Location:

Seaport F-H

Target Audience:

BSTR, HTX, ID, LTX, PATH, PEDS, PHARM

Chairs:

Sonja Schrepfer, MD, PhD, and Edward Cantu, MD

4:00 PM (377) *Transplanting the Human Respiratory Virome*; A. B. Mitchell¹, B. Mourad¹, M. A. Malouf², M. Benzimra², L. C. Morgan³, B. G. Oliver¹, A. R. Glanville⁴. ¹Molecular Biology, University of Technology, Sydney, Australia, ²Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ³Thoracic Medicine, Concord Clinical School, University of Sydney, Sydney, Australia, ⁴Thoracic Medicine, St Vincent's Hospital, Sydney, Australia

4:15 PM (378) *Differential Modulation of the IL-17A Pathway in Restrictive Allograft Syndrome (RAS) versus Bronchiolitis Obliterans Syndrome (BOS)*; A. Tigert¹, T. Saito², L. Levy¹, G. Zehong¹, K. Boonstra¹, S. Keshavjee¹, S. Juvet¹, T. Martinu¹. ¹Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada, ²Department of Thoracic Surgery, Kansai Medical University, Hirakata, Japan

4:30 PM (379) *Splenic Monocytes Promote Neutrophil Extravasation into Lung Grafts via a TLR9-IL1 β -Dependent Pathway*; H. Hsiao¹, T. Takahashi¹, Y. Liu¹, D. Scozzi¹, W. Li¹, A. S. Krupnick², A. E. Gelman³, D. Kreisel¹. ¹Surgery, Washington University in Saint Louis, Saint Louis, MO, ²Surgery, University of Virginia, Charlottesville, VA, ³Pathology and Immunology, Washington University in Saint Louis, Saint Louis, MO

4:45 PM (380) *Validation of microRNA Profiling in Different Types of Rejection Previously Identified with NGS Technology in Formalin Fixed EMBs*; A. Di Francesco¹, M. Fedrigo², F. De Pascale³, C. Castellani², G. Feltrin², G. Toscano², A. Fraiese², E. Benazzi⁴, A. Nocco⁴, G. Thiene², M. Valente², G. Valle³, G. Gerosa², A. Angelini². ¹University of Padova, Padova, Italy, ²Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ³CRIBI Biotechnology Centre, University of Padova, Padova, Italy, ⁴Organ and Tissue Transplantation Immunology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy

5:00 PM (381) *Molecular Profiling of Endomyocardial Biopsies and Clinical Phenotype of Graft Dysfunction: Taking Rejection Diagnosis Beyond Pathological Findings*; L. Borgese¹, A. Gaudenzi¹, V. Agostini², M. Masetti¹, B. Corti², J. Reeve³, F. Grigioni¹, O. Leone², P. Halloran³, L. Potena¹. ¹Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, ²Pathology, University of Bologna, Bologna, Italy, ³ATAGC, University of Alberta, Edmonton, AB, Canada

4:00 PM - 5:30 PM

ORAL SESSION 40: Drugs, Bleeding and Enzymes ... Oh My!

Location:

Coronado A-C

Target Audience:

PHARM, HTX, ID, LTX, MCS, NNSAH

Chairs:

Walter Uber, PharmD, and Rochelle M Gellatly, PharmD

4:00 PM (382) *Impact of Angiotensin II Inhibitors on the Incidence of Gastrointestinal Bleeds After Left Ventricular Assist Device Placement*; M. Converse, M. Sobhanian, A. Mardis, D. Taber, W. Uber, H. Meadows, B. Houston, N. Patel, A. Vanbakel. *Pharmacy, Medical University of South Carolina, Charleston, SC*

4:15 PM (383) *Evaluation of Prothrombin Complex Concentrate in Warfarin Reversal Prior to Heart Transplantation in Patients with Durable Mechanical Circulatory Support*; C. I. Konopka¹, E. T. Horn¹, S. Murali², R. L. Benza², R. J. Moraca³, S. H. Bailey³. ¹*Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA*, ²*Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, PA*, ³*Division of Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA*

4:30 PM (384) *Stimulated T-Cell Interferon Gamma Responses as a Biomarker of Immune Function*; S. Yogakanthi¹, A. Y. Peleg², E. Paul³, Y. Cristiano¹, G. Snell¹, G. Westall¹. ¹*Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital & Monash University, Melbourne, Australia*, ²*Department of Infectious Diseases, Alfred Hospital & Monash University, Melbourne, Australia*, ³*Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia*

4:45 PM (385) *Impact of CYP3A5, CYP3A4, and ABCB1 Genotypes on Lung Transplant Recipient Early Clinical Outcomes*; D. R. Calabrese¹, R. Boettger², K. Dewey², C. Hui², D. Torgerson¹, H. Faust³, R. Rajalingam⁴, S. Hays¹, J. Singer¹, R. Shah¹, L. Leard¹, J. Kukreja⁴, J. Golden¹, J. Greenland⁵. ¹*Department of Medicine, University of California San Francisco, San Francisco, CA*, ²*Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA*, ³*Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA*, ⁴*Department of Surgery, University of California San Francisco, San Francisco, CA*, ⁵*Medical Service, Veterans Affairs Medical Center, San Francisco, CA*

5:00 PM (386) *Tacrolimus Dosing Requirements Are Reduced in Heart Transplant Recipients with Severe Primary Graft Dysfunction on ECMO Support*; N. Breslin, D. Salerno, N. Jandovitz, D. Tsapepas, S. Restaino, F. Latif, P. Colombo, M. Farr, D. L. Jennings. *New York Presbyterian Columbia Irving Medical Center, New York, NY*

5:15 PM (387) *Relationship Between Patient-Perceived Treatment Burden and Medication Adherence in Heart Transplant Recipients*; K. M. Deininger¹, J. D. Hirsch², S. A. Graveline², A. A. Feist², S. M. Smith³, J. A. Reich¹, J. LaFleur⁴, A. V. Ambardekar¹, J. Lindenfeld⁵, C. L. Aquilante¹. ¹*University of Colorado, Aurora, CO*, ²*University of California San Diego, La Jolla, CA*, ³*University of Florida, Gainesville, FL*, ⁴*University of Utah, Salt Lake City, UT*, ⁵*Vanderbilt University, Nashville, TN*

Saturday, April 08, 2017

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 13: Mechanical Circulatory Support - The Interface of Design and Outcome

Location:

Grand Hall A

Target Audience:

MCS, BSTR, EEP, HF, HTX

Chairs:

Ulrich Steinseifer, PhD, and Robert L Kormos, MD

Session Summary: Despite the advance of mechanical circulatory support systems over the past decade they remain limited by the significant incidence of adverse events (AE). In this session approaches to understand and limit AE such as thrombosis, bleeding and infection will be addressed. Particularly, the role of system component interfaces, smart monitoring and alarms using pressure sensors and data mining techniques, and the “design thinking” paradigm for devices that embody multi-factorial challenges.

7:00 AM

Interfaces and Mechanical Circulatory Support: Challenges and Opportunities for System and Outcome Improvement

Marvin J Slepian, MD, University of Arizona, Tucson, AZ, USA

7:10 AM Q&A

7:15 AM

Will Pressure Sensors Help in Making Smarter Pumps?

Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

7:25 AM Q&A

7:30 AM

Anticipation of Adverse Events: Do the Data Speak For Themselves?

Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria

7:40 AM Q&A

7:45 AM

Design/Interconnected Thinking for Better Biomedical Devices

J. Yasha Kresh, PhD, Drexel University College of Medicine, Philadelphia, PA, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 14: The Tsunami of Adult Congenital Heart Disease (ACHD) Patients Who Need Advanced Therapies: Are We Prepared?

Location:

Grand Hall B

Target Audience:

HTX, HF, LTX, MCS, PEDS, PH

Chairs:

Heather J. Ross, MD, MHSc, FRCPC, and Sanem Nalbantgil, MD

Session Summary: A need exists for advanced therapies for Adult Congenital Heart Disease (ACHD) patients. The session will begin with the challenges of bringing ACHD patients to transplant. The session will also include talks on surgical planning and mechanical support options for these patients, accurate imaging evaluation, and treatment of pulmonary hypertension. We will discuss a team based approach to successful outcomes as well as dual organ transplantation and will end with a discussion of allocation in ACHD patients worldwide.

7:00 AM

How to Know When an Adult with Complex Congenital Heart Disease Needs Heart Transplantation

Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

7:15 AM Q&A

7:20 AM

Surgical Considerations for MCS and Heart Transplant ACHD

Martin Schweiger, MD, Children's Hospital, Zurich, Switzerland

7:35 AM Q&A

7:40 AM

Care of the ACHD Patient After MCS or Heart Transplant: The Challenge is Just Beginning

Jonathan Menachem, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 15: Extracorporeal Photopheresis: Shedding Light on Rejection?

Location:

Grand Hall C

Target Audience:

LTX, BSTR, HTX, ID, NNSAH, PATH, PEDS, PHARM

Chairs:

Matthew R Morrell, MD, and Christian Benden, MD

Session Summary: This session will explore mechanisms of and clinical indications for extracorporeal photopheresis (ECP) with a goal to increase understanding of the possible benefits of ECP and adoption of this therapy in lung and heart transplant recipients.

7:00 AM

ECP: Everything Under the Sun

Jill Adamski, MD, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA

7:17 AM Q&A

7:20 AM

ECP in Heart Transplantation: Have the Lights Gone Out?

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

7:37 AM Q&A

7:40 AM

ECP in Lung Transplantation: Light at the End of the Tunnel?

Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany

7:57 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 16: Pregnant - Scared? So Are We.... Management of Pregnancy in Our Complex Patients

Location:

Seaport F-H

Target Audience:

PHARM, HTX, LTX, MCS, NNSAH, PEDS

Chairs:

Susan M Joseph, MD, and Christa Kirk, PharmD

Session Summary: Women of reproductive age account for over 1/3 of all SOT recipients. Most are advised to avoid pregnancy for several years post-transplant, if not altogether. However, as outcomes post-transplant continue to improve, more women are able to consider pregnancy. There are numerous risks to the transplant recipient, organ, and fetus. Hence, there is a great need for expertise in addressing family planning, fertility, contraception, and care during and after pregnancy.

7:00 AM

The Facts of Life: Pregnancy after Thoracic Organ Transplant

Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium

7:10 AM Q&A

7:15 AM

Labor of Love: Pregnancy in the Heart Failure / Congenital Population

Leigh C Reardon, MD, UCLA Medical Center, Los Angeles, CA, USA

7:25 AM Q&A

7:30 AM

In the Mix: Orchestrating the Multidisciplinary Care of the Post-Transplant/MCS/Complex Congenital Pregnant Patient

Mary Canobbio, RN, FAAN, UCLA Medical Center, Los Angeles, CA, USA

7:40 AM Q&A

7:45 AM

Treating the Mother, Protecting the Baby: Drug Therapy During and After Pregnancy

Jennifer Eshelman, PharmD, Children's Hospital Colorado, Aurora, CO, USA

7:55 AM Q&A

7:00 AM - 8:00 AM

SUNRISE SYMPOSIUM 17: Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation

Location:

Coronado A-C

Target Audience:

BSTR, ALL

Chairs:

Howard Eisen, MD, and Bryan Coburn, MD, PhD, FRCPC

Session Summary: The goal of this session is to explore the role of the microbiome in affecting posttransplant outcomes or in reflecting the extent of immunosuppression. Discussion will include an overview of the effect of the microbiome on health and disease followed by transplant specific considerations. Included in this is the question of whether changes in the bacterial or viral micro biome can be used to reflect the extent of immunosuppression, thus facilitating modulation of immunosuppression to improve outcomes.

7:00 AM

The Microbiome in Health and Disease

W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

7:10 AM Q&A

7:15 AM

Microbiome in Transplantation

Maria-Luisa Alegre, MD PhD, University of Chicago, Chicago, IL, USA

7:25 AM Q&A

7:30 AM

The Microbiome and Immunosuppression in Heart Transplant

Kiran Khush, MD, MAS, Stanford University, Stanford, CA, USA

7:40 AM Q&A

7:45 AM

Microbiome in Lung transplantation and Gut-Lung Axis

Sangeeta M Borhade, MD, Northwestern Memorial Hospital, Chicago, IL, USA

7:55 AM Q&A

8:00 AM - 9:30 AM

ORAL SESSION 41: The Rhythm is Going to Get You: EP Issues in MCS

Location:

Seaport A-E

Target Audience:

MCS, HF, NHSAH

Chairs:

Ayesha K. Hasan, MD, and Daniel Zimpfer, MD

8:00 AM (460) Cardiac Resynchronization Therapy Reduces Mortality and Cardiovascular Readmissions in Left Ventricular Assist Device Recipients; A. R. Garan¹, X. Mai¹, V. K. Topkara¹, K. Takeda¹, K. J. Clerkin¹, R. Demmer¹, M. Yuzefpolskaya¹, H. Takayama¹, Y. Naka¹, J. Chyou², H. M. Spotnitz¹, N. Uriel³, J. Dizon¹, P. C. Colombo¹. ¹Columbia University, New York, NY, ²SUNY Stonybrook, Stonybrook, NY, ³University of Chicago, Chicago, IL

8:15 AM (461) Survival Benefit of Implantable Cardioverter Defibrillator Therapy on Patients with Left Ventricular Assist Device; E. Simsek¹, S. Nalbantgil¹, E. Demir¹, H. S. Kemal², I. Mutlu¹, P. Ozturk³, S. Ertugay³, C. Engin³, T. Yagdi³, M. Ozbaran³. ¹Cardiology, Ege University School of Medicine, Izmir, Turkey, ²Cardiology, Near East University School of Medicine, Lefkosa, Cyprus, ³Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey

8:30 AM (462) Impact of Cardiac Resynchronization Therapy (CRT) on Invasive Hemodynamics and Echocardiographic Parameters in Patients with Implanted Left Ventricular Assist Devices (LVADs); S. Adatya¹, D. M. Tehrani¹, N. Sarswat¹, G. H. Kim¹, J. Raikhelkar¹, C. Juricek¹, V. Kagan¹, T. Ota¹, D. Burkhoff², G. Sayer¹, V. Jeevanandam¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²Heartware International, Inc, Framingham, MA

8:45 AM (463) Right Ventricular Pacing Improves Functional Status and Quality of Life Compared to Biventricular Pacing in Left Ventricular Assist Device Patients; J. Grinstein¹, D. Medvedofsky¹, E. Flatley¹, J. Moss², D. Beiser¹, S. Adatya¹, G. Sayer¹, N. Sarswat¹, J. Raikhelkar¹, G. H. Kim¹, V. Kagan¹, W. Lee¹, T. Ota¹, V. Jeevanandam¹, R. Lang¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²University of California San Francisco, San Francisco, CA

9:00 AM (464) Postoperative Atrial Fibrillation After Left Ventricular Assist Device Placement Increases Morbidity and Resource Utilization; R. B. Hawkins¹, A. Guo¹, J. Mehaffey¹, C. Fonner², A. Speir³, J. Rich², M. Quader⁴, G. Ailawadi¹, L. Yarboro¹. ¹University of Virginia, Charlottesville, VA, ²Virginia Cardiac Services Quality Initiative, Falls Church, VA, ³INOVA Heart and Vascular Institute, Falls Church, VA, ⁴Virginia Commonwealth University, Charlottesville, VA

9:15 AM (465) Comparison of Survival and Modes of Death by ICD Status Among LVAD Recipients; X. Mai, K. Clerkin, V. K. Topkara, K. Takeda, R. Demmer, M. Yuzefpolskaya, M. Tiburcio, H. Takayama, Y. Naka, H. M. Spotnitz, J. Dizon, P. C. Colombo, A. R. Garan. Columbia University, New York, NY

8:00 AM - 9:30 AM

ORAL SESSION 42: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS

Location:

Grand Hall A

Target Audience:

MCS, HF, HTX, NNSAH

Chairs:

Theodoros Kofidis, MD, PhD, FRCS, and Brent C Lampert, DO

8:00 AM (466) Clinical Outcomes of Adults with Elevated Body Mass Index with Destination Therapy: An Analysis of INTERMACS Registry; A. Jaiswal¹, L. Myers², V. K. Topkara³, P. C. Colombo³, D. Baran⁴, T. H. Le Jemtel¹.

¹Cardiology, Tulane Heart and Vascular Institute, New Orleans, LA, ²Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, ³Cardiology, Columbia University Medical Center-New York Presbyterian, New York, NY, ⁴Heart Transplantation, Newark Beth Israel Medical Center, Newark, NJ

8:15 AM (467) Impact of Morbid Obesity After Left Ventricular Assist Device Placement; L. Coyle, G. Yost, C.

Gallagher, N. Graney, R. Siemeck, G. Bhat, A. Tatoes. *Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL*

8:30 AM (468) Factors Associated with Prolonged Survival in Destination Therapy LVAD Recipients; Y. Xia¹, S.

Forest¹, P. Friedmann¹, L. Chou¹, S. Patel², U. Jorde³, D. Goldstein¹. ¹Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, ²Internal Medicine, Cardiology, Montefiore Medical Center, Bronx, NY, ³Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

8:45 AM (469) How Old Is Too Old? The Influence of Advanced Age on VA-ECMO Outcomes; M. Salna¹, K.

Takeda², P. Kurlansky², H. Ikegami², J. Han¹, S. Stein², V. Topkara³, M. Yuzefpolskaya³, P. C. Colombo³, Y. Naka², A. R. Garan³, H. Takayama². ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Surgery (Cardiothoracic), Columbia University Medical Center, New York, NY, ³Medicine (Cardiology), Columbia University Medical Center, New York, NY

9:00 AM (470) Proteinuria in Patients Receiving Left Ventricular Assist Devices Is Highly Associated with Renal Failure and Mortality; R. Muslem¹, K. Caliskan¹, S. Akin¹, D. A. Hesselink², G. Whitman³, R. J. Tedford⁴, A. J. Bogers⁵,

O. C. Manintveld¹, S. D. Russell⁴. ¹Cardiology, Erasmus MC, Rotterdam, Netherlands, ²Nephrology, Erasmus MC, Rotterdam, Netherlands, ³Cardiac Surgery, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Cardiac Surgery, Erasmus MC, Rotterdam, Netherlands

9:15 AM (471) Adverse Events After Device Implantation Are More Common in Obese Patients: An IMACS Registry Analysis; S. J. Forest¹, R. Xie², J. K. Kirklin², J. A. Cowger³, Y. Xia¹, A. I. Dipchand⁴, C. Sivathasan⁵, C. Merry⁶,

L. H. Lund⁷, R. Kormos⁸, T. Nakatani⁹, U. Jorde¹⁰, D. J. Goldstein¹. ¹Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, ²The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO)/UAB, Birmingham, AL, ³St. Vincent Heart Center of Indiana, Indianapolis, IN, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵National Heart Centre Singapore, Singapore, Singapore, ⁶Fiona Stanley Hospital, Perth, Australia, ⁷Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, ⁸Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, ⁹Maki Hospital, Osaka, Japan, ¹⁰Medicine, Montefiore Medical Center, Bronx, NY

8:00 AM - 9:30 AM

ORAL SESSION 43: In the Mix of Heart Failure

Location:

Grand Hall B

Target Audience:

HF, BSTR, NHTSAH, PHARM

Chairs:

Ivan Knezevic, MD, and Michael M. Givertz, MD

8:00 AM (472) Exosome Signaling in Heart Failure; H. Basma, K. Dhar, D. R. Anderson, L. M. Smith, S. Rennard, B. D. Lowes. *Internal Medicine, UNMC, OMAHA, NE*

8:15 AM (473) The Effects of CD34+ Cell Therapy in Heart Failure with Preserved Ejection Fraction; B. Vrtovec¹, G. Poglajen¹, G. Zemljic¹, S. Frljak¹, A. Cerar¹, R. Okrajsek¹, M. Jaklic¹, F. Haddad². ¹*Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia*, ²*Stanford Cardiovascular Institute, Stanford, CA*

8:30 AM (474) Leukocyte Time-Dependent Biology and Outcomes in Advanced Heart Failure; G. Bondar¹, M. Cadeiras¹, N. Wisniewski¹, A. Esmaili¹, G. Godoy¹, J. Maque¹, E. Chang¹, M. Bakir¹, S. Kupiec-Weglinski², D. Chu¹, T. Bao¹, J. Hai¹, R. Yee¹, A. Li¹, M. Rai¹, D. Tran¹, L. Madrigal¹, R. Togashi¹, P. Ping³, E. Reed⁴, M. Deng¹. ¹*Medicine/Cardiology, David-Geffen Sch Med, Los Angeles, CA*, ²*Agriculture and Life Science, Cornell University, Ithaca, NY*, ³*Physiology, David-Geffen Sch Med, Los Angeles, CA*, ⁴*Pathology & Laboratory Medicine-Immunogenetics Center, David-Geffen Sch Med, Los Angeles, CA*

8:45 AM (475) Multi-Omic Biomarker Signatures Are Predictive of 9-Month Patient Outcomes in Subjects with Advanced Heart Failure; A. Singh, C. P. Shannon, S. Assadian, M. Toma, V. Chen, L. Dai, K. K. Lam, Z. Hollander, R. T. Ng, S. J. Tebbutt, B. M. McManus. *University of British Columbia, Vancouver, BC, Canada*

9:00 AM (476) Abnormalities of Cardiolipin Synthesis and Remodeling in Heart Failure: A Cornerstone of Energy Deprivation; H. N. Sabbah. *Henry Ford Health System, Detroit, MI*

9:15 AM (477) Increased Right Ventricular Sympathetic Activity and Oxygen Consumption in Patients with Right Ventricular Dysfunction; A. Ahmadi, J. M. Renaud, S. Promislow, I. Burwash, G. Dwivedi, J. Zelt, R. A. deKemp, R. S. Beanlands, L. M. Mielniczuk. *University of Ottawa Heart Institute, Ottawa, ON, Canada*

8:00 AM - 9:30 AM

ORAL SESSION 44: Optimizing Early Outcomes after Lung Transplantation

Location:

Grand Hall C

Target Audience:

LTX, BSTR, ID, PATH, PHARM

Chairs:

Hilary J Goldberg, MD, and Monique Malouf, FRACP

8:00 AM (478) Relationship of Early Lung Allograft Injury as Measured by Cell Free DNA with Donor and Recipient Characteristics; S. M. Pham¹, S. Agbor-Enoh², P. Shah³, I. Timofte⁴, S. Nathan⁵, J. Orens³, A. Brown⁵, S. Gorham², K. Bhatti², A. Marishta², M. Jang², Y. Yang², U. Fideli², I. Tunc², J. Zhu², A. Iacono⁶, H. Valantine². ¹*Surgery, University of Maryland, Baltimore, MD*, ²*NIH, Bethesda, MD*, ³*Johns Hopkins University, Baltimore, MD*, ⁴*Medicine, University of Maryland, Baltimore, MD*, ⁵*Inova, Fall Church, VA*, ⁶*University of Maryland, Baltimore, MD*

8:15 AM (479) Cell-Free DNA in Human Ex-Vivo Lung Perfusate as a Potential Biomarker to Predict the Risk of Primary Graft Dysfunction (PGD) in Lung Transplantation; T. Kanou¹, R. Zamel¹, M. Chen¹, D. Nakajima¹, Y. Watanabe¹, L. Ding¹, S. Azad¹, T. K. Waddell¹, K. Nakahira², A. M. Choi², M. Cypel¹, M. Liu¹, S. Keshavjee¹. ¹*Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, Toronto, ON, Canada*, ²*Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY*

8:30 AM (483) Early CMV Management Post Lung Transplant(LTx): A 6-Year Review of Pre-Emptive Strategy for CMV; K. Santhanakrishnan, E. Karimi, N. Yonan, M. Alaloul, R. Venkateswaran, K. Heyes. *Transplant Department, Wythenshawe Hospital, Manchester, United Kingdom*

8:45 AM (481) Gene Expression Profiling of Bronchoalveolar Lavage Cells During Lung Allograft Acute Rejection; S. S. Weigt¹, X. Wang¹, V. Palchevskiy¹, N. D. Patel¹, D. J. Ross¹, J. M. Reynolds², P. Shah³, L. Singer⁴, M. Budev⁵, S. Palmer², J. A. Belperio¹. ¹*UCLA, Los Angeles, CA*, ²*Duke University, Durham, NC*, ³*Johns Hopkins, Baltimore, MD*, ⁴*University of Toronto, Toronto, ON, Canada*, ⁵*Cleveland Clinic, Cleveland, OH*

9:00 AM (482) Treatment of Antibody Mediated Rejection of the Lung Allograft with Carfilzomib-Based Therapy; C. R. Ensor, A. Zeevi, S. A. Yousem, M. Mangiola, M. Marrari, M. R. Morrell, J. M. Pilewski, J. D'Cunha, J. F. McDyer. *University of Pittsburgh, Pittsburgh, PA*

9:15 AM (480) The Association of IL-6 and IL-8 within 72 Hours Post-Transplant and Short and Long Term Outcome; S. E. Verleden, A. Martens, E. Vandermeulen, H. Bellon, T. Heigl, A. Sacreas, A. Neyrinck, A. van Herck, D. Van Raemdonck, G. Verleden, B. Vanaudenaerde, R. Vos. *KU Leuven, Leuven, Belgium*

8:00 AM - 9:30 AM

ORAL SESSION 45: Heart Transplant in Special Populations

Location:

Grand Hall D

Target Audience:

HTX, HF, MCS

Chairs:

Jacqueline M. Smits, MD, PhD, and Tobias Deuse, MD, PhD

8:00 AM (484) Heart Transplantation and Bridge with Mechanical Circulatory Support in Cardiac Sarcoidosis: An Analysis of the UNOS Registry; T. C. Crawford¹, J. T. Magruder¹, J. Grimm¹, A. Suarez Pierre¹, B. A. Houston², K. Mandal¹, K. J. Zehr¹, G. J. Whitman¹, R. J. Tedford³, S. D. Russell³, N. A. Gilotra³. ¹Surgery, Johns Hopkins University, Baltimore, MD, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine, Johns Hopkins University, Baltimore, MD

8:15 AM (485) Survival After Heart Transplantation in Patients with Cardiac Sarcoidosis - A UNOS Registry Analysis; S. Madan¹, S. R. Patel¹, D. Sims¹, J. Shin¹, D. Goldstein², U. P. Jorde¹, O. Saeed¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, ²Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

8:30 AM (486) Heart Transplantation in Muscular Dystrophy Patients: Is It a Viable Option?; R. Rizwan¹, J. L. Jefferies², R. Bryant III¹, G. A. Pettengill¹, T. D. Ryan², A. Lorts², C. Chin², F. Zafar¹, D. L. Morales¹. ¹Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

8:45 AM (487) The Effect of Pre-Heart Transplant Obesity on Post-Transplant Mortality: An Analysis of the ISHLT Registry Data; B. S. Doumouras¹, C. S. Fan², A. I. Dipchand³, C. Manlhiot², J. Stehlik⁴, H. J. Ross¹, A. C. Alba¹. ¹Heart Failure and Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²CV Data Management Centre, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴University of Utah School of Medicine, Salt Lake City, UT

9:00 AM (488) Young African American Heart Transplant Recipients Have an Elevated Risk of Post-Transplant Mortality; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

9:15 AM (489) The Psychosocial Treadmill - Working Out a Way to Improve High Risk Psychosocial Behaviors in Heart Transplant Candidates; L. Newman, A. Kilic, A. K. Hasan, S. Smith, S. Emani, B. Whitson, B. C. Lampert. The Ohio State University Wexner Medical Center, Columbus, OH

8:00 AM - 9:30 AM

ORAL SESSION 46: Rogue One: A Graft Wars Story of Rejection and Tolerance

Location:

Seaport F-H

Target Audience:

BSTR, HF, HTX, LTX, PATH, PEDS, PHARM

Chairs:

Tereza Martinu, MD, PhD, and Stijn E Verleden, PhD

8:00 AM (490) Chronic Airway Fibrosis in Orthotopic Mouse Lung Transplantation Models - An Experimental Reappraisal; L. Dubs¹, Y. Yamada¹, J. Jang¹, T. Martinu², D. Kenkel³, K. Windirsch¹, I. Inci¹, B. Vanaudenaerde⁴, A. Boss³, W. Weder¹, W. Jungraithmayr¹. ¹Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²University of Toronto, Toronto, ON, Canada, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ⁴Laboratory of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium

8:15 AM (491) Ischemia Reperfusion Injury Augments Acute and Chronic Rejection and Alloimmune-Dependent Intrapulmonary Lymphoid Neogenesis in a Mouse Orthotopic Lung Transplant Model; T. Watanabe¹, T. Martinu¹, H. Oishi², M. Horie³, D. Hwang¹, Z. Guan¹, M. Liu¹, S. Keshavjee¹, S. Juvet¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, ²Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, ³Cardiothoracic Division, Department of Medical Imaging, Time Resolved Imaging and Image Optimization, University Health Network, Toronto, ON, Canada

8:30 AM (492) Linking Chronic Lung Allograft Dysfunction with Early Immunologic Events in a Humanized Mouse Model; T. Siemieni¹, A. Knöfel¹, F. Ius¹, K. Jansson¹, J. Salman¹, W. Sommer¹, M. Avsar¹, C. Kühn¹, C. Falk², A. Haverich¹, G. Warnecke¹. ¹Hannover HTTG, Hannover, Germany, ²Institute of Transplant Immunology, Hannover, Germany

8:45 AM (493) Selective Reprogramming and Recapitulation of CD4 and CD8 T Cells in the Neonate to Induce Tolerance to Heart Transplants; R. A. Bascom, K. Tao, L. J. West. University of Alberta, Edmonton, AB, Canada

9:00 AM (494) Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates; K. Huh¹, W. Sommer¹, K. A. Robinson¹, X. Wu¹, J. T. Paster¹, I. Hanekamp¹, A. Dehnadi¹, T. Kawai¹, R. N. Smith², R. Colvin³, G. Benichou¹, J. Madsen¹. ¹Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, ²Department of Pathology, Massachusetts General Hospital, Boston, MA, ³Center for Transplantation Sciences, Department of Pathology, Massachusetts General Hospital, Boston, MA

9:15 AM (495) Generating Hypoimmunogenic Murine Induced Pluripotent Stem Cells by the Disruption of beta-2-Microglobulin; X. Hu¹, T. Deuse², N. Kooreman³, M. Alawi⁴, G. Tediashvili¹, H. Reichenspurner⁵, S. Schrepfer¹. ¹Surgery, TSI Lab, UCSF, San Francisco, CA, ²CT Surgery, UCSF, San Francisco, CA, ³Cardiovascular Medicine, Stanford University, Stanford, CA, ⁴Heinrich Pette, UKE, Hamburg, Germany, ⁵Cardiovascular Surgery, UHZ, Hamburg, Germany

9:45 AM - 11:45 AM
PLENARY SESSION

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Andrew J Fisher, PhD FRCP, and Christian Benden, MD FCCP

9:45 AM Awards Presentations

10:40 AM (496) Advanced Therapy Utilization and Survival in Ambulatory Patients with Advanced Heart Failure: Results from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry; A. V. Ambardekar¹, M. Kittleson², M. Palardy³, M. Mountis⁴, R. Forde-McLean⁵, A. DeVore⁶, S. Pamboukian⁷, J. Thibodeau⁸, J. Teuteberg⁹, L. Cadaret¹⁰, R. Xie⁷, L. Stevenson¹¹, G. Stewart¹¹. ¹U Colorado, Aurora, CO, ²Cedars, Los Angeles, CA, ³U Michigan, Ann Arbor, MI, ⁴Cleveland Clinic, Cleveland, OH, ⁵U Penn, Philadelphia, PA, ⁶Duke, Durham, NC, ⁷UAB, Birmingham, AL, ⁸UTSW, Dallas, TX, ⁹U Pitt, Pittsburgh, PA, ¹⁰U Iowa, Iowa City, IA, ¹¹Brigham, Boston, MA

10:55 AM
Interactive Discussant
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

11:00 AM
PRESIDENT'S DEBATE (PRO): We Must Take Greater Risks for the Sake of Our Patients!
Lori J West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

11:20 AM
PRESIDENT'S DEBATE (CON): We Must Take Greater Risks for the Sake of Our Patients!
Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

12:00 PM - 1:30 PM

ORAL SESSION 47: Not the Usual Suspects: Driving Outcomes in MCS

Location:

Seaport A-E

Target Audience:

MCS, HF, HTX, NNSAH

Chairs:

Markus Johannes Barten, MD, PhD, and Maria M. Mountis, DO

12:00 PM (497) *The Effects of Patient Blood Pressure on the Occurrence of Serious Adverse Events in the ENDURANCE Trial*; J. A. Cowger¹, J. G. Rogers², C. A. Milano², J. J. Teuteberg³, N. A. Mokadam⁴, E. J. Birks⁵, S. W. Boyce⁶, K. D. Aaronson⁷, F. D. Pagani⁷. ¹St. Vincent Heart Center, Indianapolis, IN, ²Duke University Medical Center, Durham, NC, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Washington, Seattle, WA, ⁵University of Louisville, Louisville, KY, ⁶MedStar Health, Washington, DC, ⁷University of Michigan Medical Center, Ann Arbor, IL

12:15 PM (498) *How Does the Pulse Pressure Impact on Cerebral Autoregulation Between Axial and Centrifugal LVAD?*; M. Ono¹, S. K. Singh², K. K. Kibler¹, B. R. Easley¹, O. H. Frazier¹, K. M. Brady¹. ¹Baylor College of Medicine, Houston, TX, ²Brigham & Women's Hospital, Boston, MA

12:30 PM (499) *The Hemodynamic Effects of Intravascular Ventricular Assist System (iVAS) in Advanced Heart Failure Patients Awaiting Heart Transplant*; V. Jeevanandam¹, D. Onsager¹, T. Song¹, B. Chung², T. Ota¹, C. Juricek¹, T. Lammy¹, N. Uriel³. ¹CT Surgery, University of Chicago, Chicago, IL, ²University of Chicago, Chicago, IL, ³Cardiology, University of Chicago, Chicago, IL

12:45 PM (500) *Temporal Patterns of Adverse Events (AE) Occurring within 60 Days of LVAD Implantation: The Concept of the AE Cascade*; J. O. Larsen¹, A. D. Althouse², J. J. Teuteberg³, C. M. Sciortino⁴, C. V. Nikas¹, L. F. Lagazzi⁴, M. S. Sharbaugh², S. U. Iturra¹, N. M. Kunz², E. M. Dunn², K. L. Lockard², R. L. Kormos⁴. ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA

1:00 PM (501) *Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis*; V. Blumer, R. Mendirichaga, S. Chaparro. University of Miami, Miami, FL

1:15 PM (502) *A Multi-Institutional Study of Mechanical Circulatory Support in Adult Congenital Heart Disease: Is This an Effective Therapy?*; A. M. Cedars¹, C. Vanderpluym², D. Koehl³, R. Cantor³, J. K. Kirklin⁴. ¹Cardiology, Baylor University Medical Center, Dallas, TX, ²Cardiology, Boston Children's Hospital, Boston, MA, ³Kirklin Institute for Research in Surgical Outcomes, University of Alabama Birmingham, Birmingham, AL, ⁴Cardiothoracic Surgery, University of Alabama Birmingham, Birmingham, AL

12:00 PM - 1:30 PM

ORAL SESSION 48: Seeing the Patient Beyond the Device

Location:

Grand Hall A

Target Audience:

MCS, HF, NNSA

Chairs:

Jennifer A. Beckman, MSN-FNP, RN, CHFN, and Samer S Najjar, MD

12:00 PM (503) Health-Related Quality of Life and Treatment Preferences in Ambulatory Heart Failure - Results from the REVIVAL Study; J. Stehlik¹, M. Mountis², D. Haas³, M. Palardy⁴, A. Ambardekar⁵, J. Estep⁶, G. Ewald⁷, S. Russell⁸, S. Robinson⁹, U. Jorde¹⁰, N. Jeffries¹¹, C. Spino⁴, J. T. Baldwin¹¹, D. Mann⁷, G. Stewart¹², K. Aaronson⁴, .. for the REVIVAL Investigators¹. ¹University of Utah School of Medicine, Salt Lake City, UT, ²Cleveland Clinic Foundation, Cleveland, OH, ³Abington Memorial Hospital, Abington, PA, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Colorado, Denver, CO, ⁶Houston Methodist Research Institute, Houston, TX, ⁷Washington University School of Medicine, St. Louis, MO, ⁸The Johns Hopkins University School of Medicine, Baltimore, MD, ⁹University of Maryland, Baltimore, MD, ¹⁰Montefiore Medical Center, New York City, NY, ¹¹National Heart, Lung and Blood Institute, Bethesda, MD, ¹²Brigham and Women's Hospital, Boston, MA

12:15 PM (504) Glad to Have a VAD Across Intermacs Profiles; F. Pagani¹, M. Kittleson², G. Stewart³, A. DeVore⁴, M. Brinkley⁵, S. Myers⁶, M. Miller⁷, D. Naftel⁶, J. J. Teuteberg⁸, L. W. Stevenson². ¹Cardiac Surgery, University of Michigan, Ann Arbor, MI, ²Brigham & Women's Hospital, Boston, MA, ³Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA, ⁴Cardiology, Duke University Medical Center, Durham, NC, ⁵Cardiology, Vanderbilt Medical Center, Nashville, TN, ⁶Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL, ⁷National Heart Lung and Blood Institute, Bethesda, MD, ⁸Cardiology, University of Pittsburgh, Pittsburgh, PA

12:30 PM (505) Destination Therapy: Targeting & Refining Advance Care Planning; J. Woodburn¹, L. L. Staley¹, S. E. Wordingham², J. Spadafore¹, E. Boldea¹, H. M. Ross¹, D. E. Steidley³, O. E. Pajaro¹. ¹Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, ²Palliative Medicine, Mayo Clinic, Phoenix, AZ, ³Cardiology/Transplant, Mayo Clinic, Phoenix, AZ

12:45 PM (506) Long Term Neurocognitive Outcomes After Left Ventricular Assist Device Implantation; R. J. Petrucci¹, S. C. Feitell², E. J. Gracely³, K. L. Corvi⁴, T. Rowe⁵, J. W. Entwistle⁶. ¹Psychiatry, Drexel College of Medicine, Philadelphia, PA, ²Cardiology, Rochester Regional Health System, Rochester, NY, ³Family, Community and Preventative Medicine, Drexel College of Medicine, Philadelphia, PA, ⁴Psychology, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, ⁵Cardiology, Drexel College of Medicine, Philadelphia, PA, ⁶Surgery, Thomas Jefferson Univ, Philadelphia, PA

1:00 PM (507) Reducing 30-Day Hospital Readmission Rate in Left Ventricular Assist Device Patients with a Structured Readmission Improvement Plan; D. B. Sims¹, A. Luke², S. Rangasamy¹, E. Borukhov², O. Saeed¹, S. Murthy¹, S. Patel¹, J. J. Shin¹, D. J. Goldstein², U. P. Jorde¹. ¹Cardiology, Montefiore Medical Center, New York, NY, ²Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, NY

1:15 PM (508) Impact of Patient Distance from VAD Implanting Center on Outcomes; J. A. Cowger¹, P. Shah², R. Singh³, K. D. Aaronson⁴, F. D. Pagani⁵, J. Stulak⁶, S. M. Dunlay⁷, T. F. Dardas⁸, N. A. Mokadam⁹, C. T. Salerno¹⁰, A. Ravichandran¹¹. ¹St. Vincent Heart Center of Indiana, Carmel, IN, ²Cardiovascular Medicine, Inova Heart & Vascular Institute, Falls Church, VA, ³Surgery, Inova Heart & Vascular Institute, Falls Church, VA, ⁴Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, ⁵Cardiac Surgery, University of Michigan, Ann Arbor, MI, ⁶Cardiac Surgery, Mayo Clinic, Rochester, MN, ⁷Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ⁸Cardiovascular Medicine, University of Washington, Seattle, WA, ⁹Cardiovascular Surgery, University of Washington, Seattle, WA, ¹⁰Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, ¹¹Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN

12:00 PM - 1:30 PM

ORAL SESSION 49: Antibodies and Other Determinants of Cardiac Rejection: Let's ROCK and Rho

Location:

Grand Hall B

Target Audience:

HTX, BSTR, EEP, PEDS, PHARM

Chairs:

Jignesh K. Patel, MD, PhD, and Catherine M. Murks, PhD, APN

12:00 PM (509) *The Incidence of Donor-Specific Antibody in the Presence of Biopsy-Proven Antibody-Mediated Rejection After Heart Transplantation*; S. Sana, J. Patel, M. Kittleson, T. Aintablian, M. Rafiei, D. Luthringer, X. Zhang, N. Reinsmoen, L. Czer. *Cedars-Sinai Heart Institute, Los Angeles, CA*

12:15 PM (510) *Longitudinal Rho-Associated Kinase (ROCK) Activity Correlates with Rejection in Heart Transplant Recipients*; B. Chung, M. Knapp, D. Rodgers, G. Kim, S. Adatya, N. Sarswat, T. Imamura, E. Karrar, J. Zhou, L. Zhang, G. Sayer, J. Liao, N. Uriel. *Cardiology, University of Chicago, Chicago, IL*

12:30 PM (511) *Pre-Transplant Donor-Recipient Characteristics and the Relationship to Early Cardiac Allograft Injury Measured by Cell-Free DNA*; P. Shah¹, S. Agbor-Enoh², A. Ulyanov³, S. Gorham², U. Fideli², I. Tunc², J. Zhu², M. Jang², Y. Yang², K. Bhatti², A. Marishta², M. E. Rodrigo⁴, S. M. Pham⁵, K. B. Shah⁶, S. D. Russell⁷, E. Feller⁸, H. A. Valantine². ¹*Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA*, ²*Laboratory of Transplantation Genomics, NHLBI, Bethesda, MD*, ³*Bioinformatics, Inova Translational Medicine Institute, Falls Church, VA*, ⁴*Heart Failure and Transplantation, Washington Hospital Center, Washington, DC*, ⁵*Cardiothoracic Surgery, University of Maryland, Baltimore, MD*, ⁶*Cardiovascular Medicine, Virginia Commonwealth University, Richmond, VA*, ⁷*Cardiovascular Medicine, Johns Hopkins University, Baltimore, MD*, ⁸*Cardiovascular Medicine, University of Maryland, Baltimore, MD*

12:45 PM (512) *Identification and Validation of Non-HLA Antibodies in Cardiac Allograft Rejection*; C. Butler¹, N. Jiang², P. Rao¹, Y. Zheng¹, D. Gjertson¹, Q. Zhang¹, M. Cadeiras¹, M. Deng¹, B. Ray², E. Reed¹. ¹*UCLA, Los Angeles, CA*, ²*Immucor, Inc., Stamford, CT*

1:00 PM (513) *Combined Heart and Liver Transplantation in Highly Sensitized Patients: Protection of the Cardiac Allograft from Antibody Mediated Rejection by Initial Liver Implantation*; R. C. Daly, N. L. Pereira, T. Taner, M. J. Gandhi, J. K. Heimbach, J. A. Dearani, B. S. Edwards, S. S. Kushwaha. *Mayo Clinic, Rochester, MN*

1:15 PM (514) *Racial Differences in the Development of De Novo DSA and Treated AMR Following Heart Transplantation*; R. T. Cole, J. Gandhi, M. Yin, S. R. Laskar, D. Gupta, D. Nguyen, A. Smith, J. D. Vega, A. Morris. *Cardiology, Emory Univ Sch of Med, Atlanta, GA*

12:00 PM - 1:30 PM

ORAL SESSION 50: Influencing Long-term Outcomes in Lung Transplantation

Location:

Grand Hall C

Target Audience:

LTX, BSTR, ID, NNSAH, PEDS, PHARM

Chairs:

Jason D Christie, MD, and Johanna M Kwakkel-van Erp, MD, PhD

12:00 PM (515) A Study of QuantiFERON-CMV-Directed CMV Prophylaxis versus Standard-of-Care to Reduce Late CMV Reactivation Following Lung Transplantation; G. P. Westall, Y. Cristiano, A. Peleg, M. Paraskeva, B. Levvey, H. Whitford, G. Snell. *Alfred Hospital, Melbourne, Australia*

12:15 PM (516) Regulation of KLRG1 Gene Expression by T-bet Correlates with Human Cytomegalovirus-Specific CD8⁺ T Cells Effector Function; A. Hoji¹, I. Popescu¹, M. Pipeling¹, H. Mannem², J. McDyer¹. ¹UPMC, Pittsburgh, PA, ²UVA, Charlottesville, VA

12:30 PM (517) Single Nucleotide Polymorphism in a Gene Involved in Mycophenolic Acid Metabolism Is Linked to Survival Post-Lung Transplantation; L. K. Tague¹, D. Byers¹, R. Hachem¹, A. Gelman². ¹Internal Medicine, Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO, ²Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO

12:45 PM (518) Basliximab for CNI Holiday in Lung Transplant Recipients with Acute Kidney Injury; U. Goswami¹, R. Z. Brown², K. D. Rudser², M. I. Hertz¹, J. R. Patil¹, R. Tomic¹, G. Loo³, J. M. Dunitz¹. ¹Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN, ²Biostatistics, University of Minnesota, Minneapolis, MN, ³Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

1:00 PM (519) Regional Variation in Lung Transplant Outcomes; W. M. Whited, J. R. Trivedi, M. P. Fox, V. H. van Berkel. *Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY*

1:15 PM (520) The Burden of Sinus Disease in Cystic Fibrosis Lung Transplant Recipients; L. Morlacchi¹, M. Greer², I. Tudorache³, F. Blasi¹, T. Welte², J. G. Mainz⁴, J. Gottlieb². ¹Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Department of Respiratory Medicine, Lungentransplantation, Medizinische Hochschule Hannover, Hannover, Germany, ³Department of Cardiothoracic, Transplant and Vascular Surgery, Medizinische Hochschule Hannover, Hannover, Germany, ⁴Department of Paediatrics, CF-Center for Children and Adults, Jena University Hospital, Jena, Germany

12:00 PM - 1:30 PM

ORAL SESSION 51: Optimizing Outcomes After Heart Transplantation: Predictors and Risk Scores

Location:

Grand Hall D

Target Audience:

HTX, MCS, PATH

Chairs:

Shelley A Hall, MD, and George Javorsky, MBBS, FRACP

12:00 PM (521) *Is the ISHLT-Suggested Inotrope Score a Predictor of In-Hospital Mortality After Heart*

Transplantation?; M. Wright¹, K. Takeda¹, C. Mauro², P. Kurlansky¹, J. Han¹, L. Truby¹, M. Salna¹, V. Topkara¹, A. R. Garan¹, M. Yuzefpolskaya¹, P. Colombo¹, Y. Naka¹, M. Farr¹, H. Takayama¹. ¹Columbia University Medical Center, New York, NY, ²Columbia University, Mailman School of Public Health, New York, NY

12:15 PM (522) *GIMVECH: A Novel Risk Score for Stroke in the Perioperative Post Transplant Period*; N. Nair¹, S.

Yang², E. Gongora³. ¹Cardiology, Texas Tech Health Sciences Center, Lubbock, TX, ²Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX, ³Cardiothoracic Surgery, Memorial Cardiac and Vascular Institute, Hollywood, FL

12:30 PM (523) *Early Acute Humoral Rejection Does Not Alter Prognosis After Heart Transplantation*; G.

Coutance¹, L. Van Aelst¹, S. Ouldammam¹, P. Rouvier², S. Saheb³, N. Brechot⁴, G. Lebreton¹, A. Bouglé⁵, A. Combes⁴, J. Amour⁵, P. Leprince¹, S. Varnous¹. ¹Thoracic and Cardiovascular Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Laboratory of Pathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³Hemobiotherapy, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁴Medical Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁵Anesthesiology and Reanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

12:45 PM (524) *Influence of Structurally Based HLA Mismatching on Long-Term Graft Loss in Adult Heart*

Transplant Recipients; J. Nilsson¹, A. Nilsson¹, V. Jernryd¹, M. Ohlsson², B. Andersson³. ¹Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, ²Computational Biology and Biological Physics, Lund University, Lund, Sweden, ³Surgery, Lund University and Skane University Hospital, Lund, Sweden

1:00 PM (525) *Consequence of Retained Defibrillator and Pacemaker Leads Following Heart Transplantation - An*

Under-Sensed Problem?; L. Holzhauser, T. Imamura, A. Nguyen, B. Chung, T. Ota, S. Adatya, G. Kim, G. Sayer, N. Sarswat, J. Raikhelkar, V. Jeevanandam, N. Uriel. *Cardiology, University of Chicago, Chicago, IL*

1:15 PM (526) *High-Risk and Low-Risk Donor/Recipient Characteristics and 90-Day Transplant Outcomes in LVAD*

versus Standard Recipients; M. Urban, N. Robinson-Smith, A. Woods, S. Schueler, G. Parry, G. MacGowan. *Freeman Hospital, Newcastle upon Tyne, United Kingdom*

12:00 PM - 1:30 PM

ORAL SESSION 52: Does Size Matter? Center Volume, Urgency Status and Managing Complications

Location:

Seaport F-H

Target Audience:

EEP, HF, HTX, LTX, MCS, NNSAH, PEDS, PHARM

Chairs:

Axel Rahmel, MD, and Jonathan P Singer, MD, MS

12:00 PM (527) Benefits of Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart and Lung Transplantation; H. A. Tetteh¹, P. Brandenhoff², R. S. Higgins³. ¹Department of Surgery, Uniformed Services University, Bethesda, MD, ²Department of Surgery, University of California San Francisco, San Francisco, CA, ³Department of Surgery, Johns Hopkins University, Baltimore, MD

12:15 PM (528) Should Heart Transplantation in High Risk Recipients Be Performed in High Volume Centers?; C. Legeai¹, O. Bastien¹, C. Jasseron¹, C. Cantrelle¹, S. Varnous², L. Sebbag³, A. Belin⁴, R. Dorent¹. ¹Agence de la Biomédecine, Saint-Denis, France, ²Hôpital Pitié-Salpêtrière, Paris, France, ³CHU Lyon, Lyon, France, ⁴CHU Caen, Caen, France

12:30 PM (529) Effect of Broader Geographic Sharing of Donor Lungs on Regional Waitlist (WL) Mortality and Transplant Center Volume; J. Mooney¹, L. Chhatwani¹, J. Boyd², G. S. Dhillon¹. ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA

12:45 PM (530) Use of Urgent Statuses to List Adult Heart Transplant Candidates Is Increasing; W. Parker¹, M. Churpek¹, S. Fedson², E. Garrity¹. ¹Pulmonary and Critical Care, University of Chicago Medicine, Chicago, IL, ²Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX

1:00 PM (531) CANCELLED

1:15 PM (532) The Impact of Center VAD Operative Volumes on Outcomes After VAD Implant; J. A. Cowger¹, J. M. Stulak², P. Shah³, T. F. Dardas⁴, F. D. Pagani⁵, S. M. Dunlay⁶, K. D. Aaronson⁷, R. Singh⁸, N. A. Mokadam⁹, S. Maltais¹⁰, J. K. Kirklin¹¹, C. T. Salerno¹². ¹Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, ²Surgery, Mayo Clinic, Rochester, MN, ³Cardiovascular Medicine, Inova Heart & Vascular Institute, Fairfax, VA, ⁴Cardiovascular Medicine, University of Washington, Seattle, WA, ⁵Cardiac Surgery, University of Michigan, Ann Arbor, MI, ⁶Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ⁷Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, ⁸Cardiovascular Medicine, Inova Heart & Vascular Institute, Falls Church, VA, ⁹Cardiovascular Surgery, University of Washington, Seattle, WA, ¹⁰Cardiac Surgery, Mayo Clinic, Rochester, MN, ¹¹Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, ¹²Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN

8:00 AM - 9:30 AM

ORAL SESSION 53: Getting to the Heart of the Matter: Psychosocial Factors Predict Outcomes in Transplant and MCS

Location:

Coronado A-C

Target Audience:

NHSAH, ALL

Chairs:

Karen C. Uzark, PhD, PNP, and Kevin C Carney, MSN, CRNP, CCTC

(533) WITHDRAWN

12:00 PM (243) Social and Clinical Characteristics Associated with Increased Short Term Mortality in Non-Inotrope Dependent Patients Undergoing Left Ventricular Assist Device Therapy: Results from InterMACS; S. M. Joseph¹, R. L. Kormos², J. Teuteberg³, A. Althouse⁴, J. Cowger⁵. ¹Baylor University Medical Center, Dallas, TX, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵St Vincent Medical Center, Indianapolis, IN

12:15 PM (534) Depressive Symptoms and Post-Transplant Mortality: Examining the Influence of Perioperative Outcomes; P. J. Smith, S. M. Palmer, L. D. Snyder, B. M. Hoffman, K. K. Ingle, G. L. Stonerock, C. Saulino, J. A. Blumenthal. *Duke University Medical Center, Durham, NC*

12:30 PM (535) Social Desirability Response Bias in Transplant Candidates' Self-Report of Psychosocial Variables; G. L. Stonerock, P. J. Smith, B. M. Hoffman, K. K. Ingle, C. K. Saulino, J. A. Blumenthal. *Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC*

12:45 PM (536) The Impact of Pre-LVAD Psychosocial Evaluations on Post-LVAD Outcomes; M. Sobhanian, M. Converse, N. Patel, A. Mardis, D. Taber, B. Houston, B. Ramu, E. Serber, A. Agyemang, D. Heyward, W. Uber, H. Meadows. *Medical University of South Carolina, Charleston, SC*

1:00 PM (537) Cognitive Function: A Significant Predictor of Quality of Life in Adults with an Implantable Ventricular Assist Device; J. M. Casida¹, J. J. Yang¹, H. Craddock², P. Combs³. ¹School of Nursing, University of Michigan, Ann Arbor, MI, ²Heart Failure/Mechanical Circulatory Support, Washington University, Saint Louis, MO, ³VAD/Heart Failure, Jewish Hospital, Louisville, KY

1:15 PM (538) Individual and Dyad Determinants of Patient Quality of Life and Caregiver Strain in Ventricular Assist Device Therapy; J. T. Bidwell¹, J. O. Mudd², K. S. Lyons³, K. L. Grady⁴, J. M. Gelow², S. O. Hiatt³, C. V. Chien², C. S. Lee³. ¹Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, ²Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, ³School of Nursing, Oregon Health & Science University, Portland, OR, ⁴Feinberg School of Medicine, Northwestern University, Chicago, IL